CTAD 2024

Alzheimer

Clinical Trials on Alzheimer's Disease

©Designpics

Final program

In-Person + Remote

October 29 - November 1, 2024

Madrid, Spain

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11 / Monte Carlo '12
San Diego '13 / Philadelphia '14 / Barcelona '15 / San Diego '16 / Boston '17 / Barcelona '18
San Diego '19 / Virtual '20 / Boston '21 / San Francisco '22 / Boston '23

www.ctad-alzheimer.com

Email: ctad@ant-congres.com

JPAD

SUMMARY

CTAD National Organizing Commitee

Leocadio Rodriguez-Manas, MD, PhD (Hospital Universitaorio di Getafe - Getafe, Spain)

Pascual Sanchez-Juan, MD, PhD (Centro Alzheimer Fundacion Reina Sofia - Madrid, Spain)

Merce Boada, MD, PhD (ACE Alzheimer Center - Barcelona, Spain)

Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Davide ANGIONI (Toulouse, France); Laura D. BAKER (Winston-Salem, USA); Randall J. BATEMAN (St. Louis, USA); Karim BENNYS (Montpellier, France); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Lucia CRIVELLI (Buenos Aires, Brazil); Steven DEKOSKY (Miami, USA); Michael C DONOHUE (San Diego, USA); Rachelle DOODY (Houston, USA); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FILLIT (New-York, USA); Nick FOX (London, UK); Kristian Steen FREDERIKSEN (Copenhagen, Denmark); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Joshua GRILL (Los Angeles, USA); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Hamburg, Germany); Jakub HORT (Prague, Czech Republic); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Miia KIVIPELTO (Stockholm, Sweden); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T. MIDDLETON (London, UK); José Luis MOLINUEVO (Valby, Denmark); Claire PAQUET (Paris, France); Robert PERNECZKY (Munich, Germany); Ronald PETERSEN (Minnesota, USA); Michael S. RAFII (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Phoenix, USA); Stephen SALLOWAY (Providence, USA); Pascual SANCHEZ-JUAN (Madrid, Spain); Nikolaos SCARMEAS (New York, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Sietske SIKKES (Amsterdam, NL); Yong SHEN (Hefei, China); Jiong SHI (Hefei, China); Heather SNYDER (Chicago, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Duygu TOSUN (San Francisco, USA); Jacques TOUCHON* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS* (Toulouse, France); Prashanthi VEMURI (Rochester, USA); Michael W. WEINER* (San Francisco, USA); Donna M. WILCOCK (Indianapolis, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

*Organizing Committee Member

CTAD 2024
Lifetime Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research, is awarded to Lars Lannfelt MD, PhD in recognition for his pioneering work in Alzheimer's Disease Scientific Discoveries and Drug Development.

Lars Lannfelt, MD, PhD

Professor, Uppsala University, Uppsala (Sweden)

Professor of Molecular Geriatrics at Uppsala University since 2001, elected to the Royal Swedish Academy of Sciences in 2004. A major scientific achievement was the detection of the "Swedish" mutation. This genetic mutation causes Alzheimer's disease in a large family and leads to 3-5 times increased production of amyloid β (Aβ). Another major scientific breakthrough was the detection of the "Arctic" mutation, found in a family from northern Sweden. The pathogenic effect of the mutation was a propensity to generate soluble aggregated Aβ, protofibrils. These species of Aβ are toxic. This inspired him to target Aβ protofibrils with immunotherapy and they developed an antibody selective for Aβ protofibrils, mAb158. In 2003, he co-founded BioArctic, based on the discovery of the Arctic mutation. BioArctic has signed a long-term license agreement with Eisai Pharmaceuticals of Japan on the clinical development of lecanemab. Results from phase 3 came in September 2022, and primary and all key secondary end-points were being met.

He was awarded the Bengt Winblad's prize for increased understanding of the pathogenesis of Alzheimer's disease (2022), the Rudbeck Medal for scientific discoveries, Uppsala University (2021), the Khalid Iqbql Lifetime Achievement Award in Alzheimer's Disease Research and the Swedish Alzheimer's Foundation (Alzheimerfonden) Grand Research Prize (2019).

Keynotes

"Next Generation of Clinical Trials for Alzheimer's Disease and Related Disorders"

Catherine Mummery, MD, PhD

Neurologist, Head of Clinical Trials, Dementia Research Center, University College London, London (United Kingdom)

Cath Mummery is a consultant neurologist at the National Hospital for Neurology and Neurosurgery. She is chair of the NIHR Dementia Translational Research Collaboration, building a national unified trials network for early phase clinical trials and working with the Mission to accelerate and enhance dementia translational research in novel treatments. She is Head of Clinical Trials at the Dementia Research Centre at University College London, and Deputy Director for the Leonard Wolfson Experimental Neurology Centre. She has been chief investigator on over 20 early phase drug trials of potential disease modifying agents in sporadic Alzheimer's disease (AD), and genetic forms of AD and frontotemporal dementia. As clinical lead for the UCL Neurogenetic Therapies Programme, she leads a program of innovative collaboration between industry and academia to accelerate progress in genetic therapies in dementia. Her driving ambition is to ensure we not only have treatments that can alter the course of neurodegenerative diseases like Alzheimer's, but that we can deliver them promptly, safely and equitably.

"Lecanemab: from a mutation to a treatment for Alzheimer's disease"

Lars Lannfelt, MD, PhD

Professor, Uppsala University, Uppsala (Sweden)

Professor of Molecular Geriatrics at Uppsala University since 2001, elected to the Royal Swedish Academy of Sciences in 2004. A major scientific achievement was the detection of the "Swedish" mutation. This genetic mutation causes Alzheimer's disease in a large family and leads to 3-5 times increased production of amyloid β (Aβ). Another major scientific breakthrough was the detection of the "Arctic" mutation, found in a family from northern Sweden. The pathogenic effect of the mutation was a propensity to generate soluble aggregated Aβ, protofibrils. These species of Aβ are toxic. This inspired him to target Aβ protofibrils with immunotherapy and they developed an antibody selective for Aβ protofibrils, mAb158. In 2003, he co-founded BioArctic, based on the discovery of the Arctic mutation. BioArctic has signed a long-term license agreement with Eisai Pharmaceuticals of Japan on the clinical development of lecanemab. Results from phase 3 came in September 2022, and primary and all key secondary end-points were being met. He was awarded the Bengt Winblad's prize for increased understanding of the pathogenesis of Alzheimer's disease (2022), the Rudbeck Medal for scientific discoveries, Uppsala University (2021), the Khalid Iqbql Lifetime Achievement Award in Alzheimer's Disease Research and the Swedish Alzheimer's Foundation (Alzheimerfonden) Grand Research Prize (2019).

"Interim observations on developing drugs for people living with AD: What do they want, what can they have, and how can we do better?"

Rachelle Doody, MD, PhD

Houston, TX (USA)

Rachelle Doody is a distinguished neurodegeneration expert with a profound commitment to advancing treatments for neurodegenerative diseases. Extensive industry, clinical and academic medicine experience have shaped her views of personalized care and meaningful outcomes for patients. As the Global Head of Neurodegeneration and Alzheimer's disease and Neurodegeneration Franchise Head at Roche Pharmaceuticals and the US affiliate, Genentech (2016-Feb. 2024), she successfully created and led late-stage development programs for Alzheimer's, Parkinson's, and Huntington's diseases, aiming to provide comprehensive solutions from diagnostics to therapeutics. Board certified in Neurology and Psychiatry, Dr. Doody trained at Baylor College of Medicine in Houston, Texas and McGill University in Montreal. While at Baylor College of Medicine, she founded and directed the Alzheimer's Disease and Memory Disorders Center and was the Effie Marie Cain Chair in AD Research. She also holds an MA/PhD in cognitive anthropology from Rice University. Dr. Doody has served on steering committees for the National Institutes of Health-funded Alzheimer's Disease Cooperative Study and Alzheimer's Disease Neuroimaging Initiative, and the executive committee for the Alzheimer's Therapeutic Research Institute. Dr. Doody was the Principal Investigator for the Phase 2 and 3 development of donepezil (Aricept), the most widely-used AD therapy globally, and contributed to the development of most of the other approved AD treatments as well as several under development. For over 30 years, Dr. Doody has worked with biotech and pharma companies in the design and execution of trials for cognitive and behavioral treatment of AD. She has contributed to efforts to globalize approaches to AD, advising on guidelines in China, Malaysia, South Korea and the Philippines, and educating investigators throughout Europe and Asia on study design and outcome measures to support global studies. Dr. Doody has published over 235 original articles in this field, has been awarded with a Lifetime Achievement Award by the Clinical Trials in Alzheimer's Disease group in 2018, and is Immediate Past-Chair of the US Alzheimer's Association Research Roundtable. She is a Distinguished Alumna from Rice University and Distinguished Faculty Award winner from Baylor College of Medicine.

"Fluid biomarkers in research, clinical trials, and clinical practice"

Suzanne E. Schindler MD, PhD

Associate Professor of Neurology, Washington University School of Medicine, St. Louis, MO (USA)

Dr. Suzanne Schindler is a clinical neurologist and neuroscientist focused on improving the diagnosis and treatment of Alzheimer disease. She completed the MD/PhD program at Washington University, where she studied the basic biology of apolipoprotein E metabolism. Dr. Schindler then trained in clinical neurology at Washington University and completed a fellowship in dementia. Currently Dr. Schindler sees patients with memory concerns and coordinates biomarker testing for the Washington University Memory Diagnostic Center. She leads the Fluid Biomarker Core for the Knight Alzheimer Disease Research Center. She received a large R01 to evaluate novel fluid biomarkers. She is very interested in translating research findings into clinical practice. Further, she has a particular focus on understanding and reducing disparities in healthcare.

ONSITE PROGRAM

in Madrid

Available via livestream on the CTAD24 digital platform

Program at a glance

Tuesday, OCTOBER 29

2:45 p.m. POSTER WALKING TOUR

3:15 p.m. TAKING CARE – A movie

4:00 p.m. Opening Ceremony

4:20 p.m. CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research

4:30 p.m. KEYNOTE 1: Lecanemab: from a mutation to a treatment for Alzheimer's disease

4:55 p.m. ORAL COMMUNICATIONS

6:10 p.m. LATE BREAKING SYMPOSIUM: The AHEAD 3-45 Study: Design and Results of a Novel Screening Process for a Preclinical AD Trial

7:00 p.m. CTAD Networking Event with the Support of the Alzheimer's Association

Wednesday, OCTOBER 30

7:30 a.m. POSTER WALKING TOUR

8:30 a.m. LATE BREAKING COMMUNICATIONS

9:15 a.m. KEYNOTE 2: Next Generation of Clinical Trials for Alzheimer's Disease and Related Disorders

9:40 a.m. SYMPOSIUM 1: Does the Current Evidence Base Support Continued Dosing with Lecanemab for Early Alzheimer's Disease?

10:20 a.m. Coffee break and poster session

10:50 a.m. LATE BREAKING COMMUNICATIONS

11:35 a.m. ORAL COMMUNICATIONS

12:45 p.m. Lunch and poster sessions

1:45 p.m. ROUNDTABLE: Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer's Treatments

2:15 p.m. ORAL COMMUNICATIONS

3:30 p.m. LATE BREAKING SYMPOSIUM: One-Year Experience on the Use of Lecanemab in Clinical Practice

4:10 p.m. Coffee break and poster session

4:40 p.m. ORAL COMMUNICATIONS

6:10 p.m. End of the Conference Day

Thursday, OCTOBER 31

7:30 a.m. POSTER WALKING TOUR

8:30 a.m. LATE BREAKING COMMUNICATIONS

9:45 a.m. KEYNOTE 3: Interim observations on developing drugs for people living with AD: What do they want, what can they have, and how can we do better?

10:10 a.m. ORAL COMMUNICATIONS

10:55 a.m. Coffee break and poster session

11:25 a.m. ORAL COMMUNICATIONS: Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease

12:00 p.m. LATE BREAKING COMMUNICATIONS

12:30 p.m. Lunch and poster sessions

1:30 p.m. LATE BREAKING COMMUNICATIONS

2:00 p.m. KEYNOTE 4: Fluid biomarkers in research, clinical trials, and clinical practice

2:25 p.m. ORAL COMMUNICATIONS

3:10 p.m. LATE BREAKING COMMUNICATIONS

3:55 p.m. Coffee break and poster session

4:25 p.m. ORAL COMMUNICATIONS

5:10 p.m. LATE BREAKING SYMPOSIUM: Results from TOGETHER, a double-blind, placebo-controlled Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal–mild AD

5:50 p.m. End of the Conference Day

Friday, NOVEMBER 1

7:30 a.m. POSTER WALKING TOUR

8:30 a.m. LATE BREAKING COMMUNICATIONS

9:30 a.m. ORAL COMMUNICATIONS

10:30 a.m. Coffee break and poster session

11:00 a.m. LATE BREAKING ORAL COMMUNICATIONS

12:00 p.m. LATE BREAKING ROUNDTABLE

12:30 p.m. Lunch and poster sessions

1:30 p.m. LATE BREAKING SYMPOSIUM: Cannabinoid based medications for neuropsychiatric symptoms in Alzheimer's dementia

2:10 p.m. ORAL COMMUNICATIONS

3:10 p.m. Coffee break and poster session

3:40 p.m. LATE BREAKING ORAL COMMUNICATIONS

5:10 p.m. End of the Conference Day

All scientific sessions will be held in the Auditorium

Tuesday, OCTOBER 29

2:45-3:15 p.m. **POSTER WALKING TOUR**

3:15 p.m. **TAKING CARE – A movie**
Directed and produced by award-winning filmmaker James Keach, and produced by Seth Rogen and Lauren Miller Rogen. This 40-minute documentary featuring the story of Lauren and Seth's courtship and marriage as their family faces the complexities and heartbreak of Lauren's mother's advancing early-onset Alzheimer's disease.

4:00 p.m. **Opening Ceremony**
Pascual Sánchez-Juan, and Jacques Touchon on behalf of the CTAD Organizing Committee
Paul Aisen, Sandrine Andrieu, Lefkos Middleton, Reisa Sperling, Bruno Vellas and Mike Weiner and the National Organizing committee, Merce Boada and Leocadio Rodríguez Mañas

4:20 p.m. **CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research**
Presented to Lars Lannfelt, MD, PhD in recognition for his pioneering work in Alzheimer's Disease Scientific Discoveries and Drug Development
Introduction by Lefkos Middleton, Imperial College London, London (United Kingdom)

4:30 p.m. **KEYNOTE 1**
Lecanemab: from a mutation to a treatment for Alzheimer's disease
Lars Lannfelt, *Uppsala University, Uppsala (Sweden)*

4:55 p.m. **ORAL COMMUNICATIONS**
Chairs: Paul Aisen, *Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (United States),* Suzanne Craft, *Wake Forest School of Medicine - Winston Salem (United States)*

4:55 p.m. **OC1 - The Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer's Disease: Primary Outcome Results from TRAILBLAZER-ALZ 6**
Hong Wang [1], Emel S. Nery [1], Paul Ardayfio [1], Dunlei Cheng [1], Rashna Khanna [1], Diana Otero Svaldi [1], Paula Hauck [1], Sergey Shcherbinin [1], Dawn A. Brooks [1], Emily C. Collins [1], Mark A. Mintun [1], John R. Sims [1]
[1]Eli Lilly and Company - Indianapolis (United States)

5:10 p.m. **OC2 - Fosgonimeton for the Treatment of Alzheimer's Disease; Efficacy and Safety Results from the LIFT-AD Trial**
Anton P Porsteinsson[2], Kevin J Church[1], Javier San Martin[1], Michael D Hale[1], Len B Walt[4], Simon Daggett[1], Hans J Moebius[3]
[1]Athira Pharma, Inc., Bothell, WA (United States); [2]Alzheimer's Disease Care, Research and Education Program, University of Rochester School of Medicine and Dentistry, Rochester, NY (United States); [3]moebius-consult GmbH, Baar ZG (Switzerland); [4]SSI Strategy, Parsippany-Troy Hills, New Jersey (United States)

5:25 p.m. **OC3 - Immunometabolic and Vascular Modulators for Combination Therapy in AD: Results of a Phase II Trial of Intranasal Insulin and the SGLT2 Inhibitor Empagliflozin**
Jennifer Erichsen [1], Thomas Register [1], Courtney Sutphen [1], James R. Bateman [1], Melissa Rundle [1], Marc Rudolph [1], Samuel Lockhart [1], Suzanne Craft [1]
[1]Wake Forest School of Medicine - Winston-Salem (United States)

5:40 p.m. **OC4 - Anti-tau therapeutic antibody, E2814, reduces early and late tau pathology biomarkers in patients with DIAD**
Kristin Wildsmith [1], Kanta Horie [1,2], Arnaud Charil [1], Nicolas Barthelemy [2], David Verbel [1], Anthonin Reihac-Iaborde [1], Brian Gordon [2], Peter Boyd [3], Robert Bell [1], Sumit Rawal [1], Erica Andreozzi [1], Tammie Benzinger [2], Randall Bateman [2], Jin Zhou [1], Larisa Reyderman [1]
[1]Eisai Inc. - Nutley (United States), [2]Washington University School of Medicine - St Louis (United States), [3]Eisai Europe Ltd. - Hatfield (United Kingdom)

Tuesday, OCTOBER 29

5:55 p.m.

OC5 - Results from COG0201: a Randomized, Placebo-controlled, Double-blind, International, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer's Disease

Michael Woodward [1], Everard Vijverberg [2,3], Susan Catalano [4], Theresa Devins [5], Valentina Di Caro [5], Michael Grundman [6], Mary Hamby [5], Jennifer Iaci [5], Anthony Caggiano [5]

[1]Austin Health - Melbourne, Victoria (Australia), [2]Brain Research Center - Amsterdam (Netherlands), [3]UMC - Amsterdam (Netherlands), [4]Capsida Therapeutics - Thousand Oaks (United States), [5]Cognition Therapeutics, Inc., New York (United States), [6]Global R&D Partners, LLC - La Jolla (United States)

6:10 p.m.

Late breaking Symposium 1 - The AHEAD 3-45 Study: Design and Results of a Novel Screening Process for a Preclinical AD Trial

Chair: Rema Raman, *Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (United States)*

Presentation 1: The AHEAD 3-45 Study: Adaptation to Challenges

Paul Aisen, *Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (United States)*

Presentation 2: Screening Plasma Biomarkers, Amyloid and Tau PET Imaging in the AHEAD 3-45 Study

Reisa Sperling, *Brigham and Women's Hospital, Harvard Medical School and Massachusetts General Hospital, Harvard Medical School, Boston (United States)*

Presentation 3: Racial and Ethnic Differences in Plasma P-tau217 Biomarker Eligibility Rates in a Preclinical AD Trial

Doris Molina Henry, *Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (United States)*

7:00 - 8:00 p.m.

CTAD Networking Event with the Support of the Alzheimer's Association

All scientific sessions will be held in the Auditorium

Wednesday, OCTOBER 30

7:30 a.m. **POSTER WALKING TOUR**

8:30 a.m. **LATE BREAKING COMMUNICATIONS**

Chairs: Merce Boada, *Ace Alzheimer Center - Barcelona (Spain)*, Gil Rabinovici, *UCSF - San Francisco (United States)*

8:30 a.m. **LB1 - Donanemab: Appropriate Use Recommendations**

Gil Rabinovici [1], Stephen Salloway [2], Suzanne Schindler [3], Paul Aisen [4], Liana Apostolova [5], Alireza Atri [6], Steven Greenberg [7], Suzanne Hendrix [8], Ron Petersen [9], Michael Weiner [1], Dennis Selkoe [7], Jeffrey Cummings[10]

[1]UCSF - San Francisco (United States), [2]Brown - Providence (United States), [3]Washington University - St. Louis (United States), [4]USC - San Diego (United States), [5]Indiana University - Indianapolis (United States), [6]Banner Health - Phoenix (United States), [7]Harvard - Boston (United States), [8]Pentara - Millcreek (United States), [9]Mayo Clinic - Rochester (United States), [10]UNLV - Las Vegas (United States)

8:45 a.m. **LB2 - Latest Interim Results from the Brainshuttle™ AD Study, a Phase Ib/IIa Study of Trontinemab in People with Alzheimer's Disease**

Luka Kulic [1], Fabien Alcaraz [1], Gregory Klein [1], Carsten Hofmann [1], Stella Yilmaz [1], João A. Abrantes [1], Denise Sickert [1], Maddalena Marchesi [1], Jakub Wojtowicz [1], Ruth Croney [1], David Agnew [1], Silke Ahlers [2], Paul Delmar [1], Hanno Svoboda [3], Iris Wiesel[1]

[1]F. Hoffmann-La Roche Ltd. - Basel (Switzerland), [2]Excelya Germany GmbH - Freiburg (Germany), [3]F. Hoffmann-La Roche Ltd. - Penzberg (Germany)

9:00 a.m. **LB3 - Diagnostic performance of capillary pTau217 in Alzheimer's disease: The Drop-AD project**

Hanna Huber[1], Laia Montoliu-Gaya [1], Wagner S. Brum [1], Jakub Vávra [1], Yara Yakoub [1], Silke Kern [1], Haley Weninger [1], Barbara Borroni [2], Anne Corbett [3], Oskar Hansson [4], Xavier Morató [5], Henrik Zetterberg [1], Kaj Blennow [1], Nicholas J. Ashton[1]

[1]University of Gothenburg - Gothenburg (Sweden), [2]University of Brescia - Brescia (Italy), [3]University of Exeter - Exeter (United Kingdom), [4]University of Lund - Lund (Sweden), [5]Ace Alzheimer Center Barcelona - Barcelona (Spain)

9:15 a.m. **KEYNOTE 2**

Next Generation of Clinical Trials for Alzheimer's Disease and Related Disorders

Introduction: Reisa Sperling, *Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston (United States)*

Catherine Mummery, *Dementia Research Center, University College London, London (United Kingdom)*

9:40 a.m. **SYMPOSIUM 1**

Does the Current Evidence Base Support Continued Dosing with Lecanemab for Early Alzheimer's Disease?

Chair: Christopher van Dyck, *Yale University, New Haven (United States)*

Presentation 1: Mechanistic Rationale for Continued Lecanemab Dosing

Michael Irizarry, *Eisai Inc. – Nutley (United States)*

Presentation 2: Pharmacologic Support for a Maintenance Dosing Regimen with Lecanemab: An Update on the Latest Clinical Pharmacology Data and Modeling

Larisa Reyderman, *Eisai Inc. – Nutley (United States)*

Presentation 3: Evidence for a Continued Benefit for Long-Term Lecanemab Treatment: A Benefit/Risk Update from Long-Term Efficacy, Safety and Biomarker Data

Christopher van Dyck, *Yale University, New Haven (United States)*

10:20 a.m. Coffee break and poster session

Early career investigators showcase: flash session presentations in the Poster Hall

Wednesday, OCTOBER 30

10:50 a.m.

LATE BREAKING COMMUNICATIONS

Chairs: Kim Johnson, *Duke University - Durham (United States)*, Pascual Sánchez-Juan, *Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII - Madrid (Spain)*

10:50 a.m.

LB4 - Safety and Preliminary Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer's Disease – Interim Data from a Phase 1/2, Open-Label, 52-Week, Multicenter Study

Kim Johnson [1], Michael Kaplitt [2], Stephen Kaminsky [2], Gianni Amato [3], Nithya Selvan [3], Richie Khanna [3], Sandi See Tai [3], Ronald Crystal [2]

[1]Duke University - Durham (United States), [2]Cornell Medical College - New York (United States), [3]Lexeo Therapeutics - New York (United States)

11:05 a.m.

LB5 - Cognitive and behavioral outcomes in patients with dementia with Lewy bodies treated with nilotinib

Fernando Pagan [1], Yasar Torres-Yaghi [1], Michaeline Hebron [1], Barbara Wilmarth [1], Raymond Scott Turner [1], Charbel Moussa[1]

[1]Georgetown - Washington (United States)

11:20 a.m.

LB6 - Lecanemab for the Treatment of Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease in Adults that are Apolipoprotein E ε4 (ApoE ε4) Heterozygotes or Non-Carriers

Richard Perry [1], Christopher Kipps [2], Rob Mcmurray [3], Shobha Dhadda [4], Michio Kanekiyo [4], Michael Irizarry [4], Lynn Kramer [4]

[1]Imperial College London - London (United Kingdom), [2]University Hospital Southampton NHS Foundation Trust - Southampton (United Kingdom), [3]Eisai Europe Ltd - Hatfield (United Kingdom), [4]Eisai Inc. - Nutley (United States)

11:35 a.m.

ORAL COMMUNICATIONS

Chairs: Sandrine Andrieu, *IHU HealthAge - Toulouse (France)*, Michael Schöll, *University of Gothenburg - Gothenburg (Sweden)*

11:35 a.m.

OC6 - Screening and baseline results from the donanemab preclinical Alzheimer's disease TRAILBLAZER-ALZ 3 study

Karen C. Holdridge[1], Roy Yaari[1], Melissa Williamson[1], Alette M. Wessels[1], Sergey Shcherbinin[1], Vikas Kotari[1], Naohisa Hatakeyama[1], Pierre N. Tariot[2], Robert Alexander[2], Eric M. Reiman[2], Jessica B. Langbaum[2], John Sims[1]

[1]Eli Lilly and Company - Indianapolis (USA), [2]Banner Alzheimer's Institute - Phoenix (United States)

11:50 a.m.

OC7 - Efficacy, Cardiovascular Safety and Adverse Events Associated with Escitalopram in Alzheimer's Dementia: Results from the S-CitAD Trial

Hamid Okhravi [1], Manisha Parulekar [2], Sheriza Baksh [3], Emily Clark [4], Ismail Zahinoor [5], David M. Shade [3], Constantine G. Lyketsos [6,7], Anton P. Porsteinsson [4]

[1]Goldrich Neurohealth Institute, Eastern Virginia Medical School - Norfolk (United States), [2]Hackensack Meridian School of Medicine, Division of Geriatrics - Hackensack (United States), [3]Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health - Baltimore (United States), [4]Department of Psychiatry, University of Rochester School of Medicine and Dentistry - Rochester (United States), [5]University of Calgary - Calgary (Canada), [6]Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine - Baltimore (United States), [7]Johns Hopkins Bayview Medical Center - Baltimore (United States)

12:05 a.m.

OC8 - Differences in Amyloid PET Results and Social Determinants of Health by Race/Ethnicity: Results from New IDEAS

Gil Rabinovici [1], Peggye Dilworth-Anderson [2], Lucy Hanna [3], Jon Steingrimsson [3], Ilana Gareen [3], Emily Glavin [4], Bruce Hillner [5], Andrew March [4], Barry Siegel [6], Christopher Weber [7], Charles Windon [1], Rachel Whitmer [8], Constantine Gatsonis [3], Maria Carrillo [7], Consuelo Wilkins [9]

[1]University of California San Francisco - San Francisco (United States), [2]University of North Carolina - Chapel Hill (United States), [3]Brown University - Providence (United States), [4]American College of Radiology - Reston (United States), [5]Virginia Commonwealth University - Richmond (United States), [6]Washington University - St. Louis (United States), [7]Alzheimer's Association - Chicago (United States), [8]University of California Davis - Sacramento (United States), [9]Vanderbilt University - Nashville (United States)

12:20 p.m.

OC9 - First results from the REAL AD study: Validation of a realistic screening approach for early Alzheimer's disease

Kaj Blennow [1,2], Silke Kern [1,2], Iris Bosch [2], Henrik Zetterberg [1,3,4,2], Michael Schöll [1,3,2]

[1]University of Gothenburg - Gothenburg (Sweden), [2]Västra Götaland Region - Gothenburg (Sweden), [3]University College London - London (United Kingdom), [4]University of Wisconsin-Madison (United States)

12:45 p.m. Lunch and poster session

All scientific sessions will be held in the Auditorium

Wednesday, OCTOBER 30

1:.45 p.m.

ROUNDTABLE

Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer's Treatments

Howard Fillit [1], Jeffrey Cummings [2], Suzanne Hendrix [3], Jin Zhou [4], Mark Mintun[5]

[1]Alzheimer's Drug Discovery Foundation - New York (United States), [2]UNLV – Nevada, Las Vegas (United States), [3]Pentara - Salt Lake City (United States), [4]Eisai – Nutley (United States), [5]Eli Lilly and Company

2:15 p.m.

ORAL COMMUNICATIONS

Chairs: Gilda Ennis, *University of Wisconsin-Madison - Madison (United States)*, Patrick Oeckl, *Ulm University Hospital- Ulm (Germany)*

2:15 p.m.

OC10 - PROSPECT-ALZ: Results of the phase 2 study of ceperognastat, an orally available O-linked N-acetyl glucosaminidase inhibitor for the treatment of early symptomatic Alzheimer's disease

Adam S. Fleisher[1], Leanne Munsie[1], Michele Mancini[1], Eden Yun-Ju Cheng[1], Sergey Shcherbinin[1], Tomomi Nakamura[1], William Kielbasa[1], Hugh Nuthall[1], Dustin Mergott[1], Mark Mintun[1], Miroslaw Brys[1]

[1]Eli Lilly and Company - Indianapolis (United States)

2:30 p.m.

OC11 - Biomarkers of neurodegeneration and synaptic dysfunction differentiate cognitively unimpaired individuals with high levels of Alzheimer's disease (AD) neuropathology from individuals with AD dementia

Sara Fernandes-Taylor [1], Matthew Glittenberg [1], Ira Frahmand [1], Brianne Breidenbach [1], Tobey Betthauser [1], Sanjay Asthana [1], Sterling Johnson [1], Gwendlyn Kollmorgen [2], Clara Quijano-Rubio [3], Henrik Zetterberg [4], Kaj Blennow [4], Ozioma Okonkwo [1]

[1]University of Wisconsin - Madison (United States), [2]Roche Diagnostics GmbH - Penzberg (Germany), [3]Roche Diagnostics International Ltd. - Rotkreuz (Switzerland), [4]Neurochemistry Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg - Gothenburg (Sweden)

2:45 p.m.

OC12 - Study Design and Screening Experience from the Phase 2 AUTONOMY Trial of Anti-P-tau Monoclonal Antibody Posdinemab for Early Alzheimer's Disease

Dave Henley [1,2], Jennifer Bogert [3], Ziad S Saad [4], Gallen Triana-Baltzer [4], Tina Wang [4], Hartmuth C Kolb [4], Maggie Fedgchin [1]

[1]Janssen Research & Development, LLC – Titusville (United States), [2]Indiana University School of Medicine, Psychiatry – Indianapolis (United States), [3]Janssen Research & Development, LLC – Bridgewater (United States), [4]Janssen Research & Development, LLC - La Jolla (United States)

3:00 p.m.

OC13 - Performance of plasma p-tau217 in an African American cohort: Findings from the African Americans Fighting Alzheimer's in Midlife study

Gilda Ennis [1], Derek Norton [1], Fabu Carter [1], Diane Gooding [1], Alexander Gee [2], Tracy Smith [1], Hector Salazar [1], Rachael Wilson [1], Rebecca Langhough [1], Megan Zuelsdorff [1], Shenikqua Bouges [1], Sanjay Asthana [1], Sterling Johnson [1], Henrik Zetterberg [1], Carey Gleason [1]

[1]University of Wisconsin-Madison - Madison (United States), [2]Nehemiah Center for Urban Leadership Development - Madison (United States)

3:15 p.m.

OC14 - Early increase of the synaptic blood marker β-synuclein in asymptomatic individuals with autosomal dominant Alzheimer´s disease

Patrick Oeckl [1,2], Randall J. Bateman [3], Gregory S. Day [4], Nick C. Fox [5], Laura Ibanez [3], Mathias Jucker 6,7, Jae-Hong Lee [8], Johannes Levin [9,10,11], Jorge J. Llibre-Guerra [3], Eric Mc Dade [3], John C. Morris [3], Jee Hoon Roh [12], Raquel Sánchez-Valle [13], Peter R. Schofield [14, 15], Markus Otto [16]

[1]Ulm University Hospital- Ulm (Germany), [2]DZNE Ulm - Ulm (Germany), [3]Washington University School of Medicine - Saint Louis (United States), [4]Mayo Clinic in Florida - Jacksonville (United States), [5]UCL Queen Square Institute of Neurology - London (United Kingdom),[6]DZNE Tübingen - Tübingen (Germany), [7]University of Tübingen - Tübingen (Germany), [8]Asan Medical Center - Seoul (Korea, Republic of), [9]LMU Munich - Munich (Germany), [10]DZNE Munich - Munich (Germany), [11]Munich Cluster for Systems Neurology (SyNergy) - Munich (Germany), [12]Korea University College of Medicine - Seoul (Korea, Republic of), [13]University of Barcelona - Barcelona (Spain), [14]Neuroscience Research Australia - Sydney (Australia), [15]University of New South Wales - Sydney (Australia), [16]Martin-Luther-University Halle-Wittenberg - Halle (saale) (Germany)

Wednesday, OCTOBER 30

3:30 p.m.

LATE BREAKING SYMPOSIUM 2 - One-Year Experience on the Use of Lecanemab in Clinical Practice

Co-chairs: Lefkos Middleton, *ICL - London (United Kingdom)*, Bruno Vellas, *IHU HealthAge - Toulouse (France)*

Presentation 1: Lecanemab Treatment in Real World Settings in the United States

Marwan Sabbagh, *Department of Neurology Barrow Neurological Institute - Phoenix, Arizona (United States)*

Presentation 2: Lecanemab Use in Clinical Practice at an Academic Medical Center

Lawrence Honig, *Columbia University - New York (United States)*

Presentation 3: Latest data from the clinic use of Lecanemab in Japan

Takeshi Iwatsubo, *University of Tokyo - Tokyo (Japan)*

4:10 p.m. Coffee break and poster session

Early career investigators showcase: flash session presentations in the Poster Hall

4:40 p.m.

ORAL COMMUNICATIONS

Chairs: Maria Carrillo, *Alzheimer's Association - Chicago (United States)*, Oskar Hansson, *Gothenburg University - Gothenburg (Sweden)*

4:40 p.m.

OC15 - Advancing Patient Outcomes with Real-World Evidence

Ann Hartry [1], Helmut Butzkueven [2,3], Robert Perneczky [4], Craig Ritchie [5]

[1]Eli Lilly and Company - Indianapolis (United States), [2]MSBase Foundation - Melbourne (Australia), [3]Monash University - Melbourne (Australia), [4]Ludwig-Maximilians-Universität Munich - Munich (Germany), [5]University of St. Andrews - St. Andrews (United Kingdom)

4:55 p.m.

OC16 - Longitudinal trajectories of plasma p-tau217 in early Alzheimer's Disease: Implications for use in clinical trials

Bjørn-Eivind Kirsebom [1], Fernando Gonzalez-Ortiz [2], Lene Pålhaugen [3], Per Selnes [3], Jonas Alexander Jarholm [3], Berglind Gísladóttir [3], Arvid Rongve [4], Ragnhild Eide Skogseth [5], Geir Bråthen [6], Dag Aarsland [7], Michael Turton [8], Peter Harrison [8], Henrik Zetterberg [2], Kaj Blennow [2], Tormos Fladby [3]

[1]University Hospital of North Norway - Tromso (Norway), [2]University of Gothenburg - Gothenburg (Sweden), [3]Akershus University Hospital- Lørenskog (Norway), [4]Helse Fonna - Haugesund (Norway), [5]Haraldsplass Deaconess Hospital- Bergen (Norway), [6]University Hospital of Trondheim - Trondheim (Norway), [7] King's College London - London (United Kingdom), [8]Bioventix Plc- Surrey (United Kingdom)

5:10 p.m.

OC17 - Precision Neuroscience: Rationale And Design For The REtAIN Phase 2b Study With A Tau Active Immunotherapy In Preclinical Alzheimer's Disease

Lennert Steukers [1], Iva Kezic [1], Cathy Bleys [1], Lingjue Li [2], Clara Theunis [1], Athena Beckers [1], Gallen Triana-Baltzer [3], Tricia Thornton-Wells [4], TAU PE [3], David Henley [2], Fiona Elwood [4], María Cristina López López [5]

[1]Johnson & Johnson - Beerse (Belgium), [2]Johnson & Johnson - Titusville (United States), [3]Johnson & Johnson - La Jolla (United States), [4]Johnson & Johnson - Cambridge (United States), [5]Johnson & Johnson - Allschwil (Switzerland)

5:25 p.m.

OC18 - Blood biomarkers to detect Alzheimer's disease in clinical practice - a cross-sectional study in primary & secondary care

Sebastian Palmqvist [1], Pontus Tideman [1], Niklas Mattsson-Carlgren [1], Ruben Smith [1], Rik Ossenkoppele [1], Suzanne Schindler [2], Mark Monane [3], Tim West [3], Kaj Blennow [4], Philip Verghese [3], Joel Braunstein [3], Shorena Janelidze [1], Erik Stomrud [1], Gemma Salvadó [1], Oskar Hansson [1]

[1]Lund University - Malmo (Sweden), [2]Washington University School of Medicine - Saint Louis (United States), [3]C2N Diagnostics - Saint Louis (United States), [4]Gothenburg University - Gothenburg (Sweden)

5:40 p.m.

OC19 - Clinical Progression on CDR-SB: Residence Time at Each Level in the DIAN and ADNI Cohorts

Guoqiao Wang [1], Yan Li [1], Eric Mcdade [1], John Morris [1], Lon Schneider [2]

[1]School of Medicine, Washington University in St Louis - St Louis (United States), [2]Keck School of Medicine, University of Southern California, Los Angeles - Los Angeles (United States)

5:55 p.m.

LB6bis - The Global Neurodegeneration Proteomics Consortium - Biomarker and Drug Target Discovery Across >40,000 Biosamples for AD, PD, ALS, FTD, and Aging

Farhad Imam [1], Martin Bringmann [2], Varsha Krish [1]

[1]Gates Ventures - Seattle (United States), [2]Johnson&Johnson - Spring House (United States)

6:10 p.m. End of the Conference Day

All scientific sessions will be held in the Auditorium

Thursday, OCTOBER 31

7:30 a.m. **POSTER WALKING TOUR**

8:30 a.m. **LATE BREAKING COMMUNICATIONS**

Chairs: David Knopman, *Mayo Clinic - Rochester (United States),* Michael Weiner, *UCSF, San Francisco (United States)*

8:30 a.m. **LB7 - Plasma p-tau217 and related CSF proteomic markers of pathological progression are slowed by p75NTR modulation: A Phase 2a trial of LM11A31 in Alzheimer's disease**

Hayley Shanks [1], Kiran Pandey [2], Madison Bangs [3], Venky Venkatesh [4], Matthew Meyer [4], Manfred Windisch [5], Nicholas Seyfried [2,3], Stephen Massa [6,7], Frank Longo [8], Taylor Schmitz [1]

[1]Western University - London (Canada), [2]Emtherapro Inc. - Atlanta (United States), [3]Emory University - Atlanta (United States), [4]C2N Diagnostics - St. Louis (United States), [5]NeuroScios Gmbh - St. Radegund (Austria), [6]San Francisco Veterans Affairs Health Care System - San Francisco (United States), [7]University of California, San Francisco - San Francisco (United States), [8]PharmatrophiX - Menlo Park (United States)

8:45 a.m. **LB8 - Bridging the gap: parahippocampal tau-PET improves detection of the transition from age-related tauopathy to Alzheimer's disease**

Emma G. Thibault [1], Michelle E. Farrell [2], Jessie Fanglu Fu [3], Justin S. Sanchez [1], Brian C. Healy [2,4], Bernard J. Hanseeuw [1,5], Heidi I.l. Jacobs [3], Julie C. Price [3], J. Alex Becker [1], Reisa A. Sperling [2,6], Keith A. Johnson [1,6]

[1]Department of Radiology, Massachusetts General Hospital - Boston (United States), [2]Department of Neurology, Massachusetts General Hospital - Boston (United States), [3]Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital - Boston (United States), [4]Biostatistics Center, Massachusetts General Hospital - Boston (United States), [5]Department of Neurology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain - Bruxelles (Belgium), [6]Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital - Boston (United States)

9:00 a.m. **LB9 - Phase IIb/III Trial of Blarcamesine in Early Alzheimer Disease Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation**

Marwan Sabbagh [1], Juan-Carlos Lopez-Talavera [2], Kun Jin [2], William Chezem [2], Christopher Missling[2]

[1]Barrow Neurological Institute - Phoenix (United States), [2]Anavex - New York (United States)

9:15 a.m. **LB10 - Discrepancies between CSF and PET determinations of elevated brain amyloid and their prognostic significance**

David Knopman [1], Stephen Weigand [1], Heather Wiste [1], Jonathan Graff-Radford [1], Neill Graff-Radford [1], Ronald Petersen [1], Clifford Jack [1], Mary Machulda [1], Julie Fields [1], Vijay Ramanan [1], Hugo Botha [1], Stuart Mccarter [1], David Jones [1], Bryan Neth [1], Gregory Day [1], Alicia Algeciras-Schimnich [1], Joshua Bornhorst [1], Val Lowe [1], Derek Johnson [1], Bradley Boeve [1]

[1]Mayo Clinic - Rochester (United States)

9:30 a.m. **LB11 - ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer's Disease**

Todd Feaster [1], Karen Sundell [1], Maddelyn Hyland [1], Gopalan Sethuraman [1], Vladmir Skljarevski [1], June Kaplow [1], Robert A. Dean [1], Jasna Jerecic [1], Eric Siemers [1]

[1]Acumen Pharmaceuticals, Inc - Newton (United States)

9:45 a.m. **KEYNOTE 3**

Interim observations on developing drugs for people living with AD: What do they want, what can they have, and how can we do better?

Introduction: Bruno Vellas, *IHU HealthAge - Toulouse (France)*

Rachelle Doody, *Houston, TX (USA)*

Thursday, OCTOBER 31

10:10 a.m.

ORAL COMMUNICATIONS

Chairs: Miia Kivipelto, *Karolinska Institutet - Stockholm (Sweden),* Leocadio Rodríguez Mañas, *Hospital Universitario de Getafe - Getafe (Spain)*

10:10 a.m.

OC20 - Initial results from remote speech-based screening in the first 900 digitally recruited participants in ADNI-4

Caroline Skirrow[1], Jack Weston [1], Melanie J. Miller [2,3], Rachel L. Nosheny [2,4], Bruce Albala [5,6], Michael W. Weiner [2,3,4], Emil Fristed [1]

[1]Novoic Ltd - London (United Kingdom), [2]Northern California Institute for Research and Education (NCIRE) - San Francisco (United States), [3]Department of Veterans Affairs Medical Center - San Francisco (United States), [4]University of California, San Francisco - San Francisco (United States), [5]University of California Irvine - Irvine (United States), [6]Veterans Administration Long Beach Healthcare System - Long Beach (United States)

10:25 a.m.

OC21 - Validating speech-based biomarkers for measuring disease progression in AD: A head-to-head comparison of three biomarker development strategies

Michael Spilka [1], Mengdan Xu [1], Bali Toth [2], Somaye Hashemifar [2], Rainier Amora [2], Jessica Robin [1], Edmond Teng [2], Cecilia Monteiro [2], William Simpson [1]

[1]Winterlight Labs (Cambridge Cognition) - Toronto (Canada), [2]Genentech, Inc. - South San Francisco (United States)

10:40 a.m.

OC22 - Eligibility for anti-amyloid treatment in real world memory clinic populations

Anna Matton [1,2], Makrina Daniilidou [1,2], Anette Hall [3,1], Ulf Öhlund-Wistbacka [4,1], Urban Ekman [1], Anna Rennie [1], Linus Jönsson [1], Göran Hagman [4], Alina Solomon [3,1], Anna Rosenberg [3,1], Miia Kivipelto [4,1,2]

[1]Karolinska Institutet - Stockholm (Sweden), [2]FINGERS Brain Health Institute - Stockholm (Sweden), [3]University of Eastern Finland - Kuopio (Finland), [4]Karolinska University Hospital - Stockholm (Sweden)

10:55 a.m.

Coffee break and poster session

Early career investigators showcase: flash session presentations in the Poster Hall

11:25 a.m.

ORAL COMMUNICATIONS: Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease

Chair: Howard Fillit, *Alzheimer's Drug Discovery Foundation, New York (USA)*

11:30 a.m.

OC23 - Transcranial Magnetic Stimulation (TMS) for MCI: Trials using advanced stimulation and precision approaches

Joy Taylor [1], Ying-Hui Chou [2], Andreana Benitez [3]

[1]Stanford University - Palo Alto (United States), [2]University of Arizona - Tucson (United States), [3]Medical University of South Carolina - Charleston (United States)

11:45 a.m.

OC24 - Results of a 52-Week Phase II Trial of Repetitive TMS of the Default Mode Network in Mild to Moderate Alzheimer's Disease

Elias Casula[1], Sonia Bonni[1], Michele Maiella[1], Martina Assogna[1], Emiliano Santarnecchi[2], Allessandro Martorana[3], Giacomo Koch[3]

[1]Santa Lucia Foundation IRCCS - Rome (Italy), [2]Massachusetts General Hospital - Boston (United States), [3]University of Rome Tor Vergata - Rome (Italy)

12:00 p.m.

LATE BREAKING COMMUNICATIONS

Chairs: Catherine Mummery, *Dementia Research Center, University College London - London (United Kingdom)*, Suzanne Schindler, *Washington University in St. Louis - St. Louis (United States)*

12:00 p.m.

LB12 - A Phase 1 Clinical Trial of BDNF Gene Therapy in Alzheimer's Disease and MCI

Brad Elder [1], Krys Bankiewicz [1], Russell Lonser [1], Gabriel Leger [2], Doug Scharre [1], Susan Landau [3], William Jagust [3], Mark Tuszynski[2]

[1]Ohio State University - Columbus (United States), [2]UC San Diego - La Jolla (United States), [3]UC Berkeley - Berkeley (United States)

12:15 p.m.

LB13 - Plasma pTau217 alone is not enough for staging Alzheimer's disease

James D Doecke [1], Edwin Stage [2], Christopher J Fowler [3], Vincent Dore [4], Nils Boehm [2], Christoph Kleinert [2], Azadeh Feizpour [5], Larry Ward [6,7,8], Jurgen Mejan-Fripp [1], Colin L Masters [3], Christopher Rowe [5], Anthony Bannon [2]

[1]Australian E-Health Research Centre, CSIRO - Herston (Australia), [2]Abbvie Inc - North Chicago (United States), [3]The Florey Institute of Neuroscience and Mental Health - Parkville (Australia), [4]Australian E-Health Research Centre, CSIRO - Melbourne (Australia), [5]Department of Molecular Imaging & Therapy, Austin Health - Melbourne (Australia), [6]Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) - Parkville (Australia), [7]Australian Dementia Network (ADNeT) - Parkville (Australia), [8]Faculty of Medicine, Dentistry and Health Sciences - Parkville (Australia)

All scientific sessions will be held in the Auditorium

Thursday, OCTOBER 31

12:30 p.m. Lunch and poster session

1:30 p.m. **LATE BREAKING COMMUNICATIONS**

Chairs: Catherine Mummery, *Dementia Research Center, University College London - London (United Kingdom),* Suzanne Schindler, *Washington University in St. Louis - St. Louis (United States)*

1:30 p.m. **LB14 - Not all plasma tau biomarkers are equally associated with tau tangles and affected by co-pathologies**

Laia Montoliu-Gaya [1], Elizabeth Valeriano-Lorenzo [2], Nicholas J Ashton [1], Alberto Rábano [2], Henrik Zetterberg [1], Johan Gobom [1], Kaj Blennow [1], Pascual Sánchez-Juan [2]

[1]University of Gothenburg - Mölndal (Sweden), [2]Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII - Madrid (Spain)

1:45 p.m. **LB15 - Study design for TRAILRUNNER-ALZ 3: A double-blind, placebo-controlled, Phase 3 clinical trial investigating subcutaneous remternetug in early Alzheimer's disease**

Kevin Biglan [1], Erum Rizvi [1], Tongrong Wang [1], Matthew Hufford [1], Mausumi Lidogoster [1], Christina Dickson [1], Susan Warner [1], Ivelina Gueorguieva [1], Yvonne Vandenburg [1], Matan Dabora [1]

[1]Eli Lilly and Company - Indianapolis (United States)

2:00 p.m. **KEYNOTE 4**

Fluid biomarkers in research, clinical trials, and clinical practice

Introduction: Mike Weiner, *UCSF, San Francisco (United States)*

Suzanne Schindler, *Washington University in St. Louis - St. Louis (United States)*

2:25 p.m. **ORAL COMMUNICATIONS**

Chairs: Jacques Touchon, *Montpellier University - Montpellier (France)*, Christopher Van Dyck, *Yale School of Medicine, New Haven (United States)*

2:25 p.m. **OC25 - TargetTau-1: A phase 2 trial designed to evaluate the efficacy, safety, and tolerability of the anti-MTBR tau monoclonal antibody, BMS-986446, in patients with early Alzheimer's disease**

Oskar Hansson [1], Anja Kahl [2], Grigor Abelian [2], Mark Donovan [2], Manuj Ahuja [2], David Watson [3], Rik Ossenkoppele [4], Takeshi Iwatsubo [5], Christopher Van Dyck [6]

[1]Lund University and Skåne University Hospital - Malmö (Sweden), [2]Bristol Myers Squibb, Princeton (United States), [3]Alzheimer's Research and Treatment Center, Wellington (United States), [4]Lund University, Skåne University Hospital - Malmö (Sweden), [5]University of Tokyo - Tokyo (Japan), [6]Yale School of Medicine, New Haven (United States)

2:40 p.m. **OC26 - A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial**

Richard Joules [1], Robin Wolz [1], Lynne Hughes [1,2], Richard Mohs [2], John Dwyer [2], Douglas Beauregard [2]

[1]IXICO - London (United Kingdom), [2]Global Alzheimer's Platform Foundation - Washington (United States)

2:55 p.m. **OC27 - Results of SIGNAL-AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of pepinemab, SEMA4D antibody to block reactive astrogliosis, in patients with mild AD dementia**

Elizabeth Evans [1], Eric Siemers [1], Terrence Fisher [1], Megan Boise [1], Amber Foster [1], John Leonard [1], Vikas Mishra [1], Crystal Mallow [1], Raymond Turner [2], John Huffaker [3], Anton Porsteinsson [4], Maurice Zauderer [1]

[1]Vaccinex - Rochester (United States), [2]Georgetown University - Washington (United States), [3]Neuropsychiatric Research Center of Southwest Florida - Stuart (United States), [4]University of Rochester - Rochester (United States)

3:10 p.m. **LATE BREAKING COMMUNICATIONS**

Chairs: Alireza Atri, *Banner Health - Phoenix (United States)*, Reisa Sperling, *Massachusetts General Hospital / Harvard Medical School - Boston (United States)*

3:10 p.m. **LB16 - The anatomy of tau PET associations with biomarkers and cognitive decline in the A4 study**

Justin Sanchez [1], Michael Properzi [1], Aaron Schultz [1], Emma Thibault [1], Michelle Farrell [1], Alex Becker [1], Bernard Hanseeuw [1], Paul Aisen [2], Rema Raman [2], Michael Donohue [2], Reisa Sperling [1], Keith Johnson [1]

[1]Massachusetts General Hospital / Harvard Medical School - Boston (United States), [2]University of Southern California - Los Angeles (United States)

Thursday, OCTOBER 31

3:25 p.m.

LB18 - AI-derived prognostic covariates enhance the precision of lecanemab efficacy assessments and optimize Alzheimer's disease clinical trials

Viswanath Devanarayan [1], Yuanqing Ye [1], Liang Zhu [1], Lu Tian [2], Lynn Kramer [1], Michael Irizarry [1], Shobha Dhadda [1]
[1]Eisai Inc. - Nutley (United States), [2]Stanford University - Stanford (United States)

3:40 p.m.

LB19 - Comparison of one-step and two-step workflows for determining phosphorylated tau 217 cut-off points for amyloid positivity in different subgroups

Jehyun Ahn [1], Eun Hye Lee [2], Heejin Yoo [1], Boram Park [3], Henrik Zetterberg [4, 5, 6, 7], Kaj Blennow [4, 5, 8, 9], Fernando Gonazalez-Ortiz [4, 5], Nicholas J Ashton [4, 10, 11, 12], Kyunga Kim [3, 13, 14], Sang Won Seo [1, 2, 14, 15]
[1]Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul (Korea, Republic of), [2]Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of), [3]Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul (Korea, Republic of), [4]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Goteborg (Sweden), [5]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Goteborg (Sweden), [6]Department of Neurodegenerative Disease, UCL Institute of Neurology, London (United Kingdom), [7]UK Dementia Research Institute at UCL, London (United Kingdom), [8]Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris (France), [9]Neurodegenerative Disorder Research Center, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei (China), [10]King's College London, Institute of Psychiatry, London (United Kingdom), [11]NIHR Biomedical Research Centre for Mental Health London (United Kingdom), [12]Centre for Age-Related Medicine, Stavanger (Norway), [13]Department of Data Convergence and Future Medicine, Seoul (Korea, Republic of), [14]Department of Digital Health, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul (Korea, Republic of), [15]Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul (Korea, Republic of)

3:55 p.m.

Coffee break and poster session

Early career investigators showcase: flash session presentations in the Poster Hall

4:25 p.m.

ORAL COMMUNICATIONS

Chairs: Frank Jessen, *University of Cologne - Cologne (Germany)*, Lon Schneider, *Keck School of Medicine, USC, Los Angeles (United States)*

4:25 p.m.

OC28 - Design and Rationale of cAPPricorn-1, A Phase 2 Study of Mivelsiran in Patients with Cerebral Amyloid Angiopathy

Jin-Moo Lee [1], Ellis S. Van Etten [2], M. J. P. Van Osch [2], Catharina J. M. Klijn [3], Alexandre Sostelly [4], Sasikiran Goteti [4], Farshid Sepehrband [5], Andreja Avbersek [5], Robert W. Deering [4], Neal S. Parikh [4], Steven M. Greenberg [6]
[1]Washington University School of Medicine - St. Louis (United States), [2]Leiden University Medical Center - Leiden (Netherlands), [3]Radboud University Medical Centre - Nijmegen (Netherlands), [4]Alnylam Pharmaceuticals, Inc. - Cambridge (United States), [5]Regeneron Pharmaceuticals, Inc. - Tarrytown (United States), [6]Harvard Medical School, Massachusetts General Hospital - Boston (United States)

4:40 p.m.

OC29 - Use of plasma p-tau217 to identify Aβ-positive cognitively unimpaired participants for clinical trials: A multicohort study

Gemma Salvadó [1], Shorena Janelidze [1], Divya Bali [1], Joseph Therriault [2], Tammie L.s. Benzinger [3], Kaj Blennow [4], Pedro Rosa-Neto [5], Sterling C Johnson [6], Christopher C Rowe [7], Sylvia Villeneuve [8], Cliff R Jack Jr. [9], Marc Suárez-Calvet [10], Suzanne E Schindler [3], Rik Ossenkoppele [1, 11], Oskar Hansson [1]
[1]Lund University - Lund (Sweden), [2]McGill University - Montréal (Canada), [3]Washington University School of Medicine and Knight Alzheimer Disease Research Center - St. Louis (United States), [4]Sahlgrenska University Hospital - Mölndal and University of Gothenburg - Gothenburg (Sweden), [5] McGill University - Montréal (Canada), [6]University of Wisconsin-Madison and Wisconsin Alzheimer's Institute - Madison (United States), [7]CSIRO Health and Biosecurity- Victoria and Austin Health - Melbourne (Australia), [8]Douglas Mental Health University Institute - Montréal (Canada), [9]Mayo Clinic and Foundation - Rochester (United States), [10]BarcelonaBeta Brain Research Center and Hospital del Mar Research Institute - Barcelona (Spain), [11] UMC and Vrije Universiteit Amsterdam - Amsterdam (Netherlands),

4:55 p.m.

OC30 - PreventE4: a double-blind placebo-controlled clinical trial testing high dose DHA in APOE4 carriers before the onset of dementia

Hussein Yassine [1], Michael Harrington [1], Jackson Park [1], Isabella Cordova [1], Naoko Kono [1], Wendy Mack [1], Meredith Braskie [1], Lon Schneider [1]
[1]USC - Los Angeles (United States)

All scientific sessions will be held in the Auditorium

Thursday, OCTOBER 31

5:10 p.m. **LATE BREAKING SYMPOSIUM 3: Results from TOGETHER, a double-blind, placebo-controlled Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal–mild AD**

Chair: Randall J Bateman, *Washington University School of Medicine - St Louis (United States)*

Presentation 1: Identification and development of bepranemab, an antibody targeting the mid-region of tau
Martin Citron, *UCB - Braine-l'Alleud (Belgium)*

Presentation 2: Results from TOGETHER, a Phase II study of bepranemab in prodromal–mild AD
Matthew E Barton, *UCB - Raleigh (United States)*

Presentation 3: Bepranemab, the tau mid-region hypothesis, and future implications
Randall J Bateman, *Washington University School of Medicine - St Louis (United States)*

5:50 p.m. End of the Conference Day

Friday, NOVEMBER 1

7:30 a.m. **POSTER WALKING TOUR**

8:.30 a.m. **LATE BREAKING COMMUNICATIONS**

Chairs: Giovanni Frisoni, *UniGE - Geneva (Switzerland)*, Henrik Zetterberg, *University of Lund - Lund (Sweden)*

8:30 a.m. **LB21 – The Role of pTau217 in Integrated Amyloid and Tau Staging: Implications for Cognitive Trajectories in Alzheimer's Disease**

Daeun Shin [1], Hyemin Jang [2], Kyoungmin Kim [1], Heejin Yoo [1], Henrik Zetterberg [3,4,5,6], Kaj Blennow [3,4,7,8], Fernando Gonzalez-Ortiz [3,4], Nicholas J. Ashton [4,9,10,11], Theresa A. Day [12], Eun Hye Lee [1], Jihwan Yun [13], Duk L Na [14], Hee Jin Kim [14,15,16,17], Sung Hoon Kang [18], Ko Woon Kim [19], Si Eun Kim [20], Yeo Jin Kim [21], Yeshin Kim [22], Jaeho Kim [23], Chi-Hun Kim [24]

[1]Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), [2]Seoul National University Hospital, Seoul National University College of Medicine - Seoul (Korea, Republic of), [3]University of Gothenburg - Gothenburg (Sweden), [4]Sahlgrenska University Hospital - Gothenburg (Sweden), [5]UCL Institute of Neurology - London (United Kingdom), [6]UK Dementia Research Institute at UCL - London (United Kingdom), [7]ICM, Pitié-Salpêtrière Hospital, Paris (France), [8]University of Science and Technology of China and First Affiliated Hospital of USTC - Hefei (China), [9]King's College London, London (United Kingdom), [10]NIHR Biomedical Research Centre for Mental Health London (United Kingdom), [11]Stavanger University Hospital - Stravanger (Norway), [12]Eli Lilly and Company, Indianapolis (United States), [13]Soonchunhyang University Bucheon Hospital - Gyeonggi-Do` (Korea, Republic of), [14]Samsung Medical Center, Seoul (Korea, Republic of), [15]Alzheimer's Disease Convergence Research Center, Samsung Medical Center - Seoul (Korea, Republic of), [16]SAIHST, Sungkyunkwan University - Seoul (Korea, Republic of), [17]Neuroscience Center, Samsung Medical Center - Seoul (Korea, Republic of), [18]Korea University Guro Hospital, Seoul (Korea, Republic of), [19]Jeonbuk National University Jeonju (Korea, Republic of), [20]Inje University College of Medicine, Haeundae Paik Hospital - Busan (Korea, Republic of), [21]Kangdong Sacred Heart Hospital, Seoul (Korea, Republic of), [22]Kangwon National University Hospital, Chuncheon (Korea, Republic of), [23]Dongtan Sacred Heart Hospital, Hwaseong (Korea, Republic of), [24]Hallym University Sacred Heart Hospital - Anyang (Korea, Republic of)

8:45 a.m. **LB22 – Timing of changes in Alzheimer's disease plasma biomarkers using amyloid and tau PET clocks**

Marta Milà-Alomà [1], Duygu Tosun [1], Suzanne E. Schindler [2], Yan Li [2], Kellen K. Petersen [2], Leslie M. Shaw [3], Jeffrey L. Dage [4,5], Ziad S. Saad [6], David L. Raunig [7], Lei Du-Cuny [8], Carrie E. Rubel [9], Janaky Coomaraswamy, [7], Erin G. Rosenbaugh [10], Anthony W. Bannon [11], William Z. Potter [12]

[1]University of California San Francisco - San Francisco (United States), [2]Washington University School of Medicine - St. Louis (United States), [3]Perelman School of Medicine, University of Pennsylvania - Philadelphia (United States), [4]Department of Neurology, Indiana University School of Medicine - Indianapolis (United States), [5]Stark Neurosciences Research Institute - Indianapolis (United States), [6]Johnson and Johnson Innovative Medicine - San Diego (United States), [7]Takeda Pharmaceutical Company Ltd. - Cambridge (United States), [8]AbbVie - Rheinland-Pfalz (United States), [9]Biogen - Cambridge (United States), [10]Foundation for the National Institutes of Health - North Bethesda (United States), [11]AbbVie - North Chicago (United States), [12]Philadelphia (United States)

9:00 a.m. **LB23 - Effects of initial medial temporal lobe tauopathy and amyloid-beta on the timeline to caTAUstrophe**

Michelle E. Farrell [1], Emma G. Thibault [1], Grace Del Carmen Montenegro [1], Jessie Fanglu Fu [1], Julie C. Price [1], Bernard J. Hanseeuw [1], John R. Sims [2], Roy Yaari [2], Sergey Shcherbinin [2], Karen C. Holdridge [2], Rema Raman [3], Michael C. Donohue [3], Paul Aisen [3], Reisa A. Sperling [1], Keith A. Johnson [1]

[1]Massachusetts General Hospital, Harvard Medical School - Boston (United States), [2]Eli Lilly and Company - Indianapolis (United States), [3]Keck School of Medicine, University of Southern California - Los Angeles (United States)

9:15 a.m. **LB24 - Updating Diagnostic Criteria for Alzheimer's Disease: Recommendations of the International Working Group (IWG)**

Howard Feldman [1], Nicolas Villain [2], Giovanni Frisoni [3], Alexis Moscoso [4], Bruno Dubois [2]

[1]Department of Neurosciences, University of California San Diego, San Diego (United States), [2]Sorbonne Université, INSERM U1127, CNRS 7225, Institut du Cerveau - Paris (France), [3]UniGE - Geneva (Switzerland), [4]Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden)

All scientific sessions will be held in the Auditorium

Friday, NOVEMBER 1

9.30 a.m.

ORAL COMMUNICATIONS

Chairs: Karim Bennys, *Montpellier University Hospital - Montpellier (France)*, Rema Raman, ATRI, *University of Southern California - San Diego (United States)*

9.30 a.m.

OC31 - The Alzheimer's Tau Platform (ATP) and Progressive Supranuclear Palsy Trial Platform (PTP): a combination amyloid and tau therapy trial for early AD, and a tau monotherapy trial for mild-moderate PSP

Adam Boxer [1], Keith Johnson [2], Irene Litvan [3], Julio Rojas [1], Anne-Marie Wills [2], Reisa Sperling [2], Paul Aisen [4], Ron Petersen [5], Randall Bateman [6], Chihiro Sato [6], Michael Donohue [4], Rema Raman [4], Eden Barragan [3]

[1]University of California, San Francisco - San Francisco (United States), [2]MGH - Boston (United States), [3]UCSD - San Diego (United States),[4]USC - San Diego (United States), [5]Mayo Clinic - Rochester (United States), [6]Washington University - St. Louis (United States)

9.45 a.m.

OC32 - An evaluation of the impact of a multi-analyte blood biomarker test for evaluating cognitive impairment: Results of the QUIP II clinical utility study

Joel Braunstein [1], Demetrius Maraganore [2], Robert Carlile [3], Kim Johnson [4], David Merrill [5], Darren Gitelman [6], Kenneth Sharlin [7], Lawren Vandevrede [8], Kristi George [9], Jimin Wang [10], Tim West [1], Philip Verghese [1], Leslie Jacobs [1], Mark Monane [1]

[1]C2N Diagnostics, LLC - St Louis (United States), [2]Tulane University - New Orleans (United States), [3]Palmetto Primary Care Physicians - Summerville (United States), [4]Duke University - Durham (United States), [5]Pacific Brain Health Center - Santa Monica (United States), [6]Advocate Lutheran General Hospital - Park Ridge (United States), [7]Sharlin Health and Neurology - Ozark (United States), [8]University of California - San Francisco (United States), [9]JWM Neurology - Indianapolis (United States), [10]Stat4ward - Pittsburgh (United States)

10.00 a.m.

OC33 - The role of trials in health-economic evaluation of anti-amyloid treatment for early Alzheimer's disease

Ron Handels [1], Anders Wimo [2], Bengt Winblad [2], Linus Jönsson [2]

[1]Maastricht University - Maastricht (Netherlands), [2]Karolinska Institutet - Stockholm (Sweden)

10.15 a.m.

OC34 - An ultra-fast MRI protocol to aid diagnosis and treatment of Alzheimer's disease

Miguel Rosa-Grilo [1], Haroon R Chughtai [2, 3], Dave Thomas [1, 4], Christopher R S Belder [1], Millie Beament [1], Nicholas Magill [5], Moona Mazher [2], Emma Lim [6, 7], Dermot Mallon [7], H Rolf Jäger [7], Geoff J M Parker [2, 8, 9], Daniel C Alexander [2], Nick Fox [1], Cath Mummery [1], Frederik Barkhof [1, 10]

[1]Dementia Research Centre, UCL Queen Square Institute of Neurology - London (United Kingdom), [2]Centre for Medical Image Computing, Medical Physics & Biomedical Engineering, UCL - London (United Kingdom), [3]Advanced Research Computing Centre, UCL - London (United Kingdom), [4]Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology - London (United Kingdom), [5]Department of Medical Statistics, London School of Hygiene and Tropical Medicine - London (United Kingdom), [6]Department of Imaging, Imperial College Healthcare NHS Trust - London (United Kingdom), [7]Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurger - London (United Kingdom), [8]NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology - London (United Kingdom), [9]Bioxydyn Limited - Manchester (United Kingdom), [10]Department of Radiology and Nuclear Medicine, Amsterdam UMC - Amsterdam (Netherlands)

10.30 a.m.

Coffee break and poster session

Early career investigators showcase: flash session presentations in the Poster Hall

Friday, NOVEMBER 1

11:00 a.m.

LATE BREAKING ORAL COMMUNICATIONS

Chairs: Anton P. Porsteinsson, *University of Rochester - Rochester (United States)*, Charlotte Teunissen, *Amsterdam UMC, location Vrije Universiteit - Amsterdam (Netherlands)*

11:00 a.m.

LB25 - Plasma biomarker data indicates clinical activity of neflamapimod in dementia with Lewy bodies (DLB) is mediated through effects on the basal forebrain cholinergic system

John Alam [1], Charlotte Teunissen [2]

[1]CervoMed Inc. - Boston (United States), [2]Amsterdam UMC, location Vrije Universiteit - Amsterdam (Netherlands)

11:15 a.m.

LB26 –Sex Moderates Relationships Between P-Tau217 and Longitudinal Tau-PET: Findings from the A4 and LEARN studies

Gillian Coughlan [1], Hannah Klinger [1], Mabel Seto [1], Colin Birkenbihl [1], Michelle Farrell [1], Robert Rissman [2], Michael Properzi [1], Diana Townsend [1], Hyun-Sik Yang [1], Keith Johnson [1], Oliver Langford [2], Michael Donohue [2], Reisa Sperling [1], Rachel Buckley [1]

[1]Mass General Hospital/Harvard Medical School - Boston (United States), [2]Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)

11:30 a.m.

LB27 - Performance of the Lilly SPX P-tau217 blood-based immunoassay (LDT) in clinical validation cohort subpopulations

Michael E. Hodsdon [1], Samantha C. Burnham [1], Amanda Morris [1], Michael J. Pontecorvo [1], Rose C. Beck [1]

[1]Eli Lilly and Company - Indianapolis (United States)

11:45 p.m.

LB28 - Timing and Duration of Adverse Events During 24 Weeks of Brexpiprazole Treatment in Patients With Agitation Associated With Dementia due to Alzheimer's Disease: Results From a Randomized Trial and an Extension Trial

Anton P. Porsteinsson [1], Malaak Brubaker [2], Sanjeda R. Chumki [2], Anton M. Palma [2], David Wang [3], Zhen Zhang [2], Pedro Such [4], C. Brendan Montano [5]

[1]University of Rochester Alzheimer's Disease Care, Research and Education Program (AD-CARE) - Rochester (United States), [2]Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton (United States), [3]Lundbeck LLC - Deerfield (United States), [4]H. Lundbeck A/S - Copenhagen (Denmark), [5]Connecticut Clinical Research - Cromwell (United States)

12:00 p.m.

LATE BREAKING ROUNDTABLE: Plasma P-tau217 assays in clinical practice: Current uses and future considerations for diagnosing Alzheimer's disease

Chair: Marc Suárez-Calvet [1]

Presentation and Roundtable Discussion

Joel B. Braunstein [2], Rose Beck [3], Manu Vandijck [4], Margherita Carboni 5, Rebecca M. Edelmayer [6], Marwan Sabbagh [7], Jonathan M. Schott [8], Jim Hendrix [3]

[1]Barcelona Beta Brain Research Centre; Hospital del Mar - Barcelona (Spain), [2]C2N Diagnostics - St Louis (United States), [3]Eli Lilly and Company - Indianapolis (United States), [4]Fujirebio Europe N.V. - Gent (Belgium), [5]Roche Diagnostics International Ltd. - Rotkreuz (Switzerland), [6]Alzheimer's Association - Chicago (United States), [7]Barrow Neurological Institute - Phoenix (United States), [8]Dementia Research Centre, UCL, Queen Square Institute of Neurology - London (United Kingdom)

12:30 p.m.

Lunch break and poster sessions

1:30 p.m.

LATE BREAKING SYMPOSIUM 4: Cannabinoid based medications for neuropsychiatric symptoms in Alzheimer's dementia

Chair: Sagnik Bhattacharyya, *King's College London, London (United Kingdom)*

Presentation 1: Heterogeneity of treatment response: A post hoc analysis of clinical factors from a randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease

Krista L. Lanctot[1,2,3,4]

[1]Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto (Canada) [2]Department of Pharmacology and Toxicology, University of Toronto (Canada) [3]Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto (Canada) [4]Department of Psychiatry, Sunnybrook Health Sciences Centre Toronto (Canada)

Friday, NOVEMBER 1

Presentation 2: The THC-AD Study: The Efficacy and Safety of Dronabinol treatment for Agitation in Alzheimer's Dementia
Brent Forester
Tufts Medical Center, Tufts University School of Medicine, Boston (United States)

Presentation 3: Cannabidiol for behaviour symptoms in Alzheimer's dementia
Latha Velayudhan
King's College London, London (United Kingdom)

Presentation 4: The Use of THC and CBD in the Treatment of Agitated Persons Living with Dementia at the End of Life
Olga Brawman-Mintzer[1,2]
[1]Ralph H. Johnson VA Health Care System and [2]Medical University of South Carolina, Charleston (United States)

2:10 p.m. **ORAL COMMUNICATIONS**
Chairs: Claire Paquet, *APHP, Hospital Lariboisière Fernand Widal- Paris (France)*, Sharon Sha, *Stanford University - Palo Alto (United States)*

2:10 p.m. **OC35 - Anti-amyloid antibody preference for vascular Aβ aggregates does not explain ARIA rates**
Anna Francis [1], Angela Meunier [1], Amirah Anderson [1], Elizabeth Hennessey [1], Michael Miller [1], Cynthia Lemere [1], Dennis Selkoe [1], Andrew Stern [1]
[1]Brigham and Women's Hospital - Boston (United States)

2:25 p.m. **OC36 - Artificial Intelligence-enabled Safety Monitoring in Alzheimer's Disease Clinical Trials**
Gustavo Jimenez-Maggiora [1], Michael Donohue [1], Michael Rafii [1], Rema Raman [1], Paul Aisen [1]
[1]Keck School of Medicine of USC - San Diego (United States)

2:40 p.m. **OC37 - First-in-human AV-1980R/A tau vaccine for Alzheimer's prevention (IND 29644)**
Lon Schneider [1], Anahit Ghochikyan [2], Robert Alexander [3], Duygu Tosun-Turgut [4], Michael Agadjanyan [2]
[1]Keck School of Medicine, University of Southern California - Los Angeles (United States), [2]Institute for Molecular Medicine - Huntington Beach (United States), [3]Banner Alzheimer's Institute - Phoenix (United States), [4]University of California, San Francisco - San Francisco (United States)

2:55 p.m. **OC38 - Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker-guided diagnostics: head-to-head comparison among an Asian population**
Hyemin Jang [1], Daeun Shin [2], Heejin Yoo [2], Henrik Zetterberg [3, 4, 5, 6], Kaj Blennow [3, 7, 8, 9], Fernando Gonzalez-Ortiz [3, 4], Nicholas J. Ashton [3, 10, 11, 12], Theresa A. Day [13], Eun Hye Lee [2], Jihwan Yun [14], Duk L Na [2], Hee Jin Kim [2, 15, 16], Sung Hoon Kang [17], Jun Pyo Kim [2], Sang Won Seo [2, 15, 16]
[1]National University College of Medicine - Seoul (Korea, Republic of), [2]Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), [3]University of Gothenburg - Gothenburg (Sweden), [4]Sahlgrenska University Hospital, - Gothenburg (Sweden), [5]UCL Institute of Neurology - London (United Kingdom), [6]UK Dementia Research Institute - London (United Kingdom), [7]Sahlgrenska University Hospital - Gothenburg (Sweden), [8]ICM - Paris (France), [9] First Affiliated Hospital of USTC - Hefei (China), [10]King's College London - London (United Kingdom), [11]NIHR and NHS Foundation - London (United Kingdom), [12]Stavanger University Hospital - Stavanger (Norway), [13]Eli Lilly and Company - Indianapolis (United States), [14]Bucheon Hospital - Gyeonggi-Do (Korea, Republic of), [15]Samsung Medical Center, - Seoul (Korea, Republic of), [16]Sungkyunkwan University - Seoul (Korea, Republic of), [17]Korea University College of Medicine - Seoul (Korea, Republic of)

3:10 p.m. Coffee break and poster session

3:40 p.m. **LATE BREAKING COMMUNICATIONS**
Chairs: Francesa De Simone, *Fujirebio Diagnostics, Inc - Malvern (United States)*, Jacques Touchon, *Montpellier University - Montpellier (France)*

3:40 p.m. **LB29 - The use of plasma biomarkers for the prediction of Amyloid positivity**
Francesca I De Simone [1], Luna Buitrago [1], Natalya Benina [1], Rachel R Radwan [1], Douglas Hawkin [2], Abhay Moghekar [3], Marilyn Albert [3], Oskar Hansson [4, 5], Erik Stomrud [4, 5], Pallavi Sachdev [6], Diana Dickson [1]
[1]Fujirebio Diagnostics, Inc. - Malvern (United States), [2]Scottsdale Scientific LLC – Austin (United States), [3]Department of Neurology, Johns Hopkins School of Medicine – Baltimore (United States), [4]Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), [5]Memory Clinic, Skane University Hospital - Malmö (Sweden), [6]Eisai Inc. – Nutley (United States)

All scientific sessions will be held in the Auditorium

Friday, NOVEMBER 1

3:55 p.m.

LB30 - Amyloid modifies the association between late-life BMI and longitudinal cognition in cognitively unimpaired individuals

Wai-Ying Wendy Yau [1,2], Rema Raman [3], Shunran Wang [3], Neelum Aggarwal [4], Adam Brickman [5], Jasmeer Chhatwal [6,1,2], Petrice Cogswell [7], Jonathan Graff-Radford [7], Jay Pillai [7], Prashanthi Vemuri [7], Michael Rafii [3], Paul Aisen [3], Reisa Sperling [6,1,2], The A4 And Learn Study Teams [8]

[1]Massachusetts General Hospital - Boston (United States), [2]Harvard Medical School - Boston (United States), [3]University of Southern California - San Diego (United States), [4]Rush University Medical Center - Chicago (United States), [5]Columbia University - New York (United States), [6]Brigham and Women's Hospital - Boston (United States), [7]Mayo Clinic - Rochester (United States), [8]Alzheimer Clinical Trials Consortium

4:10 p.m.

LB31 - Retinal Hyperspectral Imaging and Blood-Based Biomarkers Demonstrate Comparable Performance for Predicting Brain Aβ Pathology: A Head-to-Head Comparison from the Bio-Hermes-001 Study

Sophie Grapentine [1], Alon Hazan [1], Eliav Shaked [1], Jennifer Giordano [1], Catherine Bornbaum [1], Doug Beauregard [2]

[1]RetiSpec - Toronto (Canada), [2]Global Alzheimer's Platform Foundation - Washington (United States)

4:25 p.m.

LB32 - Participants enrolled in the RewinD-LB clinical trial: a large cohort of patients with dementia with Lewy bodies (DLB) without temporal lobe neurodegeneration, as defined by absence of elevation in plasma ptau181

Stephen Gomperts [1], John-Paul Taylor [2], Paul Maruff [3], Gardner Amanda [4], Blackburn Kelly [4], Alam John [4], Galvin James [5]

[1]Massachusetts General Hospital - Charlestown (United States), [2]Newcastle University - Newcastle Upon Tyne (United Kingdom), [3]Cosgstate Ltd - London (United Kingdom), [4]CervoMed - Boston (United States), [5]U. of Miami Miller School of Medicine - Boca Raton (United States)

4:40 p.m.

LB33 - Variations in incidence, progression, and risk factors across mild cognitive impairment (MCI) subtypes

Chao-Yi Wu [1], Kevin Duff [2], Cierra Guerrero [2], Sarah Gothard [2], Raina Croff [2], Hiroko Dodge [1], Jeffrey Kaye [2]

[1]Massachusetts General Hospital/ Harvard Medical School - Charlestown (United States), [2]Oregon Health & Science University - Portland (United States)

4:55 p.m.

LB34 - Diagnostic accuracy and added value of [18F]APN-1607 PET in the clinical workup of patients with cognitive symptoms

Yu Jin-Tai [1], Wang Jun [2]

[1]Huashan Hospital, Fudan University - Shanghai (China), [2]Daping Hospital, Third Military Medical University - Chongqing (China)

5:10 p.m. **End of the Conference Day**

POSTER PRESENTATIONS

presented in Madrid
and available on the CTAD24
digital platform

CTAD24 POSTER LISTING

All posters are available in Pdf format at all times on the CTAD24 digital platform.

Posters presented remotely are indicated with this icon : 

From Tuesday, October 29 - 3:00 p.m. to Wednesday, October 30 - 5:00 p.m.		
POSTER SESSION 1	THEME 01: Clinical Trials: Methodology	P001 to P020 / LP001 to LP015
	THEME 02: Clinical Trials: Results	P021 to P040 / LP016 to LP024
	THEME 11: New Therapies and Clinical Trials	P042 to P062 / LP025 to LP035
	THEME 14: Beyond Amyloid and Tau	P063 to P075 / LP036 to LP041bis
	THEME 15: Clinical Trials Early Career Investigator Showcase	P076 to P078 / LP042 to LP043
From Thursday, October 31 - 7:15 a.m. to 5:00 p.m.		
POSTER SESSION 2	THEME 03: Clinical Trials: Imaging	P079 to P101 / LP044 to LP047
	THEME 04: Clinical Trials: Biomarkers including plasma	P102 to P144 / LP048 to LP077
	THEME 12: Proof of Concept/Translational research for AD Development interventions	P145 to P161 / LP078 to LP081
	THEME 15: Clinical Trials Early Career Investigator Showcase	P162 / LP082 to LP084
From Friday, November 1 - 7:15 a.m. to 5:00 p.m.		
POSTER SESSION 3	THEME 05: Clinical Trials: cognitive and functional endpoints	P163 to P177 / LP085 to LP092
	THEME 06: Cognitive assessment and clinical trials	P178 to P201 / LP093 to LP096
	THEME 07: Behavioral disorders and clinical trials	P202 to P205
	THEME 08: Health economics and clinical trials	P206 to P209 / LP097 to LP098
	THEME 09: Epidemiology and clinical trials	P210 to P220 / LP099 to LP103
	THEME 10: Animal Model	P221 to P225
	THEME 13: Digital health/E-trials	P226 to P249 / LP104 to LP111
	THEME 15: Clinical Trials Early Career Investigator Showcase	P250 to P253 / LP112

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

POSTER SESSION 1: From Tuesday, October 29 - 3:00 p.m. to Wednesday, October 30 - 5:00 p.m.

THEME 01: Clinical Trials: Methodology

P001 **Screening for Cognitive Impairment across Four Different European Dementia Cohorts Using an Automatic Digital Cognitive Assessment**
Johannes Tröger [1], Elisa Mallick [1], Nicklas Linz [1], Gonzalo Sánchez Benavides [2], Inez Ramakers [3], Silke Kern [4], Ingmar Skoog [4], Stefanie Köhler [5], Stefan Teipel [5], Alexandra König [1]
[1]ki elements GmbH - Saarbrücken (Germany), [2]BarcelonaBeta Brain Research Center (BBRC), Hospital del Mar Research Institute - Barcelona (Spain), [3]Maastricht University Medical Center (MUMC+) - Maastricht (Netherlands), [4]Institute of Neuroscience and Physiology at the Sahlgrenska Academy University of Gothenburg - Gothenburg (Sweden), [5]Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) - Rostock (Germany)

P002 **Increasing statistical power of early Alzheimer's disease clinical trials with the AD-PxTM prognostic model**
Angela Tam [1], César Laurent [1], Christian Dansereau [1]
[1]Perceiv AI - Montreal (Canada)

P003 **Clinical Trials in Chronic Traumatic Encephalopathy: are we there yet?**
Charles Bernick [1], Guogen Shan [2], Dawn Matthews [3], Aaron Ritter [4]
[1]Cleveland Clinic - Las Vegas (United States), [2]University of Florida - Gainesville (United States), [3]ADMDx - Chicago (United States), [4]Hoag Medical Center - Newport Beach (United States)

P004 **Storyteller as a Recruitment and Pre-Screening tool for Alzheimer's Disease Clinical Trials**
Sarah Hollingshead [1], Jeffrey Norton [1], Isabella Hernandez [1], Jack Weston [2], Emil Fristed [2], Caroline Skirrow [2]
[1]Charter Research - The Villages (United States), [2]Novoic Ltd - London (United Kingdom)

P005 **Novel pilot Phase 1 clinical trial with PV-1950R/A vaccine for Lewy Body Dementia (LBD)**
James Galvin [1], Michael Agadjanyan [2]
[1]University of Miami Miller School of Medicine - Boca Raton (United States), [2]Institute for Molecular Medicine - San Diego (United States)

P006 **Key stakeholder engagement and protocol development for the IHI-funded public-private partnership project PREDICTOM**
Zunera Khan [1], Anna-Katherine Brem [1], Mark Ashworth [1], Nick Ashton [1], Sigurd Brandt [2], Anne Corbett [3], Ellie Pickering [3], Ana Diaz [4], Holger Fröhlich [5], Martha Therese Gjestsen [6], Gaby Marquardt [7], Matthias Müllenborn [8], Spiros Nikolopoulos [9], Timo Schirmer [10], Dag Aarsland [11]
[1]IOPPN, King's College London - London (United Kingdom), [2]GN Hearing - Copenhagen (Denmark), [3]University of Exeter - London (United Kingdom), [4]Alzheimer's Europe - Luxembourg (Luxembourg), [5]Fraunhofer Institute for Algorithms and Scientific Computing SCAI - Bonn (Germany), [6]Stavanger Hospital - Stavanger (Norway), [7]Fraunhofer Institute for Algorithms and Scientific Computing SCAI - Erlangen (Germany), [8]Novo Nordisk - Copenhagen (Denmark), [9]CERTH - Thessaloniki (Greece), [10]GE Healthcare - Greater Munich (Germany), [11]IOPPN - London (United Kingdom)

P007 **Using plasma pTau217 ratio to forecast longitudinal progression substantially increases the efficiency of AD clinical trials**
Viswanath Devanarayan [1], Pallavi Sachdev [1], Arnaud Charil [1], Yuanqing Ye [1], Todd Nelson [1], Harald Hampel [1], Lynn Kramer [1], Shobha Dhadda [1], Michael Irizarry [1]
[1]Eisai Inc. - Nutley (United States)

P008 **Utilizing a Patient Burden Scoring Tool to Improve the Patient and Caregiver Experience in Clinical Research in Patients with Alzheimer's Disease and Other Forms of Dementia**
Jessica Sheldon [1], Ana Manera [2], Andreas Lysandropoulos [3]
[1]Parexel - Boston (United States), [2]Parexel - Quebec (Canada), [3]Parexel - Brussels (Belgium)

P009 **Assessing the feasibility of implementing blood-based biomarkers as confirmatory diagnostic tools for early Alzheimer's disease in real-world clinical practice: a prospective, multi-clinic implementation science and observational study**
Leah Zullig [1], Jo Vandercappellen [2], Marwan N Sabbagh [3], Soeren Mattke [4], Harald Hampel [2], Richard Batrla [2], Daryl Jones [2]
[1]Department of Population Health Sciences, Duke University School of Medicine - Durham, (United States), [2]Eisai Inc., Nutley - New Jersey (United States), [3]Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center - Phoenix (United States), [4]Center for Economic and Social Research, University of Southern California - Los Angeles (United States)

P010 **A new precision-prevention approach combining lifestyle changes and metformin repurposing for the prevention of cognitive decline: MET-FINGER trial protocol and update**
Alina Solomon [1,2,3], Mariagnese Barbera [1,2], Dinithi Perera [2,4], Arzish Haqqee [2], Jenni Lehtisalo [1,5], Malin Aspö [3,6], Mary Cross [2], Celeste De Jager [2], Emanuela Falaschetti [2], Naomi Friel [2], Jack Message [2], Geraint Price [2], Charlotta Thunborg [3,6], Francesca Mangialasche [3,4], Lefkos Middleton [2,7], Tiia Ngandu [5,3], Miia Kivipelto [3,6,2,4]
[1]University of Eastern Finland - Kuopio (Finland), [2]Imperial College London - London (United Kingdom), [3]Karolinska Institutet - Stockholm (Sweden), [4]FINGERS Brain Health Institute - Stockholm (Sweden), [5]The Finnish Institute for Health and Welfare - Helsinki (Finland), [6]Karolinska University Hospital - Stockholm (Sweden), [7]Imperial College Healthcare NHS Trust Hospitals - London (United Kingdom)

P011 **Evidence-Based Reporting of Ethnicity in Clinical Trials**
Zunera Khan [1], Daniel Kramarczyk [2], Miguel Vasconcelos Da Silva [2], Kamara Mcleish Israel [2], Dag Aarsland [2], Clive Ballard [3]
[1]Psychological Medicine - London (United Kingdom), [2]Psychological Medicine - 6 De Crespigny Park, London (United Kingdom), [3]University of Exeter - Exeter (United Kingdom)

POSTER PRESENTATIONS

P012 **Diversity in a Registrational Trial for AriBio's AR1001 for Treatment of Early Alzheimer's Disease**
Sharon Sha [1], Yaneicy Gonzalez [2], Marshall Nash [3], James Rock [4], Fred Kim [4], Adam Schindler [4], Tianyang Xi [4], Jai Jun Choung [4]
[1]Neurology & Neurological Sciences, Stanford University - Palo Alto (United States), [2]Verus Clinical Research Corp - Miami (United States), [3]Alcanza Research Site Network-NeuroStudies - Decatur (United States), [4]AriBio Co., Ltd. - San Diego (United States)

P013 **Estimating the benefits of pre-screening Alzheimer's trials using blood-based biomarkers and digital cognitive assessments**
Nicklas Linz [1], Raphael Ullmann [2], Johannes Tröger [1], Alexandra König [1], Ruth Croney [3], Tobias Bittner [4], Thanneer Perumal [2]
[1]ki:elements GmbH - Saarbrücken (Germany), [2]Roche Pharma Research and Early Development, Roche Innovation Center Basel - Basel (Switzerland), [3]Roche Products Ltd - Welwyn Garden City (United Kingdom), [4]F. Hoffmann-La Roche Ltd - Basel (Switzerland)

P014 **Comparison of the screen failure rate in Alzheimer's clinical trials of immunotherapies between the clinical research center of Toulouse and the overall rate over the past 5 years.**
Delphine Pennetier [1], Davide Angioni [1], Isabelle Carrie [1], Nathalie Sastre [1], Julien Delrieu [1], Bruno Vellas [1], Pierre Jean Ousset [1]
[1]Centre de Recherche Clinique du Gerontopole, IHU Healthage - Toulouse (France)

P015 **Comparing In-study Performance of Experienced and Naive Raters in Early AD Clinical Trials**
Xingmei Wang [1], Alan Kott [2], David Miller [1]
[1]Signant Health - Blue Bell, Pa (United States), [2]Signant Health - Prague (Czech Republic)

P016 **Automatic Screening for CDR Stages in the Swedish H70 Birth Cohort Using a Digital Speech Biomarker for Cognition SB-C**
Elisa Mallick [1], Fredrik Öhman [2], Nicklas Linz [1], Alexandra König [1], Michael Schöll [2], Silke Kern [2], Johannes Tröger [1], Ingmar Skoog [2]
[1]ki elements GmbH - Saarbrücken (Germany), [2]Institute of Neuroscience and Physiology at the Sahlgrenska Academy University of Gothenburg - Gothenburg (Sweden)

P017 **Enhancing Clinical Trial Efficiency in Alzheimer's Disease: An Application of Prognostic Scoring Adjustments to Address Heterogeneity**
Harry Parr [1], Jeffrey Lin [2], Doug Thompson [1], Dave Inman [1], Aris Perperoglou [1]
[1]GSK - London (United Kingdom), [2]GSK - Philadelphia (United States)

P018 **Impact of Travel Distance and Participant Age on Potential Alzheimer's Disease Trial Participant Attendance and Clinical Trial Eligibility**
Sarah Starling [1], Ashli Pratt [2], Adam Rosen [2], Sophie Barr [2], Bryanna Billy [2], Gaby Munoz [2], Mark Rapp [2]
[1]Adams Clinical - Watertown (United States), [2]Berman Clinical - New York (United States)

P019 **Integrating a Speech-based Prescreening Tool in Central Recruitment Strategies for Alzheimer's Disease Clinical Trials: A Pilot Study**
Caroline Skirrow [1], Allan Block [2], Nicole Hank [2], Jack Weston [1], Emil Fristed [1], James Rock [3]
[1]Novoic Ltd - London (United Kingdom), [2]Perseverance Research Center - Scottsdale, Az (United States), [3]AriBio - San Diego, Ca (United States)

P020 **Impact of screening call duration on initial evaluation attendance rate for Alzheimer's Disease drug trials**
Yu-Jay Huoh [1], Brenda Martinez [1], Sydney Hopkins [1], Elizabeth Sosa [1], Jade Sanchez [1], Jennifer Mitolo [1], Tara Parnitvithikul [1], Elly Lee [1], Ralph Lee [1]
[1]Irvine Clinical Research - Irvine (United States)

LP001 **Frequency of SAE and mortality rate in Alzheimer's Disease (AD) clinical trials: Data from Medical and Statistical reports from US FDA including seven approved medications consisting of a total database of 19,921 Subjects**
Anshu Arora [1], Arun Arora [1], Arif Khan [1]
[1]Northwest Clinical Research Center - Bellevue (United States)

LP002 **The importance of rigorous data quality assurance and management in clinical studies of the AI era: The innovative AI-Mind Study**
Vebjørn Andersson [1], Christoffer Hatlestad-Hall [1], Ainar Drews [2], Hanna Renvall [3,4], Fernando Maestú [5,6], Camillo Marra [7,8], Ira Hebold Haraldsen [1], Paolo Maria Rossini [9]
[1]Oslo University Hospital - Oslo (Norway), [2]University of Oslo - Oslo (Norway), [3]Helsinki University Hospital - Helsinki (Finland), [4]Aalto University - Helsinki (Finland), [5]Universidad Complutense Madrid - Madrid (Spain), [6]San Carlos University Hospital - Madrid (Spain), [7]Università Cattolica del Sacro Cuore - Rome (Italy), [8]Fondazione Policlinico Universitario Agostino Gemelli IRCCS, - Rome (Italy), [9]IRCCS San Raffaele Pisana - Rome (Italy)

LP003 **GAN-synthesized resting-state EEG and its clinical relevance in dementia studies**
Vebjørn Andersson [1], Christoffer Hatlestad-Hall [1], Hanna Renvall [2], Fernando Maestú [3], Camillo Marra [4], Paolo Maria Rossini [5], Anis Yazidi [6], Ira H. Haraldsen [1], Ramesh Upreti [1]
[1]Oslo University Hospital - Oslo (Norway), [2]Helsinki University Hospital - Helsinki (Finland), [3]Universidad Politécnicade Madrid - Madrid (Spain), [4]Università Cattolica del Sacro Cuore - Milan (Italy), [5]the Scientific Institute for Research, Hospitalization and HealthCare - Rome (Italy), [6]Oslo Metropolitan University - Oslo (Norway)

LP004 **SHIMMER: Baseline Data and Early Lessons from the Ongoing Phase 2 Signal-finding Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies (DLB)**
James Galvin [1], Magdalena Tolea [1], Jennifer Iaci [2], Anthony Caggiano [2], Michael Grundman [3]
[1]Comprehensive Center for Brain Health, Dept of Neurology, University of Miami Miller School of Medicine - Miami (United States), [2]Cognition Therapeutics - Purchase (United States), [3]Global R&D Partners - San Diego (United States)

LP005 **Clinical Trial Enrichment Strategy for Participant Selection in the Phase 3 HOPE study of Alzheimer's disease: Progress towards personalized medicine**
Lily Lee [1], Celine Houser [1], Alex Konisky [1], Evan Hempel [1], Chandran Seshagiri [1], Mihaly Hajos [1], Christian Howell [1], Ralph Kern [1]
[1]Cognito Therapeutics - Cambridge, Ma (United States)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

LP007 **International Registry for Alzheimer's Disease and Other Dementias (InRAD): Application of longitudinal practice-based data to augment and conduct clinical trials in early-stage Alzheimer's disease**
Robert Perneczky [1,2,3], Johan Van Beek [4], Robert Hyde [4], Ignacio Illán-Gala [5], Frank Jessen [6,7]
[1]Department of Psychiatry, LMU Hospital, LMU Munich - Munich (Germany), [2]German Center for Neurodegenerative Diseases - Munich (Germany), [3]University of Sheffield, Department of Neurosciences - Sheffield (United Kingdom), [4]TW1 Healthcare Consulting Ltd. - London (United Kingdom), [5]Hospital de La Santa Creu i Sant Pau, Department of Neurology, Memory Unit - Barcelona (Spain), [6]Department of Psychiatry, University of Cologne - Cologne (Germany), [7]German Center for Neurodegenerative Diseases - Cologne (Germany)

LP008 **Partners in Care Intervention for Persons with dementia and multimorbidity. A clinical trial feasibility study**
Ingelin Testad [1,2], Lise Birgitte Holteng [1], Marthe Therese Gjestsen [1,3]
[1]Stavanger University Hospital - Stavanger (Norway), [2]University of Exeter Medical School - Exeter (United Kingdom), [3]University of Bergen - Bergen (Norway)

LP009 **The Patient Voice in Drug Reviews: Learnings from Older Adult Engagement on Disease-Modifying Treatments for Dementia in Ontario, Canada**
Adam Morrison [1], Jessica Hogle [1]
[1]Alzheimer Society of Ontario - Toronto (Canada)

LP010 **AI-guided patient stratification improves efficiency of Alzheimer's disease clinical trial**
Zoe Kourtzi [1], Delshad Vaghari [1], Gayathri Mohankumar [2], Peter Tino [3], Craig Shering [4], Andrew Lowe [2], Keith Tan [2]
[1]University of Cambridge - Cambridge (United Kingdom), [2]AstraZeneca - Cambridge (United Kingdom), [3]University of Birmingham - Birmingham (United Kingdom), [4]AstraZeneca - Boston (United States)

LP011 **Combination Therapy Phase 3 Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Study the Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease**
Lloyd Tran [1], Fern Vu [1], Zung Tran [1]
[1]BioMed Industries, Inc. - San Jose (United States)

LP012 **Minimizing Screen Failure Rates and Accelerating Clinical Trial Recruitment with a Prognostic Model**
Angela Tam [1], César Laurent [1], Adrián Noriega [1], Christian Dansereau [1]
[1]Perceiv AI - Montreal (Canada)

LP013 **Enhancing Clinical Trial Efficiency: Increasing Screening and Randomization Rates Using RetiSpec's AI-Based Eye Scan for Pre-Screening in Eye Care Settings**
John Lehr [1], Sophie Grapentine [2], Brandon Lenox [3], Stephanie Cassidy [3], Rozana Naureen [2], Brittany Pendarvis [1], Jennifer Giordano [2], Alon Hazan [2], Eliav Shaked [2], Catherine Bornbaum [2]
[1]Magruder Eye Institute - Orlando (United States), [2]RetiSpec - Toronto (Canada), [3]K2 Medical Research - Maitland (United States)

LP014 **Development of Edaravone tablets for the treatment of Alzheimer's disease---Phase I trials in healthy volunteers and Phase II design in early AD**
Xin-Fu Zhou [1], Jun Wang [2], Yan-Jiang Wang [2]
[1]Suzhou Auzone Biotech - Suzhou (China), [2]Department of Neurology, Daping Hospital, Third Military Medical University - Chongqing (China)

LP015 **Clinical Trials Using Music Interventions for Alzheimer's Disease and Related Disorders in Ethnically Diverse Communities**
Tara Rose [1]
[1]University of Southern California - Los Angeles (United States)

THEME 02: Clinical Trials: Results

P021 **Phase 1 clinical trial of Leucettinib-21, a DYRK1A kinase inhibitor aiming at the correction of cognitive disorders in Alzheimer's disease and Down syndrome**
Laurent Meijer [1], Emilie Chrétien [1], Emmanuel Deau [1], Gaëlle Hogrel [1], Mattias F. Lindberg [1]
[1]Perha Pharmaceuticals - Roscoff (France)

P022 **Phase 1a Single Ascending Dose Study of PMN310, a monoclonal antibody directed against toxic Aβ oligomers**
Larry Altstiel [1]
[1]ProMIS Neurosciences - Cambridge, Ma (United States)

P024 **Comprehensive analysis of phase 2 trial results and post-hoc findings of ABvac40, an anti-Aβ40 vaccine**
María Pascual-Lucas [1], Ana María Lacosta [1], María Montañés [1], Jesús Canudas [1], Jorge Loscos [1], José Antonio Allué [1], Leticia Sarasa [1], Noelia Fandos [1], Judith Romero [1], Manuel Sarasa [1], Gerard Piñol-Ripoll [2], Jose Terencio [3,1], Merce Boada [4,5]
[1]Araclon Biotech-Grifols - Zaragoza (Spain), [2]Cognitive Disorders Unit, Cognition and Behaviour Study Group. Hospital Universitari Santa Maria - Lleida (Spain), [3]Grifols - Barcelona (Spain), [4]Ace Alzheimer Center Barcelona – Universitat Internacional de Catalunya - Barcelona (Spain), [5]Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III - Madrid (Spain)

POSTER PRESENTATIONS

P025 **SPECTRISTM Treatment Reduced Alzheimer's Disease Dependence Score in OVERTURE I/II Phase 2 Study**

Ralph Kern [1], Marwan Sabbagh [2], Mihaly Hajos [1], Brent Vaughan [1], Christian Howell [1], Celine Houser [1], Michael Hull [1], Lily Lee [1]
[1]Cognito Therapeutics - Cambridge (United States), [2]Barrow Neurological Institute - Phoenix (United States)

P026 **SPECTRISTM OVERTURE I responder analysis demonstrates consistent preservation of function and brain structure.**

Ralph Kern [1], Mihaly Hajos [1], Brent Vaughan [1], Celine Houser [1], Alex Konisky [1], Lily Lee [1], Joshua Christensen [2], Benjamin Haaland [2], Suzanne Hendrix [2]
[1]Cognito Therapeutics - Cambridge (United States), [2]Cognito Therapeutics - Salt Lake City (United States)

P027 **A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients With Mild to Moderate Alzheimer's Disease**

Alireza Faridar [1], Nazaret Gamez [1], Aaron Thome [1], Weihua Zhao [1], David Beers [1], Jason Thonhoff [1], Mohammad Nakawah [1], Gustavo Roman [1], Juan Toledo [1], Charles Davis [2], Maria Pascual [1], Michael Grundman [3], Joseph Masdeu [1], Stanley Appel [1]
[1]Houston Methodist Hosital - Houston (United States), [2]CSD Biostatistics - Csd Bioscience (United States), [3]Global R&D Partners - Global R&d Partners (United States)

P028 **Long-Term Effects of Fortasyn Connect (Souvenaid) on Brain Atrophy Measures in MCIAD: Results from the Double-Blind Randomised LipiDiDiet Trial**

Tobias Hartmann [1,2], Jussi Tohka [3], Yawu Liu [3], Pieter Jelle Visser [4,5], Kaj Blennow [6,7], Hilkka Soininen [8,9], Miia Kivipelto [8,10,11,12], Alina Solomon [8,10,11,12]
[1]Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University - Hamburg (Germany), [2]Department of Experimental Neurology, Saarland University - Homburg (Germany), [3]A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland - Kuopio (Finland), [4]Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht - Maastricht (Netherlands), [5]Department of Neurology, Alzheimer Center, VU University Medical Center - Amsterdam (Netherlands), [6]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg - Mölndal (Sweden), [7]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), [8]Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland), [9]Neurocenter, Department of Neurology, Kuopio University Hospital - Kuopio (Finland), [10]Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Huddinge (Sweden), [11]Clinical Trials Unit, Theme Aging, Karolinska University Hospital - Huddinge (Sweden), [12]Ageing and Epidemiology Research Unit, School of Public Health, Imperial College - London (United Kingdom)

P029 **Orally available PRI-002 for the treatment of Alzheimer´s disease: Phase 1a data and design of the phase 2a study**

Oliver Peters [1], Janine Kutzsche [2], Nicoleta Carmen Cosma [1], Gunther Kauselmann [3], Gerhard Tischler [4], Dagmar Jürgens [3], Dieter Willbold [5]
[1]Charité - Berlin (Germany), [2]FZ Jülich - Jülich (Germany), [3]Priavoid - Düsseldorf (Germany), [4]Prinnovation - Leipzig (Germany), [5]Priavoid - Jülich (Germany)

P030 **Effect of baseline amyloid level on cognitive decline in adults with preclinical Alzheimer's disease enrolled in the A4 clinical trial, measured with composite scores from the Cogstate Brief Battery**

Paul Maruff [1], Dorene Rentz [2], Kathryn Papp [2], Michael Donahue [3], Andrew Lui [3], Paul Aisen [3], Reisa Sperling [2], A4 Study Team [4]
[1]Cogstate Ltd - Melbourne (Australia), [2]Department of Neurology, Massachusetts General Hospital, Harvard Medical School and Brigham and Women's Hospital - Boston (United States),, [3]Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA - San Diego (United States), [4]A4STUDY.ORG . - San Diego (United States)

P032 **A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Ascending Doses of CS6253 in Healthy Volunteers**

Jan O. Johansson [1], Bengt Winblad [2], Daniel M. Michaelson [3], Henrik Zetterberg [4,5], Jeffrey L. Cumming [6], Hussein N. Yassine [7]
[1]Artery Therapeutics, Inc. - San Ramon (United States), [2]Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet - Solna (Sweden), [3]Tel Aviv University - Tel Aviv (Israel), [4]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), [5]Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, Dementia Research Institute - London (United Kingdom), [6]Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas - Las Vegas (United States), [7]University of Southern California - Los Angeles (United States)

P033 **Harnessing Peripheral Immunity in Early Alzheimer's Disease: Safety and Tolerability of IBC-Ab002 in a Phase 1b Clinical Trial**

Tommaso Croese [1], Kuti Baruch [1], Eti Yoles [1], Alex Kertser [1], Eliezer Schochat [2], Michal Schwartz [3], Keswani Sanjay [1]
[1]ImmunoBrain Checkpoint Inc. - New York (United States), [2]Schochat Pharma Services - Basel (Switzerland), [3]Weizmann Institute of Science - Rehovot (Israel)

P034 **Hyperbaric oxygen therapy for cognition in older adults with type 2 diabetes**

Michal Schnaider Beeri [1], Ori Benari [2,3], Shai Efrati [2], Mary Sano [4], Barbara B Bendlin [5], Abigail Livny [2], Maayan Harel [3], Ganit Almog [3], Yuxia Ouyang [4], Yael Mardor [3], Amir Hadanny [6], Ramit Ravona-Springer [3,2]
[1]Herbert and Jacqueline Krieger Klein Alzheimer's Research Center,Robert Wood Johnson Medical School, Rutgers University - New Brunswick (United States), [2]Faculty of Medicine, Tel Aviv University - Tel Aviv (Israel), [3]Sheba Medical Center - Ramat Gan (Israel), [4]Department of Psychiatry, Icahn School of Medicine at Mount Sinai - New York (United States), [5]Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison - Wisconsin (United States), [6]Shamir Medical Center - Rishon Lezion (Israel)

P035 **Health Economic Impact of Disease Modifying Therapies such as Monoclonal Antibodies**

Samuel Dickson [1], Craig Mallinckrodt [1], Suzanne Hendrix [1]
[1]Pentara Corporation - Salt Lake City (United States)

P036 **Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep**

Sung Yong Park [1], Won-Myong Bahk [2], Bo-Hyun Yoon [3], Kwanghun Lee [4], Sang-Yeol Lee [5], Hyung Mo Sung [6], Min-Kyu Song [7]
[1]Keyo Hospital - Uiwang (Korea, Republic of), [2]Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul - Seoul (Korea, Republic of), [3]Naju National Hospital - Naju-Si (Korea, Republic of), [4]College of Medicine, Dongguk University - Gyeongju (Korea, Republic of), [5]Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), [6]Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University - Gumi (Korea, Republic of), [7]St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

P037 **Analysis of the cardiovascular safety of choline alphoscerate treatment in the ASCOMALVA trial**
Enea Traini [1], Anna Carotenuto [1], Angiola Fasanaro [2], Francesco Amenta [1]
[1]University of Camerino - Camerino (Italy), [2]Neurology and Stroke Unit-Neurology, A. Cardarelli Hospital - Napoli (Italy)

P038 **Exploring the effect of baseline characteristics on the efficacy of multidomain dementia prevention in late-life: a pooled analysis of individual participant data from the MAPT and preDIVA trials**
Nicola Coley [1,2,3], Marie Hoevenaar-Blom [4,5], Jason Shourick [1,2,3], Eric Moll Van Charante [4,5], Jan-Willem Van Dalen [6,7], Willem Van Gool [5], Edo Richard [5,6], Sandrine Andrieu [1,2,3]
[1]Aging Research Team, Centre for Epidemiology and Research in Population health (CERPOP), INSERM-University of Toulouse UPS - Toulouse (France), [2]Department of Epidemiology and Public Health, Toulouse University Hospital - Toulouse (France), [3]IHU HealthAge - Toulouse (France), [4]Department of General Practice, Amsterdam UMC, University of Amsterdam - Amsterdam (Netherlands), [5]Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam - Amsterdam (Netherlands), [6]Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center - Nijmegen (Netherlands), [7]Department of Neurology, Amsterdam University Medical Center, Location AMC - Amsterdam (Netherlands)

P039 **Online advertising resulted in more educated participants and non inferior screen fail rates when compared to offline methods in an Alzheimer's disease clinical trial**
Yu-Jay Huoh [1], Ralph Lee [1], Colin Sholes [1], Brenda Martinez [1], Sydney Hopkins [1], Jennifer Mitolo [1], Tara Parnitvithikul [1], Edward Zamrini [1], Elly Lee [1]
[1]Irvine Clinical Research - Irvine (United States)

P040 **Potential Efficacy of Oral Nicotinamide Riboside (NR) Supplementation in Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment**
Chao-Yi Wu [1], Ashley Kupferschmid [1], Alison Mcmanus [1], Pia Kivisakk [1], Jake Galler [1], Nadine Schwab [1], Libby Desruisseaux [1], Victoria Williams [1], Jessica Gerber [1], Misha Riley [1], Cathrine Young [1], Hiroko Dodge [1], Rudolph Tanzi [1], Clifford Singer [2], Steven Arnold [1]
[1]Massachusetts General Hospital/ Harvard Medical School - Boston (United States), [2]Northern Light Health - Bangor (United States)

LP016 **Effects of sensory-evoked gamma oscillation on neurophysiological signals of visual and cognitive processing in Alzheimer's disease**
Roberto Fernández Romero [1], David Grant [1], Brennan Jackson [2], Chandran Seshagiri [2], Mihály Hajós [2]
[1]The University of Tennessee Medical Center - Knoxville (United States), [2]Cognito Therapeutics - Cambridge (United States)

LP017 **Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease Treatment Center**
David Watson [1], Michael Neam [1], Mark Stafford [1], Cynthia Bouchard [1], Venessa Ranney [1], Sydney Werner [1]
[1]Alzheimer's Research and Treatment Center - Wellington (United States)

LP018 **Additional Analysis of a 52-Week Phase II Trial of Neuromodulation of the Default Mode Network to Optimize Design of a Phase 3 Trial to Demonstrate Clinical Meaningfulness**
Suzanne Hendrix [1], Lisa Fosdick [2], Garrett Duncan [1], Samuel Dickson [1], Giacomo Koch [2,3]
[1]Pentara Corporation - Salt Lake City (United States), [2]Sinaptica Therapeutics - Cambridge (United States), [3]University of Rome Tor Vergata - Rome (Italy)

LP019 **Intracerebroventricular injection of autologous adipose-derived stem cells for the treatment of Alzheimer's Disease: Experience with the first of three 3-patient cohorts in a "First in Human" Phase 1 FDA trial.**
Christopher Duma [1], Gustavo Alva [2], Hans Keirstead [1], Gabriel Nistor [1], Robert Lynn [1], Jessica Buxton [1], Sawyer Farmer [1], Karlyssa Chung [1], Ashley Harris [1], Zoe Hareng [1]
[1]Regeneration Biomedical, Inc., Newport Beach, CA - Newport Beach (United States), [2]Hoag Memorial Hospital, Newport Beach, CA - Newport Beach (United States)

LP020 **Treatment of Moderate Alzheimer's Disease Subjects with Expanded Non- genetically Modified Natural Killer Cells (troculeucel; SNK01) With Enhanced Activity —Report of the Phase I results of the Phase I/IIa study**
Paul Song [1], Lucia Hui [1], Hank Lee [1], Juan Mata [1], Katia Betito [1], Harry Chung [2], Jesse Carr [2]
[1]NKGen Biotech - Santa Ana (United States), [2]Behavioral Research Specialists LLC - Glendale (United States)

LP021 **Post-marketing Study of Sodium Oligomannate: Long-Term Safety and Effectiveness of an Agent Targeting the Gut Microbiome for the Treatment of Alzheimer's Disease**
Xianliang Xin [1], Jinhe Li [1], Xia Li [2], Meiyu Geng [3], Qihao Guo [4]
[1]Green Valley (Shanghai) Pharmaceuticals Co., Ltd. - Shanghai (China), [2]Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine - Shanghai (China), [3]State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Shanghai (China), [4]Department of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine - Shanghai (China)

LP022 **Regional variation of amylin, β amyloid and amylin-β amyloid in sporadic, late-onset AD brains**
Deepak Kotiya [1], Peter T. Nelson [1], Gregory A. Jicha [1], Larry B. Goldstein [1], Florin Despa [1]
[1]University of Kentucky - Lexington (United States)

LP023 **APOE4 and Buntanetap in Phase II/III Alzheimer's patients**
Cheng Fang [1], Maria Maccecchini [1]
[1]Annovis Bio - Malvern (United States)

LP024 **A Phase 3 Study of Sublingual Dexmedetomidine for Episodic Treatment of Agitation Associated with Alzheimer's Dementia**
Robert Risinger [1], Lavanya Rajachandran [1], Heather Robinson [1], Jeffrey Cummings [2], George Grossberg [3]
[1]BioXcel Therapeutics - New Haven (United States), [2]University of Nevada - Las Vegas (United States), [3]St Louis University - St Louis (United States)

POSTER PRESENTATIONS

THEME 11: New therapies and clinical trials

P042 **Specialized infrastructure in a tertiary hospital to administer disease modifying treatments in Alzheimer's disease**
Talya Nathan [1], Elissa Ash [1,2,3], Shir Dror [1], Noa Trabulus [1], Aya Bar-David [1], Mori Hay Levy [1], Galia Wolpe [1], Tamara Shiner [1,2,3], Noa Bregman [1,2,3]
[1]Cognitive Neurology Unit, Tel Aviv Sourasky Medical Center - Tel Aviv (Israel), [2]Department of Neurology and Neurosurgery, Sackler School of Medicine, Tel Aviv University - Tel Aviv (Israel), [3]Sagol School of Neuroscience, Tel Aviv University - Tel Aviv (Israel)

P043 **Cognitive Vergence predicts AD, correlates with CSF biomarkers and improves after digital treatment.**
Hans Supèr [1]
[1]University of Barcelona - Barcelona (Spain)

P044 **Increasing Representation and Diversity in Clinical Trials of Alzheimer's Disease: Recruitment of Ethnically Diverse Participants with Alzheimer's Disease in the Phase 1 ASCENT Clinical Trials of PRX012**
Chad Swanson [1], Ferenc Martényi [1], Ryan E. Tooker [1], Donna Masterman [1], Courtney Fitzgerald [1], Ann Johnson [1], Lingnan Li [1], Mary E. Quiceno [1], Gene G. Kinney [1], Hideki Garren [1]
[1]Prothena Biosciences Inc - Brisbane (United States)

P045 **Advances in Clinical Trials for Alzheimer's Disease in Down Syndrome**
Michael Rafii [1], Juan Fortea [2], Beau Ances [3]
[1]University of Southern California - San Diego (United States), [2]Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), [3]Washington University - Saint Louis (United States)

P046 **Clinical experience with amyloid-lowering treatments in an academic dementia specialty practice**
Madeline Paczynski [1], Suzanne Schindler [1,2], Erik Musiek [1,2], David Holtzman [1,2], Tammie Benzinger [1,2], Alan Dow [3], Sheyda Namazie-Kummer [3], Zachary Posey [1,2], Dawn Ellington [1,2], John Morris 1, 2, Barbara Snider [1,2]
[1]Washington University School of Medicine - Saint Louis (United States), [2]Knight Alzheimer Disease Research Center - Saint Louis (United States), [3]Barnes Jewish Corporation - Saint Louis (United States)

P047 **A randomized, double-blind trial of the effects of a live biotherapeutic product in preclinical Alzheimer's disease**
Kun Ho Lee [1], Kyu Yeong Choi [2], Sarang Kang [1], Junho H Lee [3], Won-Seok Choi [3], Jung Hee Lee [2]
[1]Gwangju Alzheimer's & Related Dementia Cohort Research Center, Chosun University - Gwangju (Korea, Republic of), [2]Kolab Inc. - Gwangju (Korea, Republic of), [3]Chonnam National University - Gwangju (Korea, Republic of)

P049 **Self-reported sleep quality and amyloid burden in cognitively unimpaired adults from the AMYPAD study.**
Núria Tort-Colet [1,2], Laura Stankeviciute [1], Craig Ritchie [3], Mercè Boada [4,5], Wiesje Van Der Flier [6], Bernard J Hanseeuw [7], Pablo Martinez-Lage [8], Pieter Jelle Visser [9], Michael Schöll [10], Giovanni B Frisoni [11], Chris Buckley [12], Frank Jessen [13], Lyduine E. Collij [9,14], Frederik Barkhof [9,14,15], Oriol Grau-Rivera [1,2,16,17]
[1]BBRC, Pasqual Maragall Foundation - Barcelona (Spain), [2]Hospital del Mar Research Institute - Barcelona (Spain), [3]Centre for Clinical Brain Sciences, University of Edinburgh - Edinburgh (United Kingdom), [4]ACE Alzheimer Center Barcelona - Barcelona (Spain), [5] CIBERNED, Instituto de Salud Carlos III - Madrid (Spain), [6]Amsterdam UMC Location VUmc - Amsterdam (Netherlands), [7]IONS, Université Catholique de Louvain - Brussels (Belgium), [8]Fundacion CITA Alzheimer - San Sebastian (Spain), [9]Amsterdam University Medical Center, location VUmc - Amsterdam (Netherlands), [10]University of Gothenburg - Gothenburg (Sweden), [11]LANVIE, Université de Genève - Geneva (Switzerland), [12]GE Healthcare - Amersham (United Kingdom), [13]University Hospital of Cologne - Cologne (Germany), [14]Amsterdam Neuroscience, Brain Imaging - Amsterdam (Netherlands), [15]Centre for Medical Image Computing, and Queen Square Institute of Neurology, UCL - London (United Kingdom), [16]Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III - Madrid (Spain), [17]Hospital del Mar - Barcelona (Spain)

P050 **Phase 1, First-in-human, Single and Multiple Ascending Dose Study of a Novel Orally Administered TREM2 Agonist (VG-3927) in Healthy Volunteers: Interim Results**
Raj Rajagovindan [1], Francois Gaudreault [1], Ryan O'Mara [1], Jade Donaldson [1], Evan Thackaberry [1], Jessica Stromme [1], David Gray [1], Andreas Meier [2], Petra Kaufmann [1]
[1]Vigil Neuroscience, Inc - Watertown (United States), [2]Formerly Vigil Neuroscience, Inc - Watertown (United States)

P051 **Interim Safety and Biomarker Data From upliFT-D, a Phase 1b Trial of PBFT02 in Frontotemporal Dementia and Mutations in the Granulin Gene (FTD-GRN)**
Juan Chavez [1], Tiffini Voss [1], Paulette Triglia [1], Yan Ni [1], Sue Browne [1], Karen Quadrini [1], Sarang Rastogi [1], Simon Ducharme [2], David Irwin [3], Isabel Santana [4], Paul E Schulz [5], Leonel Takada [6], Maria Tartaglia [7], Leonardo Cruz De Souza [8], Mark S Foreman [1]
[1]Passage Bio - Philadelphia (United States), [2]Douglas Mental Health University Institute and Montreal Neurological Institute, McGill University - Montreal (Canada), [3]Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), [4]Centro Hospitalar Universitário de Coimbra - Coimbra (Portugal), [5]McGovern Medical School, UTHealth Houston - Houston (United States), [6]Perelman School of Medicine at the University of Pennsylvania - Sao Paulo (Brazil), [7]University Health Network, and Tanz Centre for Research In Neurodegenerative Diseases - Toronto (Canada), [8]Hospital das Clinicas Universidade Federal de Minas Gerais - Belo Horizonte (Brazil)

P052 **Alzheimer's disease and microbiota: the MICMALZ study**
Germain Busto [1], Lucy Kundura [2], Sylvaine Artero [2], Yves Dauvilliers [3], Karim Bennys [4], Sylvie Claeysen [2], Audrey Gabelle [1]
[1]Center for Memory Resources and Research (CMRR), Department of Neurology, Montpellier University Hospital, Montpellier, INM, University Montpellier, Montpellier, France - Montpellier (France), [2]IGF, University Montpellier, CNRS, INSERM, Montpellier, France. - Montpellier (France), [3]Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital and INM, University Montpellier, Montpellier, France. - Montpellier (France), [4]Center for Memory Resources and Research (CMRR), Department of Neurology, Montpellier University Hospital, Montpellier, France. - Montpellier (France)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

P053 **TREM2 Agonism Stimulates Human Microglia Responses in the Presence of Amyloid Pathology**

Manuela Polydoro [1], Ivana Geric [2], Jin Zheng [3], Tina Sommer Bisgaard [3], Leen Wolfs [2], Anke Misbaer [2], Arya Nair [2], Laura Sans [3], Maria Dalby [3], Joachim Vilstrup [3], Peter Flagstad [3], Rita Balice-Gordon [4], Bart De Strooper [5,6], Niels Plath [3]

[1]Muna Therapeutics, Copenhagen, Denmark - Boston (United States), [2]Muna Therapeutics, Copenhagen, Denmark - Leuven (Belgium), [3]Muna Therapeutics, Copenhagen, Denmark - Copenhagen (Denmark), [4]Muna Therapeutics, Copenhagen, Denmark - Philadelphia (United States), [5]UK Dementia Research Institute - London (United Kingdom), [6]KU Leuven - Leuven (Belgium)

P054 **Targeting α-Synuclein Fibril's Disordered Region with Small Molecule Inhibitors: A Therapeutic Strategy for Parkinson's Disease**

Shenqing Zhang [1], Huaijiang Xiang [2], Dan Li [1], Li Tan [2], Cong Liu [2]

[1]Shanghai Jiao Tong University - Shanghai (China), [2]Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences - Shanghai (China)

P055 **Different charged biopolymers induce α-synuclein to form fibrils with distinct structures**

Yuxuan Yao [1], Qinyue Zhao [1], Cong Liu [2], Dan Li [3]

[1]Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University - Shanghai (China), [2]Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences - Shanghai (China), [3]Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong UniBio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong Univerversity - Shanghai (China)

P056 **Development and Efficacy Assessment of a Video-Based Reminiscence Therapy Using Medial Archives for Early-Stage Dementia: A Pilot Study**

Geon Ha Kim [1], Bori R. Kim [1,2], Sumin Kim [1], Jee Hyang Jeong [3]

[1]Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine - Seoul (Korea, Republic of), [2]Ewha Medical Research Institute, Ewha Womans University - Seoul (Korea, Republic of), [3]Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine - Seoul (Korea, Republic of)

P057 **PreDXClearance, exploring new biomarkers to predict ARIA/CAA and personalize therapy in AD**

Fanni Ujvarosi [1], Line Amundsen [1], Jie Gao [1], Ira Hebold Haraldsen [2], Fernando Maestú [3], Hanna Renvall [4], Camillo Marra [5], Paolo M. Rossini [6], Erik Christensen [1], Maria J. Lagartos [1]

[1]Pre Diagnostics - Oslo (Norway), [2]Oslo University Hospital - Oslo (Norway), [3]Universidad Complutense - Madrid (Spain), [4]HUS - Helsinkie (Finland), [5]Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), [6]IRCCS San Raffaele - Rome (Italy)

P058 **Evaluation of square-stepping exercise on plasma amyloid-beta levels and cognitive function in older adults: a randomized controlled trial**

Jieun Yoon [1], Tomohiro Okura [1]

[1]University of Tsukuba - Tsukuba (Japan)

P059 **Evaluation of an Upper Alpha Neurofeedback Intervention on Mild Amnestic Cognitive Impairment: A Randomized, Double-blind, Sham-controlled Research Project (ESPERANZA study)**

Esperanza Jubera-Garcia[1,7], Carlos Escolano [1], Eduardo López-Larraz [1], Jens Klinzing [1], Jose Ventura [1], Beatriz Hornillos [1], Laura Pampliega [1], Nora Molina-Torres [2,3], Jose M. Pérez-Trullén [2,4], Elena Lobo [2,6], Antonio Lobo [2], Tristan Beckinschtein[7], Pedro Modrego [2,5], Javier Minguez [1]

[1] Bitbrain, Zaragoza (Spain), [2] Instituto de Investigación Sanitaria de Aragón, Zaragoza (Spain), [3] Servicio de Geriatría, Hospital Nuestra Señora de Gracia, Zaragoza (Spain), [4] Servicio de Neurología, Hospital Nuestra Señora de Gracia, Zaragoza (Spain), [5] Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza (Spain), [6] Department of Preventive Medicine and Public Health, Universidad de Zaragoza (Spain), [7] University of Cambridge, Department of Psychology, Cambridge (United Kingdom)

P060 **Patient Considerations in the Development and Delivery of Novel Treatments for Alzheimer's Disease**

Abigail Silber [1], Amod Athavale [1], Matthew O'Hara [1], Donna Masterman [2], Preeti S. Bajaj [2]

[1]Trinity Life Sciences - Waltham, Ma (United States), [2]Prothena Biosciences, Inc - Brisbane, Ca (United States)

P061 **The NANA study: Auditory simulation during sleep as a symptomatic treatment for mild cognitive impairment**

Jens G. Klinzing [1], Esperanza Jubera-García [1,6], Sergio Clemente Jiménez [1], Galit Fierro [1], Eduardo López-Larraz [1], Almudena Robledo-Menéndez [1], Pedro Modrego [2,3], Antonio Lobo [2,4], Jorge de Francisco Moure [2,5], Carmen Almárcegui [2,5], Javier Minguez [1]

[1] Bitbrain, Zaragoza (Spain),[2] Instituto de Investigación Sanitaria de Aragón, Zaragoza (Spain), [3] Servicio de neurología, Hospital Universitario Miguel Servet, Zaragoza (Spain), [4] Department of Medicine and Psychiatry, Universidad de Zaragoza (Spain), [5] Servicio de Neurofisiología Clínica, Hospital Universitario Miguel Servet, Zaragoza, (Spain), [6] University of Cambridge, Department of Psychology, Cambridge (United Kingdom)

P062 **Prospects for the Treatment of Alzheimer's Disease**

Amanda Scarso [1], Gustavo Santos [1], Gabrielle Almeida [1]

[1]Faculdade Sao Leopoldo Mandic de Araras, Medical School - Araras (Brazil)

LP025 **Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer's disease**

Cristina Parrado-Fernández [1,2], Ruchi Gera [3], Veronica Lidell [1], Azita Rasti [1], Sumonto Mitra [3], Maria Backlund [1], Gunnar Nordvall [1,3], Martin Jönsson [1,3], Johan Sandin [1,4], Maria Eriksdotter [3,5], Pontus Forsell [1,4]

[1]AlzeCure Pharma AB, Hälsovägen 7 - Huddinge (Sweden), [2]Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Stockholm (Sweden), [3]Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Stockholm (Sweden), [4]Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Stockholm (Sweden) - Stockholm (Sweden), [5]Theme Inflammation and Aging, Karolinska University Hospital - Stockholm (Sweden)

POSTER PRESENTATIONS

LP026 **BHV-8000, a Selective Brain-Penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Favorable PK/PD and Safety Profile in Phase 1 Studies**

Peter Ackerman [1], Nick Kozauer [1], Raj Bhardwaj [2], Bavani Shankar [1], Bharat Asware [1], Randall Killingsworth [1], Eric Ashbrenner [1], Jo Ann Malatesta [2], Emily Thompson [1], Dustin Walters [1], Alyssa Cheng [1], Lindsey Lee Lair [1], Richard Bertz [1], Bruce Car [1], Irfan Qureshi [1], Vlad Coric [1]
[1]Biohaven Pharmaceuticals - New Haven (United States), [2]Certara - Radnor (United States)

LP027 **Blocking the FAM19A5-LRRC4B complex with an anti-FAM19A5 antibody restores lost synapses and reverses cognitive decline in mouse models of Alzheimer's disease**

Han-Byul Kim [1], Sangjin Yoo [1], Hoyun Kwak [1], Shi-Xun Ma [1], Ryunhee Kim [1], Minhyeok Lee [1], Nui Ha [1], Soonil Pyo [1], Soon-Gu Kwon [1], Eun-Ho Cho [1], Sang-Myeong Lee [1], Juwon Jang [1], Wonkyum Kim [1], Yosub Park [1], Jae Young Seong [1,2]
[1]Neuracle Science Co., Ltd. - Seoul (Korea, Republic of), [2]Department of Biomedical Sciences, Graduate School of Medicine, Korea University - Seoul (Korea, Republic of)

LP028 **Comparison of visually evoked steady-state oscillations between two Spectris™ eyesets**

Julia Leach [1], Brennan Jackson [1], Miguel Hernandez [1], Olivia Rowe [1], Katharine Kolin [1], David Grant [2], Roberto Fernandez-Romero [2], Mihály Hajós [1,3], Chandran Seshagiri [1]
[1]Cognito Therapeutics - Cambridge (United States), [2]University of Tennessee Medical Center - Knoxville (United States), [3]Yale University School of Medicine - New Haven (United States)

LP029 **Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer's disease**

Brian Rash [1], Jeffrey Botbyl [1], Steven Kopcho [1], Zarin Zainul [1], Nataliya Agafonova [1], Lisa Mcclain-Moss [1], Kevin Ramdas [1], Eric Naioti [1], Brittany Varnado [1], Kevin Peterson [1], Michael Brown [1], Thiago Leal [1], Raul Carballosa [2], Paayal Patel [3], Mark Brody [3], Brad Herskowitz [3], Ana Fuquay [3], Savannah Rodriguez [3], Joshua Hare [1]
[1]Longeveron Inc - Miami (United States), [2]First Excellent Research - Miami (United States), [3]ERG Clinical - Miami (United States)

LP030 **Emerging Non-Invasive Brain Stimulation Techniques for Alzheimer's Treatment: Current State and Future Directions**

Guillaume Blivet [1], Thomas Sacrez [2], Gizem Temiz [3], Michael Weiner [4], Marwan Sabbagh [5], Jacques Touchon [2], Jeffrey Cummings [6]
[1]REGEnLIFE - Paris (France), [2]University of Montpellier - Montpellier (France), [3]TheraPanacea - Paris (France), [4]University of San Francisco - San Francisco (United States), [5]Barrow Neurological Institute - Phoenix (United States), [6]University of Nevada, Las Vegas - Las Vegas (United States)

LP031 **Phase 2a clinical trial supports therapeutic efficacy of septin modulation in mild-to-moderate Alzheimer's patients**

Jeffrey Cummings [1], Mieke Nuytten [2], Steven Ramael [2], Eline Byl [2], Eveline Debroux [2], Marieke Voets [2], Katrien Princen [2], Marc Fivaz [2], Gerard Griffioen [2]
[1]Chambers-Grundy Center for Transformative Neuroscience at UNLV - Las Vegas (United States), [2]reMYND - Leuven (Belgium)

LP034 **Use of Resveratrol to prevent mild cognitive decline and Alzheimer's Dementia**

Gustavo Santos[1,2], Bruna Fachinelli [1], Mário Roberto Maróstica Junior [2]
[1]Faculdade Sao Leopoldo Mandic de Araras,Medical School - Araras (Brazil), [2]Faculty of Food Engineering (FEA), University of Campinas (UNICAMP) - Campinas (Brazil)

LP035 **Lecanemab Experience and ARIA Observations at a Large Community-Based Health Care System**

Shawn Kile [1]
[1]Sutter Neuroscience Institute - Sacramento (United States)

THEME 14: Beyond Amyloid and Tau

P063 **Novel blood-based mitochondrial biomarkers for the prognosis of progression from mild cognitive impairment to Alzheimer's Disease Dementia**

Jose Luis Mosquera [1], Marta Blanch [1], Nuria Rojo [2], Jaume Campdelacreu [2], Joan Bello [3], Alberto Lleo [4], Pablo Martínez-Lage [5], Adrià Tort-Merino [6], Raquel Sanchez-Valle [6], Carlos Cruchaga [7], Christopher Fowler [8], Simon Laws [9], Courosh Mehanian [10], Jordi Gascon-Bayarri [2], Marta Barrachina [1]
[1]ADmit Therapeutics - Barcelona (Spain), [2]Bellvitge University Hospital -IDIBELL - Barcelona (Spain), [3]Complex Hospitalari Moisès Broggi. L'Hospitalet/Sant Joan Despí - Barcelona (Spain), [4]Institut de Recerca Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona - CIBERNED - Barcelona (Spain), [5]CITA-alzheimer Foundation - San Sebastián (Spain), [6]Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona - Barcelona (Spain), [7]Washington University School of Medicine - Sant Louis (United States), [8]The Florey Institute, The University of Melbourne - Melbourne (Australia), [9]Collaborative Genomics and Translation Group, Edith Cowan University - Joondalup (Australia), [10]University of Oregon and Global Health Labs - Eugene (United States)

P064 **Misfolding of alpha-synuclein as a direct biomarker for Parkinson's Disease and Synucleinopathies**

Klaus Gerwert [1]
[1]Ruhr-University Bochum - Bochum (Germany)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

P065 **Phenome-wide Mendelian randomization analysis reveals shared causal risk factors among Alzheimer's disease, vascular dementia, and stroke**
Chi-Hun Kim [1], Jong Hun Kim [2], Hyoung Seop Kim [2]
[1]Hallym University Sacred Heart Hospital - Anyang (Korea, Republic of), [2]Ilsan Hospital, National Health Insurance Service - Goyang (Korea, Republic of)

P066 **The N-glycan structure bisecting N-acetylglucosamine predicts cognitive decline in patients from a memory clinic cohort**
Robin Zhou [1], Bengt Winblad [1], Lars Tjernberg [1], Sophia Schedin Weiss [1]
[1]Karolinska Institutet - Solna (Sweden)

P067 **A phase III, randomized, double-blinded study of the efficacy and safety of LEvetiracetam to prevent Seizures in Symptomatic Alzheimer's Disease in adults with Down syndrome: the LESS-AD trial**
María Carmona-Iragui [1,2], Lucía Maure [1], Beatriz Sánchez Moreno [3], Isabel Barroeta [1], Gina Paola Mejía [4], Miren Altuna 5, Joaquín Escobar [6], Eloy Rodríguez [7], Juan Fortea [1,2], Diego Real De Asúa [3]
[1]Memory Unit, Alzheimer Down Unit, Neurology Department. Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), [2]Barcelona Down Medical Center, Fundació Catalana Síndrome de Down - Barcelona (Spain), [3]Internal Medicine Department, Adult Down Syndrome Unit, Hospital Universitario de La Princesa - Madrid (Spain), [4]Clinical Pharmacology Department. Hospital Universitario de La Princesa - Madrid (Spain), [5]Fundación CITA-Alzheimer Fundazioa - Donostia (Spain), [6]Neurology Department. Hospital Universitario Virgen de las Nieves - Granada (Spain), [7]Neurology Department. Hospital Universitario Marqués de Valdecilla - Santander (Spain)

P068 **Association between accelerated epigenetic and inflammatory aging and cognitive function in men and women: a cross-sectional analysis from the INSPIRE-T cohort**
Samuel Thuriot [1], Jason Shourick [1], Mathilde Strumia [1], Vanina Bongard [1], David Furman [2], Jean-Marc Lemaitre [3], Sophie Guyonnet [1], Heike Bischoff-Ferrari [1], Bruno Vellas [1], Sandrine Andrieu [1], Laure Rouch [1]
[1]IHU HealthAge - Toulouse (France), [2]Buck Institute for Research on Aging - Novato (United States), [3]INSERM 1183 Institute of regenerative medicine and Biotherapies - Montpellier (France)

P069 **Towards a cortical microstructural signature of neuroinflammation in AD**
Gerard Ridgway [1], Mario Torso [1], Ian Hardingham [1], Steven Chance [1], & For The Alzheimer's Disease Neuroimaging Initiative [2]
[1]Oxford Brain Diagnostics Ltd - Oxford (United Kingdom), [2]Alzheimer's Disease Neuroimaging Initiative - San Francisco (United States)

P070 **Associations of LATE-NC with past medical history and medication use: an exploratory analysis using data from the National Alzheimer's Coordinating Center**
Davis Woodworth [1], Joey Wong [1], Anne-Marie Leiby [1], S. Ahmad Sajjadi [1]
[1]University of California, Irvine - Irvine (United States)

P071 **Association between the long-term use of high anticholinergic drugs and its burden and the incidence of dementia in stroke.**
Ahmed Alharthi [1,2], Terry Quinn [1], Donald Lyall [1]
[1]University of Glasgow - Glasgow (United Kingdom), [2]Umm Al-Qura University - Makkah (Saudi Arabia)

P072 **Diagnostic Performance of Plasma Alzheimer's Disease Biomarkers for Predicting Amyloid/Tau/Neurodegeneration**
Hanna Cho 1, Han-Kyeol Kim [1], Jae Hoon Lee [2], Jeong-Ha Lee [1], Joong-Hyun Chun [3], Tim West [4], Kris Kermess [4], Philip Verghese [4], Daniel Connell [4], Joel Braunstein [4], Young Hoon Ryu [2], Chul Hyoung Lyoo [1]
[1]Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), [2]Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), [3]Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), [4]C2N diagnostics - St Louis (United States)

P073 **Sarcopenia is a predictor for Alzheimer's continuum and related clinical outcomes**
Sung Hoon Kang [1], Yu Jeong Park [1], Chi Kyung Kim [1]
[1]Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine - Seoul (Korea, Republic of)

P074 **Neuroinflammatory CSF markers associated with cerebrovascular lesions in Alzheimer's disease**
Linbin Dai [1], Qiong Wang [1], Feng Gao [1], Yong Shen [1]
[1]University of Science and Technology of China - Hefei (China)

P075 **Discovery of a Novel C3-Targeting and CNS Active siRNA as a Potential Therapeutic for Alzheimer's Disease**
Tara Barbour [1], Fay Touti [1], Yan Li [1], Anshu Jain [1], Elisabeth Lonie [1], Salome Funes [1], Andrew Carvalho [1], Maggie Mohr [2], Justin Guo [3], Matthew Poulin [4], Anke Geick [5], Soham Mandal [5], Zhouning Zhang [1], Kate Lane [1], Lukas Scheibler [1], David Eyerman [1]
[1]Apellis Pharmaceuticals - Waltham (United States), [2]Northern Biomedical Research - Norton Shores (United States), [3]Synoligo Biotechnologies - Morrisville (United States), [4]EpigenDx - Hopkinton (United States), [5]Axolabs GmbH - Kulmbach (Germany)

LP036 **The AGED triad: A vascular aging phenotype and its relationship to AD biomarkers**
Adrián Noriega De La Colina [1,2], Caitlin Walker [1], Meishan Ai [3], Navin Kaushal [4], Maiya R. Geddes [2,5]
[1]Montreal Neurological Institute-Hospital (The Neuro) - Montreal (Canada), [2]Department of Neurology and Neurosurgery, McGill University - Montreal (Canada), [3]Department of Psychology, Northeastern University - Boston (United States), [4]School of Health & Human Sciences - Indianapolis (United States), [5]Montreal Neurological Institute-Hospital (The Neuror) - Montreal (Canada)

POSTER PRESENTATIONS

LP037 **Inhibition of p38α MAPK pathway in early Alzheimer's disease**
Dominique Gouilly [1], Patrice Péran [2], Agathe Vrillon [3], Elsa Bertrand [4], Marie Goubeaud [4], Aurélie Pistono [5], Alexandre Da Costa [2], Anne-Sophie Salabert [2], Johanne Germain [4], Hélène Catala [4], Marie Rafiq [1], Deborah Meligne [1], Laurence Jasse [1], Benjamine Sarton [6], Pierre Payoux [7], Claire Paquet [3], Claire Thalams [4], John Alam [8], Jérémie Pariente [1]
[1]Department of Cognitive Neurology, Epilepsy, Sleep and Movement Disorders, CHU Toulouse Purpan- Toulouse (France), [2]Toulouse Neuroimaging Center, UMR 1214, Inserm/UPS - Toulouse (France), [3]Université de Paris, Cognitive Neurology Center, GHU Nord, APHP, Hospital Lariboisière Fernand Widal- Paris (France), [4]Center of Clinical Investigation, CHU Toulouse Purpan (CIC 1436)- Toulouse (France), [5]Université Toulouse 2 Jean Jaurès, - Toulouse (France), [6]Critical Care Unit, CHU Toulouse Purpan- Toulouse (France), [7]Department of Nuclear Medicine, CHU Toulouse Purpan- Toulouse (France), [8]CervoMed Inc - Boston (United States)

LP039 **Multiplex cerebrospinal fluid proteomics identifies biomarkers for diagnosis and prediction of Alzheimer's disease**
Yu Jin-Tai [1], Guo Yu [1], Huang Yu-Yuan [1]
[1]Huashan Hospital, Fudan University - Shanghai (China)

LP040 **Relationship Between Caregiving Burden and Alterations in Circadian Rhythm among Spousal Caregivers of cognitive impairment older adults**
Shin Young Park [1], Jung Been Lee [2], Take Lee [2], Yang Hee Won [1], So Yeon Jeon [3]
[1]Chungnam National University Hospital - Daejeon (Korea, Republic of), [2]Sun Moon University - Asan (Korea, Republic of), [3]Chungnam National University College of Medicine - Daejeon (Korea, Republic of)

LP041 **Middle aged and older adults' knowledge, ratings, and preferences for receiving multicomponent lifestyle-based brain health interventions**
Raymond Ownby [1], Gesulla Cavanaugh [1], Joshua Caballero [2]
[1]Nova Southeastern University - Fort Lauderdale (United States), [2]University of Georgia - Athens (United States)

LP041bis **Relationship of alpha-synuclein co-pathology to AD biomarkers and clinical progression in MCI and mild AD clinical trials**
Kyle Fraser [1], Roland Brown [1], Kyle Ferber [1], Julie Czerkowicz [1], Amanda Edwards [1], Jessica Collins [1], Gersham Dent [1], Melanie Shulman [1], John O'Gorman [1], Carrie Rubel [1], Danielle Graham [1]
[1]Biogen - Cambridge (United States)

THEME 15: Clinical Trials Early Career Investigator Showcase

P076 **Bumetanide in Patients with Alzheimer's Disease (BumxAD): A Phase II Clinical Trial**
Kyan Younes [1], Mina Kmiecik [1], Minhtrang Huu Chu [1], Annie Zhou [1], Irina Skylar-Scott [1], Niyatee Samudra [1], Pragya Tripathi [1], Maria Coburn [1], Ted Wilson [1], Zihuai He [1], Francois Haddad [1], Tony Wyss-Coray [1], Sharon J. Sha [1], Michael D. Greicius [1]
[1]Stanford University - Palo Alto (United States)

P077 **High prevalence of brain amyloidopathy among frail older adults: are they eligible for anti-amyloid treatments? Should they be treated? Evidence from the real-life Cogfrail cohort**
Davide Angioni [1], Sandrine Sourdet [1], Julien Delrieu [1], Gaelle Soriano [1], Alberta Peluso [1], Gabor Abellan [1], Pierre-Jean Ousset [1], Bruno Vellas [1]
[1]Institut Hospitalo Universitaire HealthAge, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital - Toulouse (France)

LP042 **Characteristics of patients attending our Alzheimer's disease-modifying therapy clinic in Japan: Implication for clinical trials**
Masanori Kurihara [1], Ryoko Ihara [1], Keiko Hatano [1], Akira Hatakeyama [2], Fumio Suzuki [3], Aya Midori Tokumaru [3], Kenji Ishii [4], Ko Furuta [5], Atsushi Iwata [1]
[1]Department of Neurology, Tokyo Metropolitan Institure for Geriatrics and Gerontology - Tokyo (Japan), [2]Dementia Support Center, Tokyo Metropolitan Institure for Geriatrics and Gerontology - Tokyo (Japan), [3]Department of Diagnostic Radiology, Tokyo Metropolitan Institure for Geriatrics and Gerontology - Tokyo (Japan), [4]Research Team for Neuroimaging, Tokyo Metropolitan Institure for Geriatrics and Gerontology - Tokyo (Japan), [5]Department of Psychiatry, Tokyo Metropolitan Institure for Geriatrics and Gerontology - Tokyo (Japan)

LP043 **Novel diagnostic platform enabling protein specific biomarker signature for the diagnosis of AD**
Lawren Vandevrede [1], Rebecca Snell [1], Hilary Heuer [1], Courtney Lane-Donovan [1], Peter Ljubenkov [1], Julio Rojas [1], Adam Boxer [1]
[1]Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco - San Francisco (United States)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

POSTER SESSION 2: From Thursday, October 31 - 7:15 a.m. to Thursday, October 31 - 5:00 p.m.

THEME 3: Clinical Trials: imaging

P079 **Diabetes mellitus-induced differential cerebellar volume reduction across Alzheimer's disease trajectory**

Suhyung Kim [1], Sheng-Min Wang [2], Dong Woo Kang [3], Sunghwan Kim [2], Hyun Kook Lim [2], Yoo Hyun Um [1]

[1]Department of Psychiatry, St.Vincent's Hospital, College of Medicine, The Catholic University of Korea - Suwon (Korea, Republic of), [2]Department of Psychiatry, Yeouido St.Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), [3]Department of Psychiatry, Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)

P080 **Longitudinal Regional Volume Changes in the Cerebellum Across the Alzheimer's Disease Spectrum**

Um Yoo Hyun [1], Kim Suhyung [1], Wang Sheng-Min [1], Kang Dong Woo [1], Kim Sunghwan [1], Lim Hyun Kook [1]

[1]College of Medicine, Catholic University of Korea - Seoul (Korea, Republic of)

P081 **Comparison of accumulation rates of beta-amyloid tracers and their relationship with cognitive changes**

Soo Hyun Cho [1], Heekyoung Kang [2], Hongki Ham [3], Seunghwan Moon [4], Hyemin Jang [5], Jihwan Yun [6], Eun-Hye Lee [2], Daeun Shin [2], Sohyun Yim [7], Hee Jin Kim [2], Byeong Chae Kim [1], Duk L. Na [2], Sang Won Seo [2], Jun Pyo Kim [2]

[1]Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School - Gwangju (Korea, Republic of), [2]Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), [3]Neuroscience Center, Samsung Medical Center - Seoul (Korea, Republic of), [4]Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), [5]Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Jongno-gu - Seoul (Korea, Republic of), [6]Department of Neurology, Soonchunhyang University Bucheon Hospital - Gyeonggi-Do (Korea, Republic of), [7]Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of) - Seoul (Korea, Republic of)

P082 **Data-driven subtypes of white matter lesions are differentially associated with vascular and Alzheimer's pathology**

Lyduine E. Collij [1,2], Sophie E. Mastenbroek [3,2], Katja Steijn [3,2], Carole Sudre [4], Danielle Van Westen [3], Olof Strandberg [3], Niklas Mattsson-Carlgren [3], Sebastian Palmqvist [3], Erik Stomrud [3], Jacob E. Vogel [3], Rik Ossenkoppele [2,3], Oskar Hansson [1]

[1]Lund Univeristy - Lund (Sweden), [2]Amsterdam UMC - Amsterdam (Netherlands), [3]Lund University - Lund (Sweden), [4]King's College London - London (United Kingdom)

P083 **Neuroimaging data harmonization in multisite studies of Alzheimer's Disease and potential implications on effect sizes in clinical trials.**

Dana Tudorascu [1], Alex Delbene [1], Alexandra Gogola [1], Weiquan Luo [1], Charles Laymon [1], Changlee Chen [1], Mahbaneh Torbati [1], Val Lowe [2], David Soleimani-Meigooni [3], Belen Pascual [4], Huamee Oh [5], Brian Gordon [6], Pedro Rosa-Neto [7], Tharick Pascoal [1], Suzanne Baker [8], Davneet Minhas [1]

[1]University of Pittsburgh - Pittsburgh (United States), [2]Mayo Clinic - Rochester (United States), [3]University of California at San Francisco - San Francisco (United States), [4]Houston Methodist - Houston (United States), [5]Brown University - Providence (United States), [6]Washington University of St. Louis - St. Louis (United States), [7]McGill University - Montreal (Canada), [8]Lawrence Berkeley National Laboratory - Berkeley (United States)

P084 **Novel regional flortaucipir visual read approaches to stratify subjects by tau spread: Evaluation in TRAILBLAZER-ALZ 2 phase 3 study of donanemab**

Ian Kennedy [1], Min Jung Kim [1], Anupa K. Arora [1], Ming Lu [1], Ilke Tunali [1], Leonardo Iaccarino [1], John R. Sims [1], Emily C. Collins [1], Mark A. Mintun [1], Sergey Shcherbinin [1]

[1]Eli Lilly and Company - Indianapolis (United States)

P085 **Multicenter Reader Study Assessing Diagnostic Accuracy of Amyloid-β Detection Comparing Real versus AI-based Amyloid-β PET Generated from Brain MRI**

Gregory Mathoux [1], Eliluane Pirazzo Andrade Teixeira [1], Phillippe Blanc [2], Nadya Pyatigorskaya [3], Debora-Elisa Peretti [4], Despoina Ioannidou [5], Audrey Duran [5], Gizem Temiz [5], Shibeshih Belachew [5], Nikos Paragios [5], Jacques Touchon [6], Bruno Vellas [7], Audrey Gabelle [6], Pierre Payoux [8], Giovanni Frisoni [9], Valentina Garibotto [10]

[1]Diagnostic Department, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital. - Geneva (Switzerland), [2]Nuclear Medicine Department, Centre Hospitalier d'Albi - Albi (France), [3]Neuroradiology Department, University Hospitals Pitié Salpêtrière - Paris (France), [4]Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Faculty of Medicine, Geneva University Neurocenter, University of Geneva - Geneva (Switzerland), [5]Therapanacea - Paris (France), [6]Faculty of Medicine, University of Montpellier - Montpellier (France), [7]Gérontopôle, Centre Hospitalier Universitaire de Toulouse - Toulouse (France), [8]Department of Nuclear Medicine, CHU Toulouse Purpan - Toulouse (France), [9]Department of Rehabilitation and Geriatrics, Memory Clinic, Geneva University Hospitals - Geneva (Switzerland), [10]Diagnostic Department, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, University of Geneva - Geneva (Switzerland)

P086 **Robustness of visual and quantitative assessment of [18F]PI-2620 PET scans evaluated with different mass doses**

Núria Roé-Vellvé [1], Henryk Barthel [2], Lorelei Howard [1], Norman Koglin [1], Andre Mueller [1], Audrey Perrotin [1], Aleksandar Jovalekic [1], Franziska Ruth Zientek [2], Michael Rullmann [2], Marianne Patt [2], Andreas Schildan [2], Tobias Jeschke [2], Olena Mishchenko [2], Mathias Berndt [2], Caroline Papin [1], Johnny Castillo-Melean [1], Andrew Stephens [1], Osama Sabri [2], Santiago Bullich [1]

[1]Life Molecular Imaging GmbH - Berlin (Germany), [2]Nuclear Medicine Department, University of Leipzig Medical Center - Leipzig (Germany)

P087 **Evaluation of a sensitive visual read algorithm for assessing tau PET images**

Ruben Smith [1], Valentina Garibotto [2], Douglas Hägerström [3], Jonas Jögi [4], Tomas Ohlsson [5], Olof Strandberg [1], Matteo Tonietto [6], Shorena Janelidze [1], Sebastian Palmqvist [1], Erik Stomrud [1], Gregory Klein [6], Oskar Hansson [1]

[1]Lund University, Clinical Memory Research Unit - Malmö (Sweden), [2]Division of Nuclear Medicine and Molecular Imaging, Diagnostic department, University Hospitals of Geneva - Geneva (Switzerland), [3]Skåne University Hospital, Department of Clinical Neurophysiology - Lund (Sweden), [4]Skåne University Hospital, Department of Clinical Physiology and Nuclear Medicine - Lund (Sweden), [5]Skåne University Hospital, Department of Radiation Physics - Lund (Sweden), [6]Hoffman La Roche Ltd. - Basel (Switzerland)

POSTER PRESENTATIONS

P088 **Regional Cerebral Hypometabolism and Pathological Heterogeneity in Sporadic Early Onset Alzheimer's Disease using Multi-probes PET/CT**

Zhu Zehua [1], Shi Jiong [2], Wang Shicun [3], Lv Xinyi [2], Shen Yong [2]

[1]Department of Nuclear Medcine, The First Affiliated Hospital of USTC - Hefei (China) - Hefei (China), [2]Department of Neurology, The First Affiliated Hospital of USTC - Hefei (China), [3]Department of Nuclear Medcine, The First Affiliated Hospital of USTC - Hefei (China)

P089 **First-in-human PET imaging study of intranasal insulin using the Aptar Cartridge Pump System**

Kiran K. Solingapuram Sai [1], Jennifer M. Erichsen [1], Krishna Gollapelli [1], Ivan Krizan [1], Mack Miller [1], Charles Cazzola [2], Reenal Gandhi [2], Julie Suman [2], Suzanne Craft [1]

[1]Wake Forest School of Medicine - Winston Salem (United States), [2]Aptar Pharma - Congers (United States)

P090 **FDG PET Findings according to Wandering Patterns of Patients with Drug-naïve Alzheimer's Disease**

Youngsoon Yang [1]

[1]Soonchunhyang University College of Medicine - Cheonan (Korea, Republic of)

P091 **Independent Effects of White Matter Hyperintensities on Frailty for Patients with Alzheimer's Dementia**

Won-Myong Bahk [1], Bo-Hyun Yoon [2], Kwanghun Lee [3], Hyung Mo Sung [4], Sung-Yong Park [5], Min-Kyu Song [6], Moon-Doo Kim [7], Hyun-Ju Yang [7], Sang-Yeol Lee [8]

[1]Professor, Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), [2]Psychiatrist, Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), [3]Professor, Department of Psychiatry, College of Medicine, Dongguk University - Gyeonju (Korea, Republic of), [4]Professor, Department of Psychiatry, Soonchunhyang University Gumi Hospital, - Gumi (Korea, Republic of), [5]Psychiatrist, Department of Psychiatry, Jeyo Hospital - Uiwang (Korea, Republic of), [6]Psychiatrist, St. Mary's Gon-Gam Mental Health Clinic - Siheung (Korea, Republic of), [7]Professor, Department of Psychiatry, College of Medicine, Jeju National University - Jeju (Korea, Republic of), [8]Professor, Department of Psychiatry, Wokwang University School of Medicine - Iksan (Korea, Republic of)

P092 **Olfactory Dysfunction Is Associated with Cerebral Amyloid Deposition and Cognitive Function in the Trajectory of Alzheimer's Disease**

Won-Myong Bahk [1], Bo-Hyun Yoon [2], Young-Joon Kwon [3], Kwanghun Lee [4], Sang-Yeol Lee [5], Hyung Mo Sung [6], Sung-Yong Park [7], Min-Kyu Song [8], Sheng-Min Wang [1], Hyun Kook Lim [1]

[1]Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), [2]Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), [3]Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University - Cheonan (Korea, Republic of), [4]Department of Psychiatry, College of Medicine, Dongguk University, - Gyeongju (Korea, Republic of), [5]Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), [6]Department of Psychiatry, Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University - Gumi (Korea, Republic of), [7]Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of), [8]St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of)

P093 **Sex-Related Disparities in the Resting State Functional Connectivity of the Locus Coeruelus and Salience Network in Preclinical Alzheimer's Disease**

Kwanghun Lee [1], Hyun Kook Lim [2], Sheng-Min Wang [2], Won-Myong Bahk [2], Bo-Hyun Yoon [3], Sang-Yeol Lee [4], Hyung Mo Sung [5], Sung-Yong Park [6], Min-Kyu Song [7]

[1]Department of Psychiatry, College of Medicine, Dongguk University - Gyeongju (Korea, Republic of), [2]Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), [3]Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), [4]Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), [5]Department of Psychiatry, Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University - Gumi (Korea, Republic of), [6]Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of), [7]St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of)

P094 **Sex-specific effects of APOE ε4 genotype on longitudinal hippocampal atrophy in mild cognitive impairment due to AD over a 2-year periodSex-specific effects of APOE ε4 genotype on longitudinal hippocampal atrophy in mild cognitive impairment due to AD over a 2-year period**

Hyunji Lee [1]

[1]Pusan National University Hospital - Busan (Korea, Republic of)

P095 **Multicenter study of associations between harmonized tau-PET CenTauR values and Alzheimer's disease neuropathology at autopsy: preliminary scope and study design**

Leonardo Iaccarino [1,2]

[1]Eli Lilly and Company - Indianapolis (United States), [2]Eli Lilly Italia S.p.A. - Sesto Fiorentino (Italy)

P096 **Sex differences in regional brain volume changes associated with verbal memory in patients with subjective cognitive decline**

Hyuk-Je Lee [1], Bora Yoon [1], Seonghee Ho [2], Yun Jeong Hong [3], Jee Hyang Jeong [4], Kee Hyung Park [5], Sangyun Kim [6], Min Jeong Wang [7], Seong Hye Choi [8], Dong Won Yang [1]

[1]Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), [2]Department of Neurology, Hanyang University Hanmaeum Changwon Hospital - Changwon (Korea, Republic of), [3]Department of Neurology, College of Medicine, The Catholic University of Korea, Uijeongbu St. Mary's Hospital - Uijeongbu (Korea, Republic of), [4]Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine - Seoul (Korea, Republic of), [5]Department of Neurology, Gachon University Gil Hospital - Incheon (Korea, Republic of), [6]Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), [7]Roa Neurology Clinic - Seongnam (Korea, Republic of), [8]Department of Neurology, Inha University School of Medicine - Incheon (Korea, Republic of)

P097 **TSPO PET as inflammation biomarker in dementia**

Belen Pascual [1], Quentin Finn [1], Kaitlee Ornelas [1], Alireza Faridar [1], Jon B. Toledo [1], Mohammad O. Nakawah [1], Gustavo C. Roman [1], Joseph C. Masdeu [1]

[1]Houston Methodist Research Institute - Houston (United States)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

P098 **Enhancing the effectiveness of Alzheimer's disease drug development by assessing tau PET as a promising surrogate endpoint within the pre-competitive Critical Path for Alzheimer's Disease (CPAD) consortium**

Yashmin Karten [1], Dries De Witte [2], Michael Irizarry [3], Gregory Klein [4], Antoine Leuzy [1,5], Klaus Romero [1], Eileen Priest [1], Colleen Jacobsen [1], Abad Ariel Alonso [2,6], Geert Molenberghs [2,6], Diane Stephenson [1]

[1]Critical Path Institute - Tucson (United States), [2]L-Biostat, KU Leuven - Leuven (Belgium), [3]Eisai - Nutley (United States), [4]F. Hoffmann-La Roche Ltd. - Basel (Switzerland), [5]Enigma Biomedical USA - Knoxville (United States), [6]I-BioStat, Hasselt University - Hasselt (Belgium)

P099 **Voxel-based morphometric analysis of selected brain regions in MCI subjects treated with choline alphoscerate**

Enea Traini [1], Anna Carotenuto [1], Mohamed Hossein [1], Vincenzo Andreone [2], Amenta Francesco [1]

[1]Centro Ricerche Cliniche, Telemedicina e Telefarmacia, Università di Camerino - Camerino (Italy), [2]Neurology and Stroke Unit-Neurology, A. Cardarelli Hospital - Napoli (Italy)

P100 **Association between the new sub-classified white matter hyperintensities volume and cognitive function in elderly**

Yoon Bo-Hyun [1], Bahk Won-Myong [2], Lee Kwanghun [3], Lee Sang-Yeol [4], Sung Hyung Mo [5], Song Min-Kyu [6], Park Sung-Yong [7], Kim Moon-Doo [8], Yang Hyun-Ju [8]

[1]Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), [2]Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), [3]Department of Psychiatry, College of Medicine, Dongguk University, - Gyeongju (Korea, Republic of), [4]Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), [5]Department of Psychiatry, Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University - Gumi (Korea, Republic of), [6]St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of), [7]Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of), [8]Department of Psychiatry, College of Medicine, Jeju National University - Jeju (Korea, Republic of)

P101 **Allopregnanolone Preserves White Matter Structure Independent of APOE genotype in Early Alzheimer's Disease**

Adam Raikes [1], Gerson Hernandez [1], Claudia Lopez [1], Lon Schneider [2], Roberta Brinton [1]

[1]Center for Innovation in Brain Science, University of Arizona - Tucson (United States), [2]USC School of Medicine - Los Angeles (United States)

LP045 **Frontal cognitive dysfunction corresponding to severity of cerebral white matter hyperintensities in probable Alzheimer's disease**

Mee Y. Park [1], Hyun J. Han [2], Jean S. An [3], K.Y. Ahn [1]

[1]Yeungnam Medical University Center - Daegu (Korea, Republic of), [2]Ilsanbrin neurology clinic - Ilsan (Korea, Republic of), [3]University of Ilinois Chicago - Chicago (United States)

LP046 **Concordance between FDA-approved visual interpretation of [18F]flortaucipir PET images and the CenTauR scale**

Stamatia Karagianni [1,2], Alexis Moscoso [3,4,5], Martijn Van Essen [6], Ismini Mainta [7], Valle Camacho [8], Omar Rodríguez-Fonseca [9], Jesús Silva-Rodríguez [10,11], Andrés Perissinotti [12,13], Nicolai Franzmeier [14,15,4], Michel J. Grothe [10,11], Giovanni B. Frisoni [16,17], Valentina Garibotto [7,18], Michael Schöll [19,4,20,17]

[1]Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden), [2]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Gothenburg (Sweden), [3]Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, - Gothenburg (Sweden), [4]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy- Gothenburg (Sweden), [5]Nuclear medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela- Santiago De Compostela (Spain), [6]Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden. - Gothenburg (Sweden), [7]Geneva University Hospitals- Geneva (Switzerland), [8]Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, (Spain), [9]Nuclear Medicine Department HULA - Lugo (Spain), [10]CIBER-BBN - Madrid (Spain), [11]Reina Sofía Alzheimer's Centre, CIEN Foundation, ISCIII, Madrid- Madrid (Spain), [12] Clínic Barcelona, Barcelona (Spain), [13] ISCIII, Barcelona (Spain), [14]Institute for Stroke and Dementia Research, LMU - Munich (Germany), [15]Munich Cluster for Systems Neurology (SyNergy) - Munich (Germany), [16]Geneva Memory Center, Geneva University Hospitals - Geneva (Switzerland), [17]LANVIE, University of Geneva - Geneva (Switzerland), [18]Faculty of Medicine, University of Geneva - Geneva (Switzerland), [19]Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg (Sweden), [20]Sahlgrenska University Hospital. - Gothenburg (Sweden)

LP047 **Functional connectivity, cerebral blood flow, and cortical thickness changes evaluated in patients with Alzheimer's disease receiving anti-amyloid therapy**

Antoine Hone-Blanchet [1], Tao Sun [1], Gersham Dent [1], Carrie Rubel [1], Jonathan Dubois [1], Jennifer Murphy [1], R. Matthew Hutchison [1], John O'gorman [1]

[1]Biogen - Cambridge (United States)

THEME 04: Clinical trials: biomarkers including plasma

P102 **Determination of plasma biomarkers for the early and specific detection of Alzheimer's disease**

Lourdes Álvarez-Sánchez [1], Carmen Peña-Bautista [1], Laura Ferré-González [1], Laura Cubas [2], Ángel Balaguer [3], Bonaventura Casanova-Estruch [2], Baquero-Toledo Miguel [4], Cháfer-Pericás Consuelo [4]

[1]Instituto de Investigación Sanitaria La Fe; - Valencia (Spain), [2]Division of Neuroinmunology; University and Polytechnic Hospital La Fe - Valencia (Spain), [3]Math faculty, Universitat de València - Valencia (Spain), [4]Alzheimer Disease Research Group, Instituto de Investigación Sanitaria La Fe - Valencia (Spain)

POSTER PRESENTATIONS

P103 **Evaluating the Performance of Plasma Phosphorylated-Tau 181 and Apolipoprotein E4 in Early Detection of Amyloid Pathology in a Multi-Center Study Reflective of Routine Clinical Practice**

Imke Kirste [1], Sayuri Hortsch [2], Sheila Baez-Torres [3], Mercè Boada [4], Monica Crane [5], Frederiksen Kristian Steen [6], Kevin Hanson [7], Jonathan Liss [8], Jeffrey Norton [9], Marc Suárez-Calvet [10], Craig Ritchie [11], Stephanie Rutrick [12], David Watson [13], Kelley Yokum [14], Clara Quijano-Rubio [15]

[1]Roche Molecular Solutions - Indianopolis (United States), [2]Roche Diagnostics GmbH - Penzberg (Germany), [3]K2 Medical Research Maitland - Maitland (United States), [4]ACE Alzheimer Center Barcelona - Barcelona (Spain), [5]Genesis Neuroscience Clinic/Tennessee Memory Disorders Foundation - Knoxville (United States), [6]Danish Dementia Research Centre, Department of Clinical Medicine - Copenhagen (Denmark), [7]Eastside Research Associates - Redmond (United States), [8]Columbus Memory Center - Columbus (United States), [9]Charter Research Lady Lake - The Villages (United States), [10]Barcelona Beta Brain Research Center - Barcelona (Spain), [11]Brain Health Scotland - Edinburgh (United Kingdom), [12]Adams Clinical - Watertown (United States), [13]Alzheimer's Research and Treatment Center - Wellington (United States), [14]K2 Medical Research, LLC - Tampa (United States), [15]Roche Diagnostics International Ltd - Rotkreuz (Switzerland)

P104 **Plasma pTau181 and pTau217 similarly predict asymptomatic amyloid accumulation with performances comparable to amyloid-PET**

Steffi De Meyer [1], Jolien Schaeverbeke [1], Emma Luckett [1], Elena Blujdea [2], Patrick Dupont [1], Koen Van Laere [3], Jeroen Vanbrabant [4], Erik Stoops [4], Eugeen Vanmechelen [4], Guglielmo Di Molfetta [5], Henrik Zetterberg [5], Nicholas Ashton [5], Charlotte Teunissen [6], Koen Poesen [3], Rik Vandenberghe [3]

[1]KU Leuven - Leuven (Belgium), [2]UMC Amsterdam - Amsterdam (Netherlands), [3]UZ Leuven - Leuven (Belgium), [4]ADx NeuroSciences - Ghent (Belgium), [5]Sahlgrenska Academy - Mölndal (Sweden), [6]UMC Amsterdam - Amsterdam (Sweden)

P105 **Use of Non- genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity in Subjects with Active Alzheimer's Disease. Further Biomarker Analysis and Implications for Use in Prevention.**

Paul Song [1], Clemente Humberto Zúñiga Gil [2], Blanca Isaura Acosta Gallo [3], Cesar Alejandro Amescua [3], Rufino Menchaca Díaz [3], Sean Hong [1], Juan Mata [1], Katia Betito [1], Hank Lee [1], Yoonmi Kang [1], Lucia Hui [1]

[1]NKGen Biotech - Santa Ana (United States), [2]Tijuana General Hospital - Tijuana (Mexico), [3]Hospital Angeles - Tijuana (Mexico)

P106 **Analytical validation of an ultrasensitive immunoassay for detection of phosphorylated Tau217 in human biofluids**

Jacqueline Surls [1], Kolby Janzen [1], Hannah Rawlins [1], Robyn Vega Ibanez [1], Lindsey Brown [1], Joshua Kemp [1]

[1]Rules-Based Medicine, a Q Squared Solutions Company - Austin (United States)

P107 **Plasma p-tau217 Concentrations in Patients Undergoing Evaluation for Anti-Amyloid Therapy**

Alicia Algeciras-Schimnich [1], Susan Ashrafzadeh Kian [1], Joshua Bornhorst [1], Daniel Figdore [1], Jonathan Graff-Radford [1], Ronald Petersen [1], Vijay Ramanan [1]

[1]Mayo Clinic - Rochester (United States)

P108 **Integrative analysis of clinical stages, plasma biomarkers, and cognitive trajectories according to AT classification in Alzheimer's disease related cognitive impairment, subcortical vascular cognitive impariment, and frontotemporal dementia**

Soyeon Yoon [1], Min Young Chun [2], Jihwan Yun [3], Daeun Shin [1], Eun Hye Lee [1], Hyemin Jang [4], Jun Pyo Kim [1], Hee Jin Kim [1], Duk L Na [1], Sang Won Seo [1]

[1]Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Gangnam-Gu, Seoul (Korea, Republic of), [2]Department of Neurology, Yonsei University College of Medicine - Seoul (Korea, Republic of), [3]Department of Neurology, Soonchunhyang University Bucheon Hospital - Gyeonggi-Do (Korea, Republic of), [4]Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine - Jongno-Gu, Seoul (Korea, Republic of)

P109 **Association of plasma Aβ42/Aβ40 with brain amyloidosis and conversion to mild cognitive impairment after a 5-year follow-up in individuals with subjective cognitive decline: data from the FACEHBI cohort.**

José Antonio Allué [1], María Pascual-Lucas [1], Leticia Sarasa [1], Noelia Fandos [1], Jorge Loscos [1], Juan Pablo Tartari [2], Ángela Sanabria [2,3], Montserrat Alegret [2,3], Óscar Sotolongo-Grau [2], Lluís Tàrraga [2,3], Agustín Ruiz [2,3], María Eugenia Sáez [4], Marta Marquié [2,3], Jose Terencio [1,5], Mercè Boada [2,3]

[1]Araclon Biotech-Grifols - Zaragoza (Spain), [2]Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya - Barcelona (Spain), [3]CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases. National Institute of Health Carlos III. - Madrid (Spain), [4]CAEBI, Centro Andaluz de Estudios Bioinformáticos. - Sevilla (Spain), [5]Grifols S.A. - Barcelona (Spain)

P110 **Prediction of Alzheimer's disease using an AI driven screening platform: PREDICTOM study design**

Anna-Katharine Brem [1], Zunera Khan [1], Mark Ashworth [1], Nicholas Ashton [1], Sigurd Brandt [2], Anne Corbett [3], Ana Diaz [4], Holger Fröhlich [5], Martha Therese Gjestsen [6], Dianne Gove [4], Sandeep Kaushik [7], Gaby Marquardt [8], Matthias Müllenborn [9], Spiros Nikolopoulos [10], Dag Aarsland [1]

[1]King's Colleg London - London (United Kingdom), [2]GN Hearing - Copenhagen (Denmark), [3]University of Exeter - Exeter (United Kingdom), [4]Alzheimer Europe - Luxembourg (Luxembourg), [5]Fraunhofer SCAI - Bonn (Germany), [6]Stavanger University - Stavanger (Norway), [7]Alzheimer GE Healthcare - Munich (Germany), [8]Siemens Healthineers - Erlangen (Germany), [9]Novo Nordisk - Copenhagen (Denmark), [10]CERTH - Thessaloniki (Denmark)

P111 **Cerebrospinal fluid levels of VAMP-2 and SNAP-25 are associated with executive function in dementia with Lewy bodies, an effect that is cofounded by Alzheimer comorbidity**

Alba Cervantes González [1,2], Julie Goosens [3], Nele Dewit [4], Laia Lidón [1,2], Danna Perlaza [1,2], Juan Fortea [1,2], Daniel Alcolea [1,2], Alberto Lleo [1,2], Eugeen Vanmechelen [3], Olivia Belbin [1,2]

[1]Sant Pau Memory Unit, Neurology Department and IIB-Sant Pau, Hospital de La Santa Creu I Santa Pau, Universitat Autonoma de Barcelona - Barcelona (Spain), [2]Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), - Madrid (Spain), [3]ADx NeuroSciences NV, Zwijnaarde - Ghent (Belgium), [4]Medpace Reference Laboratories (A.A.), Flow Cytometry Unit - Louvain (Belgium)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

P113 **Novel plasma assay for p-Tau217: Evaluation in a cohort of individuals with cerebral amyloidosis and Alzheimer's disease.**

Etienne Mondesert [1], Anne Marie Dupuy [1], Paul Wynveen [2], Corey Carlson [2], Miklos Szabo [2], Kevin Ley [2], Chris Knutson [2], Jean-Sebastien Blanchet [3], Constance Delaby [1], Germain Busto [4], Christophe Hirtz [1], Jean-Paul Cristol [5], Sylvain Lehmann [1]

[1]LBPC-PPC, University Montpellier, CHU Montpellier, INM INSERM, Montpellier, France - Montpellier (France), [2]Beckman Coulter Diagnostics - Chaska (United States), [3]Beckman Coulter France - Villepinte (France), [4]CMRR, University Montpellier, CHU Montpellier, INM INSERM - Montpellier (France), [5]Biochimie Lapeyronie, University Montpellier, CHU Montpellier - Montpellier (France)

P114 **Plasma p-tau217 measurement as a screening tool for future AD neuropathology proxy status in dementia-free individuals from the British 1946 birth cohort**

Ashvini Keshavan [1], William Coath [1], David M. Cash [1], Frederik Barkhof [2, 3, 4], Amanda Heslegrave [5], Henrik Zetterberg [5, 6, 7, 8], Jonathan M. Schott [1]

[1]Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology - London (United Kingdom), [2]Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centre - Amsterdam (Netherlands), [3]Centre for Medical Image Computing, University College London - London (United Kingdom), [4]Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square - London (United Kingdom), [5]UK Dementia Research Institute, University College London, London - London (United Kingdom), [6]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg - Molndal (Sweden), [7]Hong Kong Center for Neurodegenerative Diseases, Science Park - Hong Kong (China), [8]School of Medicine and Public Health, University of Wisconsin-Madison - Madison, Wisconsin (United States)

P115 **Levels of p-tau217 in blood and its capacity to predict patterns change of cognitive trajectories in elderly: 10 years follow-up Vallecas Project.**

Elizabeth Valeriano Lorenzo [1,2], Sonia Wagner [1], David García [3], Alicia Ruiz [1], Ana Belén Pastor [1], Belén Frades [1], Meritxell Valentí [1], Mario Ricciardi [1], Maria Ascencion Zea [1], Marta Antón [1], Teodoro Del Ser [1], Pascual Sánchez-Juan [1]

[1]Fundacion CIEN - Madrid (Spain), [2]Universidad Autónoma de Madrid - Madrid (Spain), [3]Universidad Complutense de Madrid - Madrid (Spain)

P116 **Using neural derived EV-bound biomarkers in blood for the accurate classification of alpha synuclein aggregation in the brain**

Nicholas Rui Yuan Ho [1], Rasheed Samat [1], Gladys Ho [1], Peter Maimonis [2], Mario Morken [2], Marc Cantillon [2]

[1]Sunbird Bio - Singapore (Singapore), [2]Sunbird Bio - Cambridge, Ma (United States)

P117 **Plasma pTau181 predicts clinical progression in mild Alzheimer's Disease in a randomized controlled trial**

Dana Hilt [1], Jack Taylor [1], Mark Jaros [2], Christopher Chen [3], John Harrison [4, 5, 6]

[1]Actinogen Medical - Sydney (Australia), [2]Summit Analytical - Chicago (United States), [3]Memory Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), [4]Scottish Brain Sciences, Edinburgh, United Kingdom - Edinburgh (United Kingdom), [5]King's College - London (United Kingdom), [6]Alzheimercentrum, AUmc - Amsterdam (Netherlands)

P118 **Introduction of multi-dimension biomarkers application for a randomized, double-blind, single-simulated clinical trial of sodium oligomannate on Alzheimer's disease**

Wang Qiong [1], Dai Linbin [2], Gao Feng [2], Shi Jiong [2], Shen Yong [2]

[1]The first Affiliated Hospital of USTC - Hefei (China), [2]The first Affiliated hospital of USTC - Hefei (China)

P119 **Plasma p-tau and Amyloid biomarkers discrimination accuracy of biologically-defined Alzheimer's disease in a memory clinic setting: a head-to-head study**

Federica Anastasi [1], Aida Fernández-Lebrero [1], Nicholas J. Ashton [2], Paula Ortiz-Romero [1], Esther Jiménez-Moyano [1], Javier Torres-Torronteras [1], Marta Milà-Alomà [1], José Contador [1], Greta García-Escobar [3], Oriol Grau-Rivera [1], Henrik Zetterberg [2], Marta Del Campo [1], Kaj Blennow [2], Albert Puig-Pijoan [3], Marc Suárez-Calvet [1]

[1]BarcelonaBeta Brain Research Center - Barcelona (Spain), [2]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden - Gothenburg (Sweden), [3]Hospital del Mar Research Institute, Barcelona, Spain

P120 **Associations of dementia risk scores with glucose and lipid-related metabolic blood biomarkers in the persons at-risk of dementia**

Sabsil Ana Lopez Rocha [1], Ruth Stephen [1], Alina Solomon [2], Tiia Ngandu [3], Jenni Lehtisalo [3], Tiina Laatikainen [3], Patrizia Mecocci [4], Jaakko Tuomilehto [5], Miia Kivipelto [1], Francesca Mangialasche [1]

[1]Karolinska Institutet - Stockholm (Sweden), [2]University of Eastern Finland - Kuopio (Finland), [3]Finnish Institute for Health and Welfare - Helsinki (Finland), [4]Università di Perugia - Perugia (Italy), [5]Univeristy of Helsinki - Helsinki (Finland)

P121 **Acceleration of epigenetic age as a biomarker for cognitive impairment: findings from the Diet and Healthy Aging cohort**

Kaisy Ye [1]

[1]National University of Singapore - Singapore (Singapore)

P122 **The clinical impact of blood-based biomarkers: the PLASMAR study**

Gianmarco Iaccarino [1,2], José Miguel Contador [1, 3, 4], Isabel Estragués [5, 3, 6], Leydi Dayana Martìnez [7, 4, 3], Aida Fernandez Lobrero [5, 8, 3], Irene Navalpotro-Gomez [5], Greta García-Escobar [3], Rosa Maria Manero [9], Oriol Grau-Rivera [5, 4, 10], Juan Jose Hernandez-Sanchez [11], Anna Padròs-Fluvià [11], Paula Ortiz-Romero [5], Javier Torres-Torronteras [5], Marta Del Campo [5, 12, 3], Albert Puig-Pijoan [3, 4], Marc Suárez-Calvet [5, 3, 4, 10]

[1]BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain) - Barcelona (Spain), [2]Università Campus Bio-Medico - Roma (Italy), [3]Hospital del Mar Research Institute - Barcelona (Spain), [4]Servei de Neurologia, Hospital del Mar - Barcelona (Spain), [5]BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), [6]Servei de Neurologia, Hospital del Mar, - Barcelona (Spain), [7]BarcelonaBeta Brain Research Center (BBRC) - Barcelona (Spain), [8]Cognitive Decline and Movement Disorders Unit, Neurology Department - Barcelona (Spain), [9]Hospital del Mar Research Institute - Barcelona (Spain) - Barcelona (Spain), [10]Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III - Madrid (Spain), [11]Laboratori de Referència de Catalunya - Barcelona (Spain), [12]Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities - Madrid (Spain)

POSTER PRESENTATIONS

P123 **Is serum p-tau217 a viable blood source as a biomarker for Alzheimer's disease?**

Andrea L. Benedet [1], Burak Arslan [1], Kubra Tan [1], Hanna Hulbert [1], Ilaria Pola [1], Guglielmo Di Molfetta [1], Kaj Blennow [1], Henrik Zetterberg [1], Nicholas J. Ashton [2]

[1]Gothenburg University - Gothenburg (Sweden), [2]Banner Health - Phoenix (United States)

P124 **A Two-Stage Approach to Risk Stratification in Early-Stage Alzheimer's Disease: Utilizing MRI and Plasma p-Tau217**

Sohyun Yim [1], Henrik Zetterberg [2, 3, 4, 5], Kaj Blennow [2, 3, 6, 7], Hyemin Jang [8], Junpyo Kim [9], Heejin Kim [9, 10, 11, 12], Duk L Na [9, 10], Sungbum Park [13], Sangwon Seo [9, 3, 11, 12], Kichang Kwak [13]

[1]Department of Neurology, Samsund - Seoul (Korea, Republic of), [2]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg - Gothenberg (Sweden), [3]Clinical Neurochemistry Laboratory, Sahlgenska University Hospital - Gothenberg (Sweden), [4]Department of Neurodegenerative Disease, UCL Institute of Neurology - London (United Kingdom), [5]UK Dementia Research Institute at UCL - London (United Kingdom), [6]Paris Brain Institute, ICM, Pitie-Salpetriere Hospital, Sorbonne University - Paris (China), [7]Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC - Hefei (Sweden), [8]Department of Neurology, Seoul National University Hospital, Seoul National University College of Medcine - Seoul (Korea, Republic of), [9]Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), [10]Alzheimer's Disease Convergence Research Center, Samsung Medical Center - Seoul (Korea, Republic of), [11]Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University - Seoul (Korea, Republic of), [12]Neuroscience Center, Samsung Medical Center - Seoul (Korea, Republic of), [13]R&D Center, BeauBrain Healthcare - Seoul (Korea, Republic of)

P125 **Fluid biospecimens and genetic data collection and dissemination: new pipelines to serve the dementia research community from the UCSF Memory and Aging Center**

Argentina Lario Lago [1], Julia Webb [1], Taylor Young [1], Kristina Noyes [1], Rose George [1], Karen Smith [1], Ana Tyler [1], Eliana Ramos [2], Hilary Heuer [1], Mary Koestler [1], Lawren Vandevrede [1], Renaud Lajoie [1], Gil Rabinovici [1], Bruce Miller [1], Julio Rojas [1], Kaitlin Casaletto [1], Jennifer Yokoyama [1], Adam Boxer [1]

[1]Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. - San Francsico (United States), [2]Department of Neurology, University of California Los Angeles. - Los Angeles (United States)

P126 **Associations between Cognitive Impairment, ApoE genotype and Plasma p-tau Biomarkers in European MCI Populations: Insights from the AI-Mind Project**

Guido Maria Giuffrè [1, 2], Ana Perez [3], Soraya Alfonsin [4, 5], Christoffer Hatlestad-Hall [3], Timo Saarinen [6], Naike Caraglia [1], Erik Christensen [7], Gwendlyn Kollmorgen [8], Kaj Blennow [9, 10], Henrik Zetterberg [9, 10], Fernando Maestú [4, 5], Hanna Renvall [6, 11], Ira Hebold Haraldsen [3], Paolo Maria Rossini [12], Camillo Marra [1, 2]

[1]Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), [2]Department of Neuroscience, Catholic University of the Sacred Heart - Rome (Italy), [3]Department of Neurology, Oslo University Hospital - Oslo (Norway), [4]Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), [5]Department of Experimental Psychology, Cognitive Psychology and Speech and Language Therapy, Universidad Complutense de Madrid - Pozuelo De Alarcón (Spain), [6]BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science - Helsinki (Finland), [7]Pre Diagnostics AS - Oslo (Norway), [8]Roche Diagnostics GmbH - Penzberg (Germany), [9]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), [10]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), [11]Department of Neuroscience and Biomedical Engineering, Aalto University - Helsinki (Finland), [12]Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele - Rome (Italy)

P127 **Fully automated ultrasensitive Simoa assay for brain-derived tau: enhancing the characterization of Alzheimer's disease-related neurodegeneration in blood**

Jing Shi [1], Casey Sheehy [1], Julio Herrera [1], David Wilson [1], Prasad Gawande [1], Mike Miller [1], Kishore Malyavantham [1]

[1]Quanterix - Billerica (United States)

P128 **Evaluation of the effects of repeated lumbar punctures on Alzheimer's Disease CSF and blood biomarkers**

Anne Biever [1], Yixuan Zou [1], Cassandra Arneja [1], Schauer Stephen [1], Calderon Emilia [1], Ceniceros Ryan [1], Gwendlyn Kollmorgen [2], Tobias Bittner [3], Lyle Jew [4], Thomas Kremer [3], Venissa Machado [3], Bastian Zinnhardt [3], Cross Nicholas [5], Kaj Blennow [6], Edmond Teng [1]

[1]Genentech Inc - San Francisco (United States), [2]Roche Diagnostics - Penzberg (Germany), [3]Roche - Basel (Switzerland), [4]Genentech Inc - San Francisco (Switzerland), [5]New Zealand Clinical Research - Christchurch (New Zealand), [6]Department of Psychiatry and Neurochemistry - Gothenburg (Sweden)

P129 **Concordance between the updated Elecsys CSF immunoassays and amyloid PET for the diagnosis of Alzheimer's disease: Findings from the Apollo study**

Henrik Schinke [1], Magnus Förnvik Jonsson [2, 3], Mayme Gummesson [2], Rikard Nilsson [2], Stefanie Gaupp [1], Ekaterina Manuilova [1], Silja Mcilwrick [1], Margherita Carboni [4], Erik Stomrud [5, 6]

[1]Roche Diagnostics GmbH - Penzberg (Germany), [2]Department of Clinical Chemistry and Pharmacology, Skåne University Hospital - Lund (Sweden), [3]Department of translational medicine, Lund university - Lund (Sweden), [4]Roche Diagnostics Int. AG - Rotkreuz (Switzerland), [5]Clinical, Memory Research Unit, Department of Clinical Sciences Malmö - Malmö (Sweden), [6]Memory Clinic, Skåne University Hospital - Malmö (Sweden)

P130 **Unraveling the Enigma in Cerebral Amyloid Angiopathy, Plasma Alzheimer's Downstream Markers, and Cognitive Decline: in relation to amyloid uptakes**

Sung Hoon Kang [1], Eun Hye Lee [2], Jun Pyo Kim [2], Sang Won Seo [2]

[1]Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine - Seoul (Korea, Republic of), [2]Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of)

P131 **Detection of Cerebral Amyloid Angiopathy (CAA) in Alzheimer's Disease (AD) using blood biomarkers.**

Mario Ricciardi [1], Elizabeth Valeriano-Lorenzo [1], María Ascensión Zea-Sevilla [1], Meritxell Valentí [1], Belén Frades [1], Alicia Ruiz-González [1], Ana Belén Pastor [1], Francisco López-González [1], Paloma Ruiz [1], Laura Saiz [1], Iván Burgueño-García [1], María José López-Martínez [1], Alberto Rábano [1], Teodoro Del Ser [1], Pascual Sánchez-Juan [1]

[1]Alzheimer's Centre Reina Sofía-CIEN Foundation-ISCIII - Madrid (Spain)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

P132 **Davos Alzheimer's Collaborative Healthcare System Preparedness: Accurate Diagnosis Project Methodology**
Amy Deckert [1], Katherine J. Selzler [1], Monica Zigman Suchsland [1], Tim Macleod [1], Alissa Kurzman [1], Karen Weyrauch [1]
[1]Davos Alzheimer's Collaborative - Wayne (United States)

P133 **Preliminary evaluation of plasma ALZpath p-tau217 for detecting amyloid pathology in a diverse community-based cohort**
Michelle Mielke [1]
[1]Wake Forest University School of Medicine - Winston Salem (United States)

P134 **Advancing Detection of Neurological Biomarkers in Blood Using a Novel Ultrasensitive Single Molecule Counting Technology**
Renee Tobias [1], Peter Wagner [1], Johanna Sandlund [1], Kazushige Moriyama [2], Masayasu Imaizumi [2], Yukina Kawada [2], Kumiko Hamano [2], Frank Zaugg [1], Gipshu Dave [1], Daigo Inaoka [1], Hayato Kimura [1], Ko Kobayashi [1], Valerie Brachet [1]
[1]Fluxus, Inc. - Sunnyvale (United States), [2]Fujirebio, Inc. - Tokyo (Japan)

P135 **A two-stage machine learning model predicts amyloid β positivity accurately and cost effectively**
Wenjun Zhu [1], Li Sun [1], So-Youn Shin [1], Joseph Donahue [1], Jeanne Latourelle [1]
[1]Aitia - Somerville (United States)

P136 **Use of CSF sTREM2/total-tau ratio as a potential prognostic biomarker to identify fast progressors in early Alzheimer's disease**
Jennifer Sorinas [1], Neva Coello [2], Nicole Pezous [2], Edward Khokhlovich [3], Alexandra Rogojina [2], Jelena Curcic [1], Harsha Kocherla [2], Kristin Hannesdottir [3]
[1]Biomedical Research, Novartis - Basel (Switzerland), [2]Novartis Pharma AG - Basel (Switzerland), [3]Biomedical Research, Novartis - Cambridge (United States)

P137 **Exploring the association between p-tau217 and performance-based digital assessment of cognitive functioning in mild cognitive impairment**
Ana Perez [1,2], Soraya Afonsin [3,4], Guido Giuffrè [5], Erik Christensen [6,2], Fernando Maestú [3,7], Hanna Renvall [8,4], Camillo Marra [5], Paolo Rossini [9], Christoffer Hatlestad-Hall [1], Ira Haraldsen [1,10]
[1]Department of Neurology, Oslo University Hospital - Oslo (Norway), [2]Department of Experimental Psychology, Cognitive Psychology and Speech and Language Therapy, Universidad Complutense de Madrid - Madrid (Spain), [3]Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), [4]Department of Neuroscience, Catholic University of the Sacred Heart - Rome (Italy), [5]Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), [6]Pre Diagnostics AS - Oslo (Norway), [7]BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science, - Helsinki (Finland), [8]Department of Neuroscience and Biomedical Engineering, Aalto University - Helsinki (Finland), [9]Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele - Rome (Italy), [10]Institute of Clinical Medicine, Faculty of Medicine, University of Oslo - Oslo (Norway)

P138 **New high-throughput, fully automated immunoassay for plasma neurofilament light chain**
Jeff Todtleben [1], Dusten Unruh [1], Miklos Szabo [1], Corey Carlson [1], Kara Curtis [1], Katie Hoffmann [1], Laura Mediger [1], James Mendoza [1], Mikaela Nichova-Doseva [1]
[1]Beckman Coulter Inc - Chaska, Mn (United States)

P139 **Clinical and analytical validation of LucentAD Complete, multi-marker algorithmic lab developed test (LDT) for high accuracy plasma detection of amyloid pathology**
David Wilson[1] Karen Copeland[2], Meenakshi Khare[1], Michele Wolfe[1], Patrick Sheehy[1], Lyndal Hesterberg[3], Ann-Jeanette Vasko[1], Wiesje van der Flier[4], Argonde van Harten[4], Inge Verberk[4], Charlotte Teunissen[4], Mike Miller[1]
[1]Quanterix Corporation - Billerica (United States) [2] Boulder Statistics - Steamboat Springs (United States) [3]HCS, Inc - Denver (United States) [4] Amsterdam UMC, Vrije Universiteit Amsterdam -Amsterdam, (Netherlands)

P140 **The diagnostic impact of plasma p-tau217 combined with structural magnetic resonance imaging in a memory clinic cohort.**
Jonas Jarholm [1,2], Sandra Tecelão [1], Bjørn-Eivind Kirsebom [3,4], Fernando Gonzalez-Ortiz [5,6], Lene Pålhaugen [1,2], Berglind Gísladóttir [1], Henrik Zetterberg [5,6,7,8], Kaj Blennow [5,6,9,10], Per Selnes [1,2], Tormod Fladby [1,2]
[1]Department of Neurology, Akershus University Hospital - Lørenskog (Norway), [2]Institute for Clinical Medicine, University of Oslo - Oslo (Norway), [3]Department of Neurology, University Hospital of North Norway - Tromsø (Norway), [4]Department of Psychology, Faculty of Health Sciences, The Arctic University of Norway - Tromsø (Norway), [5]Inst. of Neuroscience and Physiology, University of Gothenburg - Mölndal (Sweden), [6]Clinical Neurochemistry Lab, Sahlgrenska University Hospital - Mölndal (Sweden), [7]Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square - London (United Kingdom), [8]UK Dementia Research Institute at UCL - London (United Kingdom), [9]Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University - Paris (France), [10]Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC - Hefei (China)

P141 **Geographic Access to Amyloid PET Scans in the U.S.: Implications for Clinical Trials and Real-World Treatment**
Mark Hanson [1], Ying Liu [1], Hao Yin [1], Soeren Mattke [1]
[1]University of Southern California - Los Angeles (United States)

P142 **Implementation of p-tau181/Aβ42 and total-tau/Aβ42 Roche Elecsys ratios: Evaluation of cut-offs for p-tau181, total-tau and Aβ42**
Jessica Colon-Franco [1], Lynn Bekris [2], Sarah Zilka [1], Katie Troike [1], Maria Khrestian [2], Tousi Babak [3], Elizabeth Tuason [2], James Leverenz [3]
[1]Laboratory Medicine, Diagnostic Institute, Cleveland Clinic - Cleveland (United States), [2]Genomic Medicine Institute, Cleveland Clinic - Cleveland (United States), [3]Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic - Cleveland (United States)

P143 **Exploring the utility of plasma microRNA for early diagnosis of Alzheimer's disease.**
Joanna Williams [1], Diane Guevremont [1], Chris Fowler [2], Colin Masters [2], Ralph Martins [3], Wickliffe Abraham [1], Warren Tate [1], Nicholas Cutfield [1]
[1]University of Otago - Dunedin (New Zealand), [2]The Florey Institute - Melbourne (Australia), [3]Macquarie University - New South Wales (Australia)

P144 **The Plasma pTau181/217 ratio is highly sensitive to discriminate Alzheimer´s disease from other dementias– a pilot study in a memory clinic population**
Michaela Defrancesco [1], Alex Hofer [1], Christian Humpel [1]
[1] Medical University of Innsbruck - Innsbruck (Austria)

POSTER PRESENTATIONS

LP048 **Plasma Oligomer Beta-Amyloid is Associated with Disease Severity and Cerebral Amyloid Deposition in Alzheimer's Disease Spectrum**

Sheng-Min Wang [1], Dong Woo Kang [1], Yoo Hyun Um [1], Sunghwan Kim [1], Chang Uk Lee [1], Philip Scheltens [1], Hyun Kook Lim Lim [1]

[1]Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)

LP049 **A Multiomic Blood Biomarker Panel to Enhance AD Patient Selection and Therapy Outcomes**

Benoit Souchet [1], Elodie Fountis [2], Robert Popp [3], Adriano M. C. Pimenta [4], Baptiste Billoir [1], Evgeniy V. Petrotchenko [4], Christoph H. Borchers [4], Dimitri Petinataud [2], Jerome Braudeau [1]

[1]AgenT - Paris (France), [2]Inovie - Marseille (France), [3]MRM proteomics - Montreal (Canada), [4]McGill University - Montreal (Canada)

LP050 **Development of Blood-Based pTau217 Assay Using a Novel Ultrasensitive Single-Molecule Counting Technology**

Kumiko Hamano [1], Yukina Kawada [1], Masayasu Imaizumi [1], Gipshu Dave [2], Ko Kobayashi [2], Mariya Soban [2], Hayato Kimura [2], Kazushige Moriyama [1], Katsumi Aoyagi [1], Frank Zaugg [2], Peter Wagner [2], Johanna Sandlund [2], Renee Tobias [2], Valerie Brachet [2]

[1]Fujirebio, Inc., - Tokyo (Japan), [2]Fluxus, Inc. - Sunnyvale (United States)

LP051 **Analytical Performance of the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio**

Luna Buitrago [1], Francesca I. De Simone [1], Natalya Benina [1], Rachel R. Radwan [1], Jessica Junfola [1], Andie Graney [1], Natalie Goepfert [1], Eric Jones [1], M. Craig Miller [2], Abhay Moghekar [3], William T. Hu [4], Diana Dickson [1]

[1]Fujirebio Diagnostics Inc. - Malvern, Pa (United States), [2]Statistical Consultant, Fujirebio Diagnostics Inc. - Quakertown, Pa (United States), [3]Department of Neurology, Johns Hopkins School of Medicine - Baltimore, Md (United States), [4]Department of Neurology, Rutgers-Robert Wood Johnson Medical School and Center for Healthy Aging, Rutgers Institute for Health, Health Care Policy, and Aging Research - New Brunswick, Nj (United States)

LP052 **Exploring the association between blood-based biomarkers and cognitive-related oculomotor behaviours in asymptomatic carriers of the autosomal dominant mutation E280A-PSEN1.**

Mario Parra [1], Yakeel Quiroz [2], David Aguillon [3], Francisco Lopera [3], Danilo Verge [4], Gerardo Fernandez [5]

[1]Glasgow University - Glasgow (United Kingdom), [2]Harvard - Massachussets (United States), [3]Universidad de Antioquia - Medellin (Colombia), [4]ViewMind - Copenhagen (Denmark), [5]ViewMind - Bahia Blanca (Argentina)

LP053 **Impact of preanalytical factors on the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio**

Luna Buitrago [1], Francesca I. De Simone [1], Natalya Benina [1], Rachel R. Radwan [1], Amanda Calabro [1], Jessica Junfola [1], Natalie Goepfert [1], Abhay Moghekar [2], Diana Dickson [1]

[1]Fujirebio Diagnostics Inc. - Malvern, Pa (United States), [2]Department of Neurology, Johns Hopkins School of Medicine - Baltimore, Md (United States)

LP054 **Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD)**

Eden Barragan [1], Hilary Heuer [1], Rachel Nosheny [2,3], Monica Camacho [2,4], Krista Navarra [2,4], Paul Aisen [5], Annalise Rahman-Filipiak [6], J. Scott Roberts [6,7], Adeyinka Ajayi [8], Desiree Byrd [9], Monica Rivera-Mindt [8,10], Gil Rabinovici [1], Adam Boxer [1]

[1]Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco - San Francisco (United States), [2]VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center - San Francisco (United States), [3]Department of Psychiatry, University of California San Francisco - San Francisco (United States), [4]Northern California Institute for Research and Education (NCIRE) - San Francisco (United States), [5]VA Advanced Alzheimer's Therapeutic Research Institute, University of Southern California Imaging Research Center, San Francisco Veteran's Administration Medical Center - San Diego (United States), [6]Michigan Alzheimer's Disease Research Center, University of Michigan Alzheimer's Therapeutic Research Institute, University of Southern California Imaging Research Center, San Francisco Veteran's Administration Medical Center - Ann Arbor (United States), [7]Department of Health Behavior and Health Education, School of Public Health, University of Michigan - Ann Arbor (United States), [8]Department of Neurology, Icahn School of Medicine at Mount Sinai - New York (United States), [9]Department of Psychology, Queens College - Flushing (United States), [10]Departments of Psychology, Latin American Latino Studies, and African and African American Studies, Fordham University - New York (United States)

LP055 **Clinical performance of the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio**

Francesca I. De Simone [1], Luna Buitrago [1], Natalya Benina [1], Jessica Junfola [1], Stephen Menkes [1], James Koch [1], Douglas Hawkins [2], James Rock [3], Oskar Hansson [4,5], Erik Stomrud [4,5], Richard C. Mohs [6], Elaine Peskind [7,8], Jefferson Kinney [9], Sterling Johnson [10], Rachel R. Radwan [1]

[1]Fujirebio Diagnostics Inc. - Malvern, Pa (United States), [2]Scottsdale Scientific LLC - Austin, Tx (United States), [3]AriBio Co., Ltd - La Jolla, Ca (United States), [4]Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), [5]Memory Clinic, Skane University Hospital - Malmo (Sweden), [6]Global Alzheimer's Platform Foundation - Washington, Dc (United States), [7]Veterans Affairs Northwest Network Mental Illness Research, Education, and Clinical Center, Veteran Affairs Puget Sound Health Care System - Seattle, Wa (United States), [8]Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle, Wa, [9]Department of Brain Health, University of Nevada - Las Vegas, Nv (United States), [10]Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health - Madison, Wi (United States)

LP057 **Investigating personalized genomic profiling in Alzheimer's Disease using synchronized cells from autopsy-validated skin and blood samples**

Florin Chirila [1], Daniel L. Alkon [2]

[1]Spot Dx - Morgantown (United States), [2]Synaps Dx - Rockville (United States)

LP059 **Non-Invasive Detection of Dementia using Plasma Cell-Free DNA sequencing and Artificial Intelligence**

Jonathan Wan [1], Jay Ganbat [1], Tim Liu [1], Hannah Thompson [1], Henrik Zetterberg [1], Sofia Tonniolo [1], Husain Masud [1], Ivan Koychev [1], Ravi Solanki [1]

[1]CFDX - London (United Kingdom)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

LP060 **Plasma p-tau217, PET and cognition in an African American Sample: Results from the AA-FAIM study**
Rebecca Langhough [1], Lianlian Du [2], Rachael Wilson [1], Ramiro Reyes [1], Gilda Ennis [1], Fabu Carter [1], Nia Norris [1], Diane Gooding [3], Lauren Mclester-Davis [1], Carol Van Hulle [1], Nathaniel Chin [1], Megan Zuelsdorff [4], Henrik Zetterberg [1], Sterling Johnson [1], Carey Gleason [1]
[1]University of Wisconsin School of Medicine and Public Health - Madison (United States), [2]Rush University - Chicago (United States), [3]Dept of Psychology, University of Wisconsin, Madison - Madison (United States), [4]University of Wisconsin School of Nursing - Madison (United States)

LP061 **NULISA Assays for Inflammatory Markers in Fecal Samples from Patients with or at Risk for AD**
Sandra Harding [1], Barbara Bendlin [1], Margo Heston [1], Jea Woo Kang [1], Alfred Braceros [1], Joseph Luke Wheeler [1], Sushma Shankar [1], Alyssa Mickol [1], Hana Chow [1], Eric Zhang [1], Eleanor Clements [1], Faith Taylor [1], Aaliyah Mushtaque [1], Darby Peter [1], Sterling Johnson [1], Sanjay Asthana [1], Henrik Zetterberg [2], Blennow Kaj [2], Tyler K Ulland [1], Federico Rey [1]
[1]University of Wisconsin - Madison (United States), [2]University of Gothenburg - Gothenburg (Sweden)

LP062 **Advancing Alzheimer's Disease Stratification: Integrating APOE Genotyping with AI-Driven Biomarker Analysis**
Miguel Casanova [1], Seval Kuhl [1], Nicolas Scalzitti [2], Lucas Pham-Van [1], Gabriel Sanchez [3], Stéphanie Boutillier [1], Jean-Christophe Bier [4], Tamer Demiralp [5], Frédéric Blanc [6], François Sellal [7], Bruno Dubois [8], Hüseyin Firat [1]
[1]AMONETA - Huningue (France), [2]FIRALIS - Huningue (France), [3]FMP - Huningue (France), [4]ERASME Hospital - Bruxelles (Belgium), [5]Istanbul Faculty of Medicine - Istanbul (Turkey), [6]CHU Strasbourg - Strasbourg, France (France), [7]Hopitaux civils de colmar - Colmar (France), [8]AP-HP, Hôpitaux de Paris) - Paris (France)

LP063 **Elevated P-Tau217 is More Strongly Associated with Changes in Tau-PET and Cognition in Younger Adults: Findings from the A4 and LEARN studies.**
Gillian Coughlan [1], Hannah Klinger [1], Mabel Seto [1], Colin Birkenbihl [1], Michelle Farrell [1], Robert Rissman [2], Michael Properzi [1], Diana Townsend [1], Hyun-Sik Yang [1], Keith Johnson [1], Oliver Langford [2], Michael Donohue [2], Reisa Sperling [1], Rachel Buckley [1], Study Team A4/learn [1]
[1]Mass General Hospital/Harvard Medical School - Boston (United States), [2]Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)

LP064 **Plasma pTau217 as a single rule-in biomarker to diagnose underlying AD in early dementia patients.**
Thomas Wegehaupt [1], Patrick Sommer [1], Oliver Goldhardt [1], Josef Priller [1], Dennis Hedderich [1], Igor Yakushev [1], Timo Grimmer [1]
[1]Technical University of Munich, School of Medicine and Health, TUM University Hospital - Munich (Germany)

LP065 **Revamping Alzheimer's Disease Diagnostics: Evaluating Future IVD Plasma p-Tau 181 and ApoE4 Immunoassays for Amyloid Detection in a Multi-Center Study Reflective of Routine Clinical Practice**
Imke Kirste [1], Sayuri Hortsch [2], Sheila Baez-Torres [3], Mercè Boada [4], Monica Crane [5], Frederiksen Kristian Steen [6], Kevin Hanson [7], Jonathan Liss [8], Jeffrey Norton [9], Marc Suárez-Calvet [10], Craig Ritchie [11], Stephanie Rutrick [12], David Watson [13], Kelley Yokum [14], Clara Quijano-Rubio [15]
[1]Roche Molecular Solutions - Indianapolis (United States), [2]Roche Diagnostics GmbH - Penzberg (Germany), [3]K2 Medical Research - Maitland (United States), [4]ACE Alzheimer Center - Barcelona (Spain), [5]Genesis Neuroscience Clinic/Tennessee Memory Disorders Foundation - Knoxville (United States), [6]Danish Dementia Research Centre, Department of Clinical Medicine - Copenhagen (Denmark), [7]Eastside Research Associates - Redmond (United States), [8]Columbus Memory Center - Columbus (United States), [9]Charter Research Lady Lake - The Villages (United States), [10]Barcelona Beta Brain Research Center - Barcelona (Spain), [11]Brain Health Scotland - Edinburgh (United Kingdom), [12]Adams Clinical - Watertown (United States), [13]Alzheimer's Research and Treatment Center - Wellington (United States), [14]K2 Medical Research, LLC - Tampa (United States), [15]Roche Diagnostics International Ltd - Rotkreuz (Switzerland)

LP066 **Novel β-synuclein specific assays**
Julie Goossens [1], Charlotte De Rocker [1], Sherif Bayoumy [2], Megan De Pauw [1], Shreaysee Das [1], Wiesje Van Der Flier [2], Inge M. Verberk [2], Charlotte Teunissen [2], Eugeen Vanmechelen [1]
[1]ADx NeuroSciences - Gent (Belgium), [2]Amsterdam UMC - Amsterdam (Netherlands)

LP067 **High-throughput, fully automated immunoassay for detecting zygosity of apolipoprotein ε4 (APOE ε4) in EDTA plasma**
Brian Engel [1], Miklos Szabo [1], Katie Hoffmann [1], Ben Schlichtmann [1], Kara Curtis [1], Laura Mediger [1], Corey Carlson [1], James Mendoza [1], Mikaela Nichkova-Doseva [1]
[1]Beckman Coulter, Inc. - Chaska, Mn (United States)

LP068 **Plasma pTau-217 versus plasma pTau-217/Aβ1-42 ratio performance in predicting amyloid positivity compared to CSF Aβ42/40 ratio or PET in a screening cohort from a phase 3 registration study: Implications for a triage model**
Sharon Sha [1], James Rock [2], Fred Kim [2], Rachel Radwan [3], Francesca De Simone [3], Natalya Benina [3], Douglas Hawkins [4]
[1]Neurology & Neurological Sciences, Stanford University - Palo Alto (United States), [2]AriBio Co., Ltd. - San Diego (United States), [3]Fujirebio Diagnostics, Inc. - Malvern (United States), [4]Scottsdale Scientific LLC - Austin (United States)

LP069 **Head-to-head comparison of the fully automated Elecsys pTau217 plasma assay and the Lumipulse pTau217 plasma assay**
Robert Perneczky [1,2,3,4,5], Laura Stoeckl [6], Margherita Carboni [7], Sayuri Hortsch [6], Christina Rabe [8], Alexander Jethwa [6], Tobias Bittner [9,8]
[1]University Hospital of Munich - Munich (Germany), [2]German Center for Neurodegenerative Diseases - Munich (Germany), [3]Munich Cluster for Systems Neurology - Munich (Germany), [4]Ageing Epidemiology Research Unit, - London (United Kingdom), [5]Sheffield Institute for Translational Neuroscience - Sheffield (United Kingdom), [6]Roche Diagnostics GmbH - Penzberg (Germany), [7]Roche Diagnostics International Ltd - Rotkreuz (Switzerland), [8]Genentech Inc. - San Francisco (United States), [9]F. Hoffmann-La Roche Ltd - Basel (Switzerland)

LP070 **Biomarkers of Neuropathology in Patients screened for clinical trials who have cognitive impairment but are Amyloid PET negative**
Richard Mohs [1]
[1]Global Alzheimer's Platform Foundation - Washington Dc (United States)

POSTER PRESENTATIONS

LP071 **Glymphatic dysfunction affects plasma downstream markers for Alzheimer's disease and clinical progression.**
Sung Hoon Kang [1], Seongmi Kim [2,3], Beonseok Sohn [4], Sang Won Seo [2,5,6,7]
[1]Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine - Seoul (Korea, Republic of), [2]Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), [3]Alzheimer's disease convergence research center, Samsung Medical Center - Seoul (Korea, Republic of), [4]Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, - Seoul (Korea, Republic of), [5]Alzheimer's Disease Convergence Research Center, Samsung Medical Center, - Seoul (Korea, Republic of), [6]Department of Digital Health, SAIHST, Sungkyunkwan University, - Seoul (Korea, Republic of), [7]Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, - Seoul (Korea, Republic of)

LP072 **CAPS Plus: A clinical biomarker scoring system to predict Aβ positivity and facilitate enrolment in anti-amyloid clinical trials**
Durjoy Lahiri [1], Jennifer Cooper [2], Bruna Seixas-Lima [3], Carlos Roncero [3], Cheryl Wellington [2], Howard Chertkow [3]
[1]Queen's University - Kingston (Canada), [2]University of British Columbia - Vancouver (Canada), [3]University of Toronto - Toronto (Canada)

LP073 **Introduction of multi-dimension biomarkers application for a randomized, double-blind, singlesimulated clinical trial of sodium oligomannate on Alzheimer's disease**
Qiong Wang [1], Linbin Dai [1], Feng Gao [1], Jiong Shi [1], Yong Shen [1]
[1]The first Affiliated Hospital of USTC - Hefei (China), [2]The first Affiliated hospital of USTC - Hefei (China) - Hefei (China)

LP074 **Biomarker data showed buntanetap reduced neurotoxic proteins, improved axonal integrity, reduced inflammation, and neuronal functions in Alzheimer's clinical studies.**
Cheng Fang [1], David Feng [2], Melissa Gaines [1], Eve Damiano [1], Maria Maccecchini [1]
[1]Annovis Bio - Malvern (United States), [2]TCM - Princeton (United States)

LP075 **Levels of age-related CD8 T cells binding HLA track with Alzheimer's disease status in HLA-A2+ and HLA-A2- patients: expansion of a flow cytometric blood biomarker assay to all patients.**
Christopher Wheeler [1], Debbie Van Dam [2], Yannick Vermeiren [2], Hans De Reu [3], Paul De Deyn Peter [2]
[1]T-Neuro Pharma, Inc. (United States), [2]Institute Born-Bunge - Antwerp (Belgium), [3]Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute, Laboratory of Experimental Hematology,- Antwerp (Belgium)

LP076 **Monitoring treatment effects of sodium selenate in Alzheimer's disease and behavioural variant frontotemporal dementia using fluid biomarkers.**
Fernando Gonzalez-Ortiz [1], Cassandra Marotta [2], Henrik Zetterberg [1], Michael Turton [3], Peter Harrison [3], Christopher M. Hovens [4], Terence J. O'Brien [2], Kaj Blennow [1], Lucy Vivash [4]
[1]Gothenburg University - Gothenburg (Sweden), [2]Monash University - Melbourne (Australia), [3]Bioventix - Farnham (United Kingdom), [4]University of Melbourne - Parkville (Australia)

LP077 **Exploring the link between differences in spectral power across ocular states in resting-state EEG and p-tau181 levels in mild cognitive impairment**
Christoffer Hatlestad-Hall [1], Lukas Gemein [2], Federico Ramirez-Toraño [3,4], Ricardo Bruña [3,5], Gwendlyn Kollmorgen [6], Margherita Carboni [6], Jörg Hipp [2], Kaj Blennow [7,8], Henrik Zetterberg [7,8], Fernando Maestú [3,4], Hanna Renvall [9,10], Camillo Marra [11,12], Paolo Maria Rossini [13], Denis Engemann [2], Ira Hebold Haraldsen [1]
[1]Dept. of Neurology, Oslo University Hospital - Oslo (Norway), [2]Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, F. Hoffmann–La Roche Ltd. - Basel (Switzerland), [3]Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), [4]Department of Experimental Psychology, Cognitive Psychology and Speech and Language Therapy, Universidad Complutense de Madrid - Pozuelo De Alarcón (Spain), [5]Department of Radiology, Rehabilitation and Physiotherapy, School of Medicine, Universidad Complutense de Madrid - Madrid (Spain), [6]Roche Diagnostics GmbH - Penzberg (Germany), [7]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), [8]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), [9]BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science - Helsinki (Finland), [10]Department of Neuroscience and Biomedical Engineering, Aalto University - Helsinki (Finland), [11]Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), [12]Department of Neuroscience, Catholic University of the Sacred Heart - Rome (Italy), [13]Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele - Rome (Italy)

THEME 12: Proof of concept/Translational research for Alzheimer Drug Development interventions

P145 **APOE-Targeted Epigenome Therapy for Alzheimer's Disease**
Boris Kantor [1], Bernadette O'Donovan [1], Elena Korsakova [2], Joseph Rittiner [1], Elaine Hamm [2], Ornit Chiba-Falek [1]
[1]Duke - Durham (United States), [2]CLAIRIgene - Durham (United States)

P146 **Nasal Immunotherapy clears intracellular tau pathology through TRIM21 and improves cognitive functions in aged tauopathy mice**
Rakez Kayed [1]
[1]University of Texas Medical Branch - Galveston (United States)

P147 **Mediation of beta-amyloid pathology for the association between serum cortisol, neurodegeneration, and cognitive impairment**
Gihwan Byeon [1], Jeongsim Kim [2], Dahyun Yi [3], Hyejin Ahn [3], Gijung Jung [3], Joon Hyung Jung [4], Yoon Young Chang [5], Kyungtae Kim [6], Hyeji Choi [6], Jeongmin Choi [6], Yu Kyeong Kim [2], Jun young Lee [2], Koung Mi Kang [6], Chul-Ho Sohn [6], Yun sang Lee [6], Min Soo Byun [6], Dong Young Lee [6]
[1]Seoul St. Mary's Hospital - Seoul (Korea, Republic of), [2]SMG SNU Boramae Medical Center - Seoul (Korea, Republic of), [3]Institute of Human Behavioral Medicine, Medical Research Center Seoul National University - Seoul (Korea, Republic of), [4]Chungbuk National University Hospital - Cheongju (Korea, Republic of), [5]Inje University Sanggye Paik Hospital - Seoul (Korea, Republic of), [6]Seoul National University Hospital - Seoul (Korea, Republic of)

P148 **Brain Health Services for the prevention of dementia: evidence from pilot experiences**
Federica Ribaldi [1], Giovanni B Frisoni [1]
[1]UNIGE - Geneva (Switzerland)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

P149 **De novo designed TfR1 binding peptide to shuttle antibody therapeutics across blood brain barrier**
Hao Wu [1], Yibo Qiu [1], Fei Sheng [1], Yue Wu [1]
[1]ChainGen Bio - Shanghai (China)

P150 **Tau PET Measures Optimized for Detecting Treatment Effects on Tau Spread in Alzheimer Disease**
Janice Wong [1], Tina Wang [2], Ritobrato Datta [2], Dave Henley [3,4], Hartmuth C. Kolb [2], Ziad S. Saad [2]
[1]Janssen Research & Development, LLC - Cambridge, Massachusetts (United States), [2]Janssen Research & Development, LLC - La Jolla, California (United States), [3]Janssen Research & Development, LLC - Titusville, New Jersey (United States), [4]Indiana University School of Medicine, Psychiatry - Indianapolis, Indiana (United Kingdom)

P151 **Prediction of cognitive outcome and progression to dementia using Polyunsaturated fatty acids Omega6/3 ratio**
Victor Andrade [1,2], Luca Kleineidam [3,4], Holger Wagner-Thelen [5], Rafael Campos [5], Tommaso Ballarini [2,6], Sarah Egert [7], Pamela Martino-Adami [1], Leonie Weinhold [8], Sophie Guyonnet [9], Bruno Vellas [10], Frank Jessen [6,11], Matthias Schmid [8,6], Anja Schneider [4,6], Michael Wagner [4,6], Alfredo Ramirez [1,2]
[1]Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy. University of Cologne, Medical faculty Köln (Germany), [2]Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn - Bonn (Germany), [3]Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy. University of Cologne, Medical faculty. - Köln (Germany), [4]Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn. - Bonn (Germany), [5]Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy. University of Cologne, Medical faculty - Köln (Germany), [6]DZNE- Bonn (Germany), [7]Department of Nutrition and Food Sciences, Nutritional Physiology, University of Bonn - Bonn (Germany), [8]Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn - Bonn (Germany), [9]Centre d'Epidémiologie et de Recherche en santé des POPulations de Toulouse - Toulouse (France), [10]Gérontopôle, Toulouse University Hospital - Toulouse (France), [11]Department of Psychiatry, Medical Faculty, University of Cologne - Köln (Germany)

P152 **MRI monitoring of Alzheimer disease patients in the new era of disease-modifying therapies: a real-world case study**
Salvatore Napoli [1], Celine Maes [2], Rafay Khan [2], An Tanghe [2], Silvina Catuara Solarz [2], Jill Claes [2], Nuno Pedrosa De Barros [2], Diana Sima [2], Wim Van Hecke [2], Dirk Smeets [2], Annemie Ribbens [2]
[1]Neurology and Infusion Center of New England - Foxborough (United States), [2]icometrix - Leuven (Belgium)

P154 **Mild behavioral impairment: building the killifish-mouse-human pipeline in the INSPIRE-t cohort.**
Emmanuel Gonzalez-Bautista [1,2,3], Bruno Guiard [3,4], Isabelle Ader [3,5], Sophie Guyonnet [3,2], Jason Shourick [6], Adelaide De Mauleon [1], Estelle Dubus [1], Marie Mommeja [1], Jean-Philippe Pradere [3,5], Maria Soto [1,2,3]
[1]Research and Clinical Alzheimer's Disease Center, CMRR, CHU Toulouse - Toulouse (France), [2]Maintain Aging Research team, CERPOP, Inserm, Université Paul Sabatier - Toulouse (France), [3]IHU HealthAge, Inserm, CHU Toulouse - Toulouse (France), [4]Equipe REMEMBeR. Centre de Recherches sur la Cognition Animale, CRCA, Univ. P. Sabatier-Toulouse (France), [5]Institut RESTORE - UMR 1301- Inserm/5070-CNRS/EFS/ Université Paul Sabatier - Toulouse (France), [6]Maintain Aging Research team, CERPOP, Inserm, Université Paul Sabatier- Toulouse (France)

P155 **ADDITION-MCI: A clinical trial to fully exchange the blood plasma of older cognitively impaired individuals with young donor plasma.**
Sara Nygaard [1,2], Lana Nagmadin Karim [3], Andreas Engvik [4], Håkon Ihle-Hansen [5], Petter Holland [1], Arne Søraas [1]
[1]Dept. of Microbiology, Oslo University Hospital - Oslo (Norway), [2]Dept. of Acute Medicine, Oslo University Hospital - Oslo (Norway), [3]Dept. of Immunology and Transfusion Medicine, Oslo University Hospital - Oslo (Norway), [4]Dept. of Endocrinology, Obesity and Preventive Medicine, Oslo University Hospital - Oslo (Norway), [5]Dept of Medicine, Bærum Hospital, Vestre Viken Hospital Trust - Drammen (Norway)

P156 **Expanding IMPACT-AD to include international trainees: A pilot program**
Margaret D. Mastrolorenzo [1], Rema Raman [1], Joshua Grill [2], Maria Carrillo [3], Heather Snyder [3]
[1]Alzheimer's Therapeutic Research Institute (ATRI), University of Southern California - San Diego, Ca (United States), [2]Institute of Memory Impairment and Neurological Disorders, Department of Psychiatry & Human Behavior, Department of Neurobiology & Behavior, University of California at Irvine - Irvine, Ca (United States), [3]Alzheimer's Association - Chicago, Il (United States)

P157 **Implantable device for intrathecal pseudodelivery of immunotherapies: preclinical testing of a prototype for humans**
Ester Perez-Martin [1], Maria Rodiguez-Cañon [1], Gabriel Alvarez [1], Catuxa Prado [1], Cristina Tomas-Zapico [2,3], Manuel Menendez-Gonzalez [2,3,4]
[1]Neuroscience Innovative Technologies - Llanera (Spain), [2]Universidad de Oviedo - Oviedo (Spain), [3]Instituto de Investigación Sanitaria del Principado de Asturias - Oviedo (Spain), [4]Hospital Universitario Central de Asturias - Oviedo (Spain)

P158 **ONESTX-01, a potent inhibitor of Steroid Sulphatase (STS), that restores neuron cholinergic activity and decreases cognitive impairment: design of a phase IIa clinical study.**
Viñas Andrés-Simón [1], Javier Valle-Galisteo [2], Juan Antonio Fernández-Cabrera [3], Almudena Ramos-Pozo [2], José María Hernández-Curiel [3], Sandra Gavaldá-Martín [1], Cristina García-Gutierrez [2], Inés Sánchez Romero [3], Mercedes Pérez-Jiménez [2], Elena Rodríguez Sandoval [3], Antonio Aires-Trapote [1], Manuel Jesús Muñoz-Ruíz [2], Ángel Manuel Carrión [3], Ángel Cebolla-Ramírez [1]
[1]Olavide Neuron STX SL - Seville (Spain), [2]Universidad Pablo de Olavide, Centro Andaluz de Biología del Desarrollo (CABD), CSIC, JA - Seville (Spain), [3]Universidad Pablo de Olavide, Department of Physiology, Anatomy and Cellular Biology - Seville (Spain)

P159 **Novel Cyclodextrins with Reduced Cellular Toxicity: Application in Treating Pathologic Tau-Related Lipid Accumulations**
Ji-Yeong Lee [1], Heegon Kim [2], Sun Ah Park [1,3,4]
[1]Lab of Neurodegenerative Dementia, Department of Anatomy, Ajou University School of Medicine - Suwon (Korea, Republic of), [2]Renatus - Daejeon (Korea, Republic of), [3]Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University Graduate School of Medicine, - Suwon (Korea, Republic of), [4]Department of Neurology, Ajou University School of Medicine - Suwon (Korea, Republic of)

P160 **Enhanced Imaging Techniques for ARIA Detection and Treatment Efficacy Monitoring in Lecanemab Therapy for Alzheimer's Disease**
Jude-Patrick N. Okafor [1], Jacob Stefanko [1], Hope Shimony [1], Austin Mccullough [1], Nayid Jana [1], Nelly Jospeh-Mathurin [1], Stephen Jarman [1], Edmond Knopp [2], Tammie Benzinger [1]
[1]Washington University School of Medicine - Saint Louis (United States), [2]Hyperfine Inc. - Guilford (United States)

P161 **CRISPR-Cas9-Mediated Upregulation of Melatonin Receptor 1 Attenuates Cognitive Impairment in Alzheimer's Disease**
Jongpil Kim [1]
[1]Dongguk University - Seoul (Korea, Republic of)

POSTER PRESENTATIONS

LP078 **Brain Shuttles to Novel Receptors to Overcome Liabilities of First-Generation Shuttled Anti-Amyloid Therapeutics**
Shane Lofgren [1]
[1]*Manifold Bio - Boston (United States)*

LP080 **Therapeutic potential of novel GAS6 fusion protein (GAIA) - Overcoming neuroinflammation via efferocytosis in anti-Aβ immunotherapies**
Jin Kyung Lee [1], Soomin Ji [1], Sanghoon Park [1], Chan Hyuk Kim [2], Won-Suk Chung [3]
[1]*Illimis Therapeutics., Inc. - Seoul (Korea, Republic of)*, [2]*College of Pharmacy, Seoul National University - Seoul (Korea, Republic of)*, [3]*Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST) - Daejeon (Korea, Republic of)*

LP081 **Targeting Disulfide-Linked Protein Aggregation with Small Molecules: A Potential Strategy for Neurodegenerative Disease Therapy**
Nataliia Lukianenko [1,2], Lim Sungsu [1], Yun Kyung Kim [1,2]
[1]*Center for Brain Disorders, Korea Institute of Science and Technology, Seoul, Republic of Korea - Seoul (Korea, Republic of)*, [2]*Division of Bio-Medical Science & Technology, University of Science and Technology (UST), Daejeon, Republic of Korea - Daejeon (Korea, Republic of)*

THEME 15: Clinical trials Early Career Investigator Showcase

P162 **PET Imaging of Microtubules in Cognitively Normal and Impaired Older Adults: A Pilot Study**
Bhuvanachandra Bhoopal [1], Mack Miller [1], Naresh Damuka [1], Krishna Gollapelli [1], Ivan Krizan [1], Samuel Lockhart [1], Akiva Mintz [2], Suzanne Craft [1], Kiran K . Solingapuram Sai [1]
[1]*Wake Forest School of Medicine - Winston Salem (United States)*, [2]*Columbia University School of Medicine - New York (United States)*

LP082 **Effect of EGb761 on blood markers of inflammation and oxidative stress in a cohort of patients with Mild Cognitive Impairment (ACE-2020-EGb761)**
Xavier Morató [1], Juan Pablo Tartari [1], Maria Eugenia Saez [2], Maria Capdevila-Bayo [1], Amanda Cano [1], Laia Montoliu-Gaya [3], Hanna Huber [3], Asuncion Lafuente [1], Marta Ibarria [1], Susana Diego Gullon [1], Yahveth Cantero Fortiz [1], Nuria Aguilera [1], Sara Jofresa [1], Laia Cañada [1], Natalia Tantinya [1], Marta Marquié [1], Sergi Valero [1], Henrik Zetterberg [3], Agustin Ruiz [1], Mercè Boada [1]
[1]*FUNDACIO ACE - Barcelona (Spain)*, [2]*Andalusian Bioinformatics Research Centre (CAEBi) - Sevilla (Spain)*, [3]*University of Gothenburg - Mölndal (Spain)*

LP083 **Differentiating underlying pathologies in early Alzheimer's clinical phenotypes: Interest of acoustic markers for predicting CSF biomarkers and clinical evolution**
Eloïse Da Cunha [1,2,3], Valeria Manera [1,3], Raphaël Zory [4], Auriane Gros [1,5,3]
[1]*CoBTeK (Cognition, Behaviour, Technology) Laboratory, Université Côte d'Azur - Nice (France)*, [2]*3IA Côte d'Azur (Interdisciplinary Institue of Artificial Intelligence) - Nice (France)*, [3]*Speech and Language Pathology department of Nice, Faculty of Medicine, Université Côte d'Azur - Nice (France)*, [4]*LAHMESS Laboratory, Université Côte d'Azur - Nice (France)*, [5]*Centre Mémoire Ressources et Recherche, CHU de Nice - Nice (France)*

LP084 **Potential role of MRI to optimize the design of clinical trials for PSP and CBD**
Ignacio Illan-Gala [1], Jesus García-Castro [1], Lawren Vandevrede [2], Hillary Heuer [2], Rema Raman [3], Michael Donohue [3], Barragan Eden [2], Julio Rojas [2], Anne-Marie Wills [4], Irene Litvan [5], Adam Boxer [2]
[1]*Hospital de la Santa Creu i Sant Pau - Barcelona (Spain)*, [2]*Memory and Aging Center, University of California San Francisco - San Francisco (United States)*, [3]*Alzheimer's Therapeutic Research Institute (ATRI) Keck School of Medicine, University of Southern California - San Diego (United States)*, [4]*Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)*, [5]*Department of Neurosciences, University of California San Diego - San Diego (United States)*

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

POSTER SESSION 3: From Friday, November 1 - 7:15 a.m. to Friday, November 1 - 5:00 p.m.

THEME 5: Clinical trials: Cognitive and functional endpoints

P163 **Impairments of visual information processing in dementia**

Mark Stemmler [1], Monika Daseking [2]
[1]Friedrich-Alexander University of Erlangen-Nuremberg - Erlangen (Germany), [2]Helmut-Schmidt-University Hamburg - Hamburg (Germany)

P164 **Home-based transcranial alternating current stimulation over the precuneus in Alzheimer's disease: a double-blind, randomized, placebo-controlled trial followed by an open label phase**

Valentina Cantoni [1], Elias Paolo Casula [2], Chiara Cupidi [3], Daniele Altomare [4], Enrico Premi [5], Elisa Zummo [3], Romina Esposito [2], Nadine Huber [6], Eino Solje [7,8], Maria Sofia Cotelli [1], Alessandro Martorana [9], Giacomo Koch [2,10,11], Annakaisa Haapasalo [12], Alberto Benussi [13], Barbara Borroni [1,10]
[1]Department of Continuity of Care and Frailty, ASST Spedali Civili of Brescia - Brescia (Italy), [2]Department of Clinical and Behavioral Neurology, Santa Lucia Foundation IRCCS - Rome (Italy), [3]Neurology Unit, Fondazione Istituto G. Giglio - Cefalù (Italy), [4]Department of Clinical and Behavioral Neurology, Santa Lucia Foundation IRCCS - Brescia (Italy), [5]Stroke Unit, ASST Spedali Civili of Brescia - Brescia (Italy), [6]A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, - Kuopio (Finland), [7]Institute of Clinical Medicine, University of Eastern Finland, - Kuopio (Finland), [8]Neuro center, Neurology - Kuopio (Finland), [9]Department of Systems Medicine, Memory Clinic, University of Rome Tor Vergata, - Rome (Italy), [10]Department of Clinical and Experimental Sciences, University of Brescia - Brescia (Italy), [11]Department of Neuroscience and Rehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT), - Ferrara (Italy), [12]A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland - Kuopio (Finland), [13]Neurology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste - Trieste (Italy)

P165 **Assessing informal caregivers´ self-perceived sense of competence in Mild Cognitive Impairment: Psychometric evaluation of the 7-item Sense of Competence Questionnaire (SCQ)**

Pascual Sanchez-Juan [1], Elena Garcia-Arcelay [2], Mircea Balasa [3], Gerard Piñol-Ripoll [4], Mercè Boada [5], Lamberto Landete [6], Eloisa Navarro [7], Inmaculada Abellán [8], Angel Berbel [9], Beatriz Espejo [10], Mariló Almagro [11], Jesús Rodrigo [11], Jorge Maurino [2], Sagrario Manzano-Palomo [7], Javier Ballesteros [12]
[1]Fundación CIEN - Madrid (Spain), [2]Roche Farma - Madrid (Spain), [3]Hospital Clínic, IDIBAPS - Barcelona (Spain), [4]IRBLLeida - Lleida (Spain), [5]Ace Alzheimer Center Barcelona - Barcelona (Spain), [6]Hospital Universitario Dr. Peset - Valencia (Spain), [7]Hospital Universitario Infanta Leonor, - Madrid (Spain), [8]Hospital San Vicente del Raspeig, - Alicante (Spain), [9]Hospital de la Cruz Roja Madrid - Madrid (Spain), [10] Unit Hospital Clínico San Cecilio - Granada (Spain), [11]CEAFA - Madrid (Spain), [12]UPV/EHU, CIBERSAM - Leioa (Spain)

P166 **The effect of high-definition transcranial direct current stimulation (HD-tDCS) on cognitive function in patients with mild cognitive impairment: a randomized, triple-blind, sham-controlled, study**

Che-Sheng Chu [1], Chih-Chuan Pan [1], Cheng-Ho Chang [1], Yung-Chih Chiang [1], Hsin-Ya Kuo [1], Shiou-Lan Chen [2], Cheng-Sheng Chen [2]
[1]Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan - Kaohsiung (Taiwan, Republic of China), [2]Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan - Kaohsiung (Taiwan, Republic of China)

P167 **The longitudinal relationship between cardiorespiratory fitness, amyloid-β, and cognitive performance in adults at risk for Alzheimer's disease.**

Adam J. Paulsen [1,2], Brianne M. Breidenbach [1,2], Matthew Glittenberg [1,2], Sanjay Asthana [1,2,4], Sterling C. Johnson [1,2], Tobey J. Betthauser [1], Dane B. Cook [5,6], Ozioma C. Okonkwo [1,2,4]
[1]Wisconsin Alzheimer's Disease Research Center, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health - Madison (United States), [2]Wisconsin Alzheimer's Institute, Madison - Madison (United States),[4]Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital - Madison (United States), [5]Department of Kinesiology, University of Wisconsin-Madison - Madison (United States), [6]William S. Middleton Memorial Veterans Hospital - Madison (United States)

P168 **Evaluating the Performance of Participant-Report, Study Partner-Report, and Performance-Based Assessments of Daily Functioning in Older Adults as Functional Endpoints in Alzheimer's Disease Clinical Trials**

Hannah Truitt [1,2], Rebecca Amariglio [1,3,2], Sharon Wang [3], Onyinye Udeogu [3], Ariel Brathwaite [3], Dorene Rentz [1,2], Gad Marshall [1,3,2], Mark Dubbelman [1,3,2]
[1]Brigham and Women's Hospital - Boston (United States), [2]Harvard Medical School - Boston (United States), [3]Massachusetts General Hospital - Boston (United States)

P169 **Mapping Alzheimer's disease progression via changes in the CDR-Global for accurate clinical trial design**

Rodrigo Canovas [1], Christopher Fowler [2], Simon Laws [3,4,5,6], Stephanie Rainey-Smith [7,8,9,10], Colin Masters [2], Ralph Martins [7,11], Paul Maruff [2], James Doecke [12]

[1]Australian E-Health Research Centre, CSIRO - Parkville (Australia), [2]Florey Institute, The University of Melbourne - Parkville (Australia), [3]Centre for Precision Health, Edith Cowan University - Joondalup (Australia), [4]Collaborative Genomics and Translation Group, Edith Cowan University, - Joondalup (Australia), [5]School of Medical and Health Sciences, Edith Cowan University, - Joondalup (Australia), [6]Curtin Medical School, Curtin University - Bently (Australia), [7]School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), [8]School of Psychological Science, University of Western Australia - Crawley (Australia), [9]Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch (Australia), [10]Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute - Nedlands (Australia), [11]Department of Biomedical Sciences, Macquarie University - Macquarie (Australia), [12]Australian E-Health Research Centre, CSIRO - Herston (Australia)

POSTER PRESENTATIONS

P170 **Time-saved due on treatment: validation in a real-world population study**

Rodrigo Canovas [1], Marcela Cespedes [2], Christopher Fowler [3], Stephanie Rainey-Smith [4, 5, 6, 7], Colin Masters [3], Ralph Martins [4, 8], Paul Maruff [3], James Doecke [2]

[1]Australian E-Health Research Centre, CSIRO - Parkville (Australia), [2]Australian E-Health Research Centre, CSIRO - Herston (Australia), [3]Florey Institute, The University of Melbourne - Parkville (Australia), [4]School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), [5]School of Psychological Science, University of Western Australia - Crawley (Australia), [6]Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch (Australia), [7]Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute - Nedlands (Australia), [8]Department of Biomedical Sciences, Macquarie University - Macquarie (Australia)

P171 **Streamlining Recruitment for AD Clinical Trials: Concurrent Detection of Cognitive Impairment and Amyloid-Beta PET Status with a Machine Learning-Enabled Digital Cognitive Assessment**

Ali Jannati [1], Karl Thompson [1], Claudio Toro-Serey [1], Connor Higgins [1], Russell Banks [1], Jeff Pobst [1], John Showalter [1], David Bates [1], Sean Tobyne [1], Pascual-Leone Alvaro [1]

[1]Linus Health - Boston (United States)

P173 **Neurogenesis Hypothesis- Clinical Trials of NA-831 for Alzheimer's Disease and NA-901 for Major Depressive Disorder**

Lloyd Tran [1], Fern Vu [1], Zung Tran [1]

[1]Biomed Industries, Inc. - San Jose (United States)

P174 **Preliminary Findings on the Effects of Donepezil on Visuospatial Abilities in amylod PET-positive Mild Cognitive Impairment Assessed Using Eye-Tracking**

Ko Woon Kim [1], Qi Wang [2], Su Jeong Wang [3], Byoung-Soo Shin [3]

[1]Jeonbuk National University Medical School and Hospita - Jeonju (Korea, Republic of), [2]Jeonbuk National University Medical School - Jeonju (Korea, Republic of), [3]Jeonbuk National University Hospital - Jeonju (Korea, Republic of)

P175 **Understanding the Early Alzheimer's Disease Experience: Perspectives from Patients and Caregivers**

Jennifer Dine [1], Jae Lee [2], Anand Shewale [2], Jonathan Stokes [2], Bonita Basnyat [1], Michelle Brown [1], Amy Greenblatt [1], Elaheh Shirneshan [2]

[1]RTI International - Research Triangle Park (United States), [2]AbbVie - North Chicago (United States)

P176 **Impact of Rater Change on Clinical Dementia Rating Data: A Retrospective Analysis**

David Miller [1], Xingmei Wang [1], Alan Kott [2]

[1]Signant Health - Blue Bell, Pa (United States), [2]Signant Health - Prague (Czech Republic)

P177 **A strategic approach to rigorous clinical endpoint strategies in drug development – An example from a phase 2 trial in early Alzheimer´s disease (EXPLAIN-AD)**

Flavia Loreto [1], Alex Sverdlov [2], Nicole Pezous [1], Neva Coello [1], Alex Murphy [3], Peggy Allred [4], Peter Rock [1], Gul Erdemli [3], Joann Whittle [5], Jaffar Saleh Subaie [6], Jon G. Snædal [7], Jelena Curcic [8], Kristin Hannesdottir [4]

[1]Novartis - Basel (Switzerland), [2]Novartis - East Hanover (United States), [3]Novartis - Cambridge (United States), [4]Novartis Biomedical Research - Cambridge (United States), [5]Novartis Biomedical Research - Chicago (United States), [6]Novartis - Mexico City (Mexico), [7]National University Hospital of Iceland | LSH · Department of Geriatrics - Reykjavik (Iceland), [8]Novartis Biomedical Research - Basel (Switzerland)

LP085 **Cognitive Assessment and Wearable Sensor-Based Gait and Balance Assessment in Studies of Alzheimer's Disease and Mild Cognitive Impairment: A Preliminary Review.**

Prateek Verma [1]

[1]Clario - London (United Kingdom)

LP086 **Associations between central and peripheral biomarkers for Alzheimer's disease in community-dwelling older adults at risk of dementia.**

Mario Parra [1], Alfredis Gonzalez Hernandez [2], Jasmin Bonilla Santos [2], Rodrigo Gonzalez Montealegre [2], Yisela Cala [2], Danilo Verge [3], Gerardo Fernandez [4]

[1]Glasgow University - Glasgow (United Kingdom), [2]Surcolombiana - Neiva (Colombia), [3]ViewMind - Copenage (Denmark), [4]ViewMind - Bahia Blanca (Argentina)

LP087 **The effect of education on ATN biomarkers of Alzheimer's disease**

Kim Yeshin [1], Kim Sunghoon [1], Kim Sungheon [1]

[1]Kangwon National University Hospital - Chuncheon (Korea, Republic of)

LP089 **Validation of a precision measure of cognitive change in a phase II clinical trial in early AD: The Early and Mild Alzheimer's Cognitive Composite (EMACC)**

Sarah Barnum [1], Judith Jaeger [2], Lisle Kingery [3]

[1]Cognition Metrics LLC - Lake Orion (United States), [2]Cognition Metrics LLC - Hixson (United States), [3]Consultant Neuropsychologist - Geneva (United States)

LP090 **Pilot study of a conversational AI voicebot to administer the autobiographical recall questions of the Clinical Dementia Rating**

Rachel Nosheny [1], Jack Weston [2], Emil Fristed [2], Juliet Fockler [1], Joseph Eichenbaum [1], Derek Flenniken [1], Krista Moulder [3], John Morris [3], Michael Weiner [1]

[1]University of California, San Francisco - San Francisco (United States), [2]Novoic, Ltd. - London (United Kingdom), [3]Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine - St. Louis (United States)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

LP091 **Clinical meaningfulness of cognitive decline measured using the Preclinical Alzheimer's Disease Cognitive Composite score (PACC), in the preclinical stage of Alzheimer's disease**

Rodrigo Canovas [1], Rosita Shishegar [1], Marcela Cespedes [2], Christopher Fowler [3], Hamid Sohrabi [4], Jurgen Fripp [2], Yen Ying Lim [5], Jason Hassenstab [6], Paul Maruff [7], James Doecke [2], Adopic Research Group [8]

[1]Australian E-Health Research Centre, CSIRO, - Melbourne (Australia), [2]Australian E-Health Research Centre, CSIRO, - Brisbane (Australia), [3]The University of Melbourne - Melbourne (Australia), [4]Murdoch University - Perth (Australia), [5]Monash Univerrsity - Melbourne (Australia), [6]Washington University - Saint Louis (United States), [7]Cogstate - Melbourne (Australia), [8]ADOPIC - Melbourne (Australia)

LP092 **Incorporating personally defined brain health priorities in clinical trials outcomes: the electronic Person Specific Outcome Measure approach in the US**

Stina Saunders [1,2], Ali Jannati [1,3], Shane Sheehan [2], Sean Tobyne [1], Álvaro Pascual-Leone [1,3,4]

[1]Linus Health - Boston (United States), [2]Usher Institute, University of Edinburgh - Edinburgh (United Kingdom), [3]Department of Neurology, Harvard Medical School - Boston (United States), [4]Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife - Boston (United States)

THEME 6: Cognitive assessment and clinical trials

P178 **Neuropsychological Testing in Patients with Converted and Stable Mild Cognitive Impairment**

Yunjin Lee [1], June Sic Kim [2], Hee-Jin Kim [1]

[1]Hanyang University - Seoul (Korea, Republic of), [2]Konkuk University Medical Center - Seoul (Korea, Republic of)

P179 **Longitudinal analysis of the factor structure of a multidomain cognitive task battery in ageing and preclinical AD**

Nicholas Taptiklis [1], Michele Veldsman [1], Francesca Cormack [1], Alex Kaula [1], Nora Stang [2], Ana Perez [2], Soraya Alfonsí [3], Timo Saarinen [4], Fernando Maestú [3], Hanna Renvall [4], Camillo Marra [5], Paolo Rossin [6], Christoffer Hatlestad-Hall [2], Ira Haraldsen [2]

[1]Cambridge Cognition - Cambridge (United Kingdom), [2]Department of Neurology, Oslo University Hospital - Oslo (Norway), [3]Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), [4]BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science - Helsinki (Finland), [5]Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), [6]Department of Neurosciences & Neurorehabilitation. IRCCS San Raffaele - Rome (Italy)

P180 **Interpersonal Effects of ADRD Screening on older primary care patients and their family members wellbeing: Results from the Caregiver Outcomes of Alzheimer's Disease Screening (COADS) Trial**

Nicole Fowler [1], Yifan Lou [2], Christina Baucco [3], Malaz Boustani [1], Joan Monin [2]

[1]Indiana University School of Medicine - Indianapolis (United States), [2]Yale University - New Haven (United States), [3]IU Center for Aging Research - Indianapolis (United States)

P181 **Advancements in identifying stage 2 preclinical Alzheimer's disease: reliable methods to define objective memory decline associated with cerebrospinal fluid and plasma biomarkers**

David López-Martos [1], Marc Suárez-Calvet [1], Armand González-Escalante [1], Marta Milà-Alomà [1], Juan Domingo Gispert [1], Carolina Minguillon [1], Clara Quijano-Rubio [2], Gwendlyn Kollmorgen [3], Henrik Zetterberg [4], Kaj Blennow [4], Oriol Grau-Rivera [1], Gonzalo Sánchez-Benavides [1]

[1]BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), [2]Roche Diagnostics International Ltd - Rotkreuz (Switzerland), [3]Roche Diagnostics GmbH - Penzberg (Germany), [4]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg - Mölndal (Sweden)

P182 **Identification of Cognitive Impairment in Alzheimer's Disease with Drawing and Speech-Based Assessments and Metrics**

Tanya Talkar [1], Karl Thompson [1], Ali Jannati [1,2], Russell Banks [1], John Showalter [1], David Bates [1], Alvaro Pascual-Leone [1,2,3], Sean Tobyne [1]

[1]Linus Health - Boston (United States), [2]Department of Neurology, Harvard Medical School - Boston (United States), [3]Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife - Boston (United States)

P183 **Exploring Novel RT-Based Measures Calculated from Detailed Paired Associate Learning Task Data: Preliminary Analyses**

Alexander Kaula [1], Nick Taptiklis [1], Francesca Cormack [1,2], Nora Stang [3], Ana Perez [3], Soraya Alfonsín [4], Timo Saarinen [5], Fernando Maestú [4], Hanna Renvall [5], Camillo Marra [6], Paolo Rossini [7], Christoffer Hatlestad-Hall [3], Ira Haraldsen [3]

[1]Cambridge Cognition - Cambridge (United Kingdom), [2]Department of Psychiatry, University of Cambridge - Cambridge (United Kingdom), [3]Dept. of Neurology, Oslo University Hospital - Oslo (Norway), [4]Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), [5]BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science - Helsinki (Finland), [6]Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), [7]Department of Neurosciences & Neurorehabilitation. IRCCS San Raffaele - Rome (Italy)

P184 **The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Detect the Presence of Amyloid in Clinical Samples with Cognivue Clarity®**

James Galvin [1], Michael Kleiman [1], Paul Estes [2], Heather Harris [2], Ernest Fung [2]

[1]University of Miami Miller School of Medicine - Boca Raton (United States), [2]Cognivue, Inc - Victor (United States)

P185 **Evaluating Cognition across Latin America: Insights from the LatAm-FINGERS Study**

Lucía Crivelli [1], Nicolás Corvalán [1], Ricardo F. Allegri [1], Ismael L. Calandri [1], Paulo Caramelli [2], Mark A. Espeland [3], Francisco Lopera [4], Ricardo Nitrini [5], Kathryn V. Papp [6], Gustavo E. Sevlever [1], Rosa María Salinas [7], Ana Luisa Sosa [7], Claudia Kimie Suemoto [8], Monica Sanches Yassuda [9], Laura Baker [10]

[1]Fleni - Buenos Aires (Argentina), [2]Faculty of Medicine - Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), [3]Departments of Internal Medicine and Biostatistics and Data Science,Wake Forest University School of Medicine,Winston-Salem - North Carolina (United States), [4]Grupo de Neurociencias de Antioquia, Universidad de Antioquia - Medellín (Colombia), [5]Cognitive and Behavioral Neurology Unit - University of São Paulo - São Paulo (Brazil), [6]Brigham and Women's Hospital, Harvard Medical School - Massachusetts (United States), [7]Dementias Laboratory, National Institute of Neurology and Neurosurgery - Ciudad De México (Mexico), [8]Division of Geriatrics, Department of Internal Medicine, University of Sao Paulo Medical School - São Paulo (Brazil), [9]University of São Paulo - São Paulo (Brazil), [10]Wake Forest University School of Medicine - Winston-Salem, North Carolina (United States)

POSTER PRESENTATIONS

P186 **Exploring the role of education on cognitive outcomes in Hispanic/Latino Adults in Southern California: Insights from Community Based Intervention, SERVE-OC**

Alissa Kurzman [1], Bruce Albala [1], Aryanna Chavez [1], Jeffrey Wing [2], Desiree Gutierrez [3], Darnisha Draughter [3], Bernadette Boden-Albala [3]
[1]University of California Irvine - Irvine (United States), [2]Ohio State University - Columbus (United States), [3]University of California, Irvine - Irvine (United States)

P187 **Longitudinally defined objective subtle memory decline in cognitively unimpaired individuals is associated with tau deposition in Braak I/II regions**

Gonzalo Sánchez-Benavides [1,2,3], David López-Martos [1,2], Mahnaz Shekari [1], Edilio Borroni [4], Gregory Klein [4], Matteo Tonietto [4], Marc Suarez-Calvet [1,2,3,5], Juan Domingo Gispert [1,2], Oriol Grau-Rivera [1]
[1]BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), [2]Hospital del Mar Medical Research Institute (IMIM) - Barcelona (Spain), [3]Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, - Madrid (Spain), [4]Roche Pharma Research and Early Development, Neuroscience and Rare Disease, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), [5]Servei de Neurologia, Hospital del Mar - Barcelona (Spain)

P188 **Severe COVID-19 leads to accelerated dementia onset**

Sasha Mukhija [1,2,3], Max Sunog [1,2], Colin Magdamo [1,2], Mark W. Albers [1,2]
[1]Harvard Medical School - Boston (United States), [2]Massachusetts General Hospital - Boston (United States), [3]University Hospital of Zurich - Zurich (Switzerland)

P189 **Effect of disease stage and amyloid level on harmonized data from neuropsychological tests in three natural history studies.**

Rosita Shishegar [1], Vincent Dore [1], Pierrick Bourgea [2], Simon Laws [3], Tenielle Porter [3], Samantha Burnham [4], Azadeh Feizpour [5], Michael Weiner [6], Jason Hassenstab [7], Christopher Row [5], Victor Villemagne [8], Colin Masters [5], Jurgen Fripp [2], James Doecke [2], Hamid Sohrabi [9], Paul Maruff [10]
[1]The Australian e-Health Research Centre, CSIRO - Melbourne (Australia), [2]The Australian e-Health Research Centre, CSIRO - Brisbane (Australia), [3]School of Biomedical Sciences, Faculty of Health Sciences, Curtin University - Perth (Australia), [4]Avid, Eli Lilly and Company - Boston (United States), [5]Florey Institute of Neuroscience and Mental Health, The University of Melbourne - Melbourne (Australia), [6]Center for Imaging of Neurodegenerative Diseases, University of California-San Francisco - San Francisco, (United States), [7]Institute of Clinical and Translational Sciences, Washington University School of Medicine - St Louis (United States), [8]Department of Psychiatry, University of Pittsburgh - Pittsburgh (United States), [9]Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Perth (Australia), [10]Cogstate Ltd - Melbourne (Australia)

P191 **ClinCloud Successfully Democratizes POLARIS-AD Phase 3 Early Alzheimer's Disease Study to Maximize Trial Exposure to Diversified and Underserved Populations**

Maria Biban [1], James Rock [2], Jessica Branning [1], Caroline Skirrow [3], Geraldine Marino [1], Landon Estes [1], Karem Sapp [1], Natalie Gadea [1]
[1]ClinCloud, LLC - Maitland (United States), [2]AriBio Co., LTD - San Diego (United States), [3]Novoic LTD - London (United Kingdom)

P192 **Associations between body composition metrics, Clinical Dementia Rating Scale (CDR©) scores, gender, and race/ethnicity among older adults with and without cognitive impairment**

Giovanna Pilonieta [1], David Geldmacher [1]
[1]The University of Alabama at Birmingham - Birmingham (United States)

P193 **Relationship between body composition metrics and performance on the Dementia Rating Scale (DRS-2) in older adults with and without cognitive impairment.**

David Geldmacher [1], Giovanna Pilonieta [1]
[1]The University of Alabama at Birmingham - Birmingham (United States)

P194 **Effects of the Davos Alzheimer's Collaborative Early Detection of Cognitive Impairment Program on Clinician Attitudes and Confidence**

Soeren Mattke [1], Tabasa Ozawa [1], Valeria Baldivieso [2], Otelo Corrêa Dos Santos Filho [3], Ishtar Govia [4], Hisatomo Kowa [5], Mariana Lopez-Ortega [6], Alison Mckean [7], Amy Deckert [8], Katherine Selzler [8]
[1]University of Southern California - Los Angeles (United States), [2]AdventHealth - Orlando (United States), [3]State University of Rio de Janeiro - Rio De Janeiro (Brazil), [4]Jamaica Mental Health Advocacy Network - Kingston (Jamaica), [5]Kobe University - Kobe (Japan), [6]National Institute of Geriatrics - Mexico City (Mexico), [7]Brain Health Scotland - Edinburgh (United Kingdom), [8]Davos Alzheimer's Collaborative - Wayne (United States)

P195 **Davos Alzheimer's Collaborative Healthcare System Preparedness Early Detection Program: Key Roles for Successful DCA Implementation**

Amy Deckert [1], Katherine J. Selzler [1], Laura Chavira-Razo [1], Alissa Kurzman [1], Tim Macleod [1]
[1]Davos Alzheimer's Collaborative - Wayne (United States)

P196 **Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) changes anchored with CDR progression in a preclinical AD population**

Catarina Cunha [1], Raymond Blattner [1], Barbara Echevarria [1], Selam Negash [1], Christopher Randolph [1]
[1]WCG Clinical Research Solution - Princeton (United States)

P197 **An Assessment of the Utility of the Montreal Cognitive Assessment (MoCA) in predicting Amyloid PET Positivity in Alzheimer's Disease (AD) Clinical Trials**

Elizabeth Sosa [1]
[1]Irvine Clinical Research - Irvine (United States)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon : 

P198 **Development and validation of a 4-years all-cause dementia prediction tool based on sleep-related symptoms using a score risk prediction model**
Hyukjun Lee [1], Ji Won Han [1], Jong Bin Bae [1], Dong Gyu Moon [1], Jin Shin [2], Dae Jong Oh [3], Eunji Lim [4], Bong Jo Kim [5], Dong Woo Lee [6], Jeong Lan Kim [7], Joon Hyuk Park [8], Jung Jae Lee [9], Kyung Phil Kwak [10], Seok Bum Lee [9], Ki Woong Kim [11]
[1]Department of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), [2]Department of Neuropsychiatry, Seoul National University Bundang Hospital, - Seongnam (Korea, Republic of), [3]Workplace Mental Health Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, - Seoul (Korea, Republic of), [4]Department of Neuropsychiatry, Gyeongsang National University Changwon Hospital - Changwon (Korea, Republic of), [5]Department of Psychiatry, Gyeongsang National University, School of Medicine - Jinju (Korea, Republic of), [6]Department of Neuropsychiatry, Inje University Sanggye Paik Hospital - Seoul (Korea, Republic of), [7]Department of Psychiatry, School of Medicine, Chungnam National University - Daejeon (Korea, Republic of), [8]Department of Neuropsychiatry, Jeju National University Hospital - Jeju (Korea, Republic of), [9]Department of Psychiatry, Dankook University Hospital - Cheonan (Korea, Republic of), [10]Department of Psychiatry, Dongguk University Gyeongju Hospital - Gyeongju (Korea, Republic of), [11]Department of Psychiatry, Seoul National University, College of Medicine - Seoul (Korea, Republic of)

P199 **Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease in AdventHealth**
Valeria Baldivieso [1], Steven R. Smith [1], Richard E. Pratley [1], Magda Baksh [1], Gayle Shepherd [1], Janice Lopez [1]
[1]AdventHealth - Orlando (United States)

P200 **Clinical Management during the Davos Alzheimer's Collaborative Early Detection of Cognitive Impairment Program in Six Countries**
Soeren Mattke [1], Tabasa Ozawa [1], Jiahe Chen [1], Valeria Baldivieso [2], Otelo Corrêa Dos Santos Filho [3], Ishtar Govia [4], Hisatomo Kowa [5], Mariana Lopez-Ortega[6], Alison McKean [7], Deanna Willis [8], Amy Deckert [9], Katherine Selzler [9]
[1]University of Southern California - Los Angeles (United States), [2]AdventHealth - Orlando (United States), [3]State University of Rio de Janeiro - Rio De Janeiro (Brazil), [4]Jamaica Mental Health Advocacy Network - Kingston (Jamaica), [5]Kobe University - Kobe (Japan), [6]National Institute of Geriatrics - Mexico City (Mexico), [7]Brain Health Scotland - Edinburgh (United Kingdom), [8]Indiana University School of Medicine - Indianapolis (United States), [9]Davos Alzheimer's Collaborative - Wayne (United States)

P201 **Accounting for Wordlist Feature Differences across Alternate Forms of the ADAS-Cog Word Recall Test**
Jason Bock [1,2], Junko Hara [1,3], Dennis Fortier [1], Tushar Mangrola [1], Michael Lee [2]
[1]Embic Corporation - Newport Beach (United States), [2]Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), [3]Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States)

LP093 **Comparability and Usability of Cambridge Neuropsychological Test Automated Battery (CANTAB®) tests delivered via a smartphone**
Emily Thorp [1], Alexander Kaula [1], Nick Taptiklis [1], Elizabeth Wragg [1], Francesca Cormack [1,2]
[1]Cambridge Cognition Ltd. - Cambridge (United Kingdom), [2]Department of Psychiatry, University of Cambridge - Cambridge (United Kingdom)

LP094 **Evaluation of a multicomponent PFAS assay in blood samples to assess the impact of cognitive function**
Heesoo Eun [1], Hiroshi Hata [1], Mayumi Ohnishi-Kameyama [1], Jieun Yoon [2]
[1]National Agriculture and Food Research Organization (NARO) - Tsukuba (Japan), [2]University of Tsukuba - Tsukuba (Japan)

LP095 **Psychometric Validity of Neurocognitive Biomarkers from ViewMind: insights from Classical Cognitive Screenings**
Gerardo Fernandez [1], Alfredis Gonzalez Hernandez [2], Jasmin Bonilla Santos [2], Rodrigo Gonzalez Montealegre [2], Yisela Cala [2], Valentin Barco [1], Danilo Verge [3], Mario Parra [4]
[1]ViewMind - Bahia Blanca (Argentina), [2]SurColombiana - Neiva (Colombia), [3]ViewMind - Copenhage (Denmark), [4]Glasgow University - Glasgow (United Kingdom)

LP096 **Remote and unsupervised digital monitoring of memory decline in patients with mild cognitive impairment**
Sarah Polk [1], Kristin Basche [2], Luca Kleineidam [3], Wenzel Glanz [1], Robert Pernecky [4], Annika Spottke [3], Anja Schneider [3], Jens Wiltfang [5], Stefan Teipel [6], Michael Wagner [3], Sterling Johnson [2], Lindsay Clark [2], Frank Jessen [3], Emrah Düzel [1], David Berron [1]
[1]German Center for Neurodegenerative Diseases (DZNE) - Magdeburg (Germany), [2]University of Wisconsin School of Medicine and Public Health - Madison (United States), [3]German Center for Neurodegenerative Diseases (DZNE) - Bonn (Germany), [4]German Center for Neurodegenerative Diseases (DZNE) - München (Germany), [5]German Center for Neurodegenerative Diseases (DZNE) - Göttingen (Germany), [6]German Center for Neurodegenerative Diseases (DZNE) - Rostock (Germany)

THEME 7: Behavioral disorders and clinical trials

P202 **EHR-Based Identification and Pre-qualification of Patients with Behavioral Symptoms of Alzheimer's Disease for Neuropsychiatric Clinical Trials**
Sahaj Mahesh [1], Erin Beck [1], Daniel Gautieri [1]
[1]SiteRx - New York (United States)

P203 **Baseline Demographics of the ECT-AD Trial: Electroconvulsive Therapy for the Management of Treatment-Refractory Agitation and Aggression in Advanced Dementia**
Maria Lapid [1], Martina Mueller [2], Adriana Hermida [3], George Petrides [4], Louis Nykamp [5], Anthony Chatham [3], David Harper [6], Simon Kung [1], Sandeep Pagali [1], Regan Patrick [6], Cristina Pritchett [3], Patricio Riva Posse [3], Sohag Sanghani [7], Steve Seiner [6], Brent Forester [8]
[1]Mayo Clinic - Rochester (United States), [2]Medical University of South Carolina - Charleston (United States), [3]Emory University School of Medicine - Atlanta (United States), [4]RWJBarnabas Health System, Trinitas Regional Medical Center - Elizabeth (United States), [5]Pine Rest Christian Mental Health Services - Grand Rapids (United States), [6]McLean Hospital - Belmont (United States), [7]Northwell - New Hyde Park (United States), [8]Tufts University School of Medicine - Boston (United States)

P204 **Caregiving-related depression increases neuroinflammation in spousal caregivers of individuals with cognitive impairment: a longitudinal study**
So Yeon Jeon [1], Hee Won Yang [1], Jeong Lan Kim [1]
[1]Chungnam National University Hospital - Daejeon (Korea, Republic of)

POSTER PRESENTATIONS

P205 **Predicting suicide risk in individuals with cognitive decline: integrating sociodemographic and clinical predictors**
Eva Vidovic [1], Jernej Rudi Finžgar [2], Anja Kokalj Palandacic [1], Polona Rus Prelog [1,3]
[1]University Psychiatric Clinic Ljubljana - Ljubljana (Slovenia), [2]Technical University Munich, School of CIT, Department of Computer Science - Garching (Germany), [3]Faculty of Medicine, University of Ljubljana - Ljubljana (Slovenia)

THEME 8: Health economics and clinical trials

P206 **Risk prediction models of mild cognitive impairment using electronic health record data**
Gang Li [1], Viswanath Devanarayan [1], Rachel Halpern [2], Stephane Borentain [1], Susan Desanti [1], Jo Vandercappellen [1], Ara Khachaturian [3], Richard Crislip [2], Jeffrey Meyerhoff [2], Joanne Bell [1], Mattke Soeren [4], Harald Hampel [1]
[1]Eisai - Nutley (United States), [2]Optum - Prairie (United States), [3]PAD2020 - Washington (United States), [4]University of Southern California - Los Angles (United States)

P207 **Development of a simulation model of Alzheimer's Disease to evaluate disease modifying treatments in a memory clinic population**
Pieter Van Der Veere [1,2,3], Hana Broulikova [4,5], Jeroen Hoogland [6], Jort Vijverberg [1,3], Wiesje Flier [1,2,3], Hans Berkhof [2]
[1]Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center - Amsterdam (Netherlands), [2]Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, VU University Medical Center - Amsterdam (Netherlands), [3]Amsterdam Neuroscience, Neurodegeneration - Amsterdam (Netherlands), [4]Department of Health Science, Faculty of Science, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), [5]Department of Public Mental Health, National Institute of Mental Health - Klecany (Czech Republic), [6]Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, VU University Medical Center - Amsterdam (Netherlands) - Amsterdam (Netherlands)

P208 **Estimation of Long-term Care Utilization and Lifetime Distribution of Medical Cost for Dementia in Korea**
Jun Hong Lee [1]
[1]NHIS Ilsan Hospital - Goyang-Si (Korea, Republic of)

P209 **Use of a Mobile Research Unit to Address Health Disparities in Alzheimer's Clinical Trials**
Santiago Santelis [1], Sandra Carmona Torres [1], Rachel Rittichier [1], Gisel Kautz [1], Lucy Lenox [1], Brina Quaning [2]
[1]K2 Medical Research - Orlando (United States), [2]MetroHealth Inc. - Orlando (United States)

LP097 **Cost-effectiveness of diagnosing and treating patients with early Alzheimer´s Disease with anti-amyloid treatment**
Anders Wimo [1], Ron Handels [2], Kaj Blennow [3], Jaka Bon [4], Andreja Emersic [4], Bjørn-Eivind Kirsebom [5], Fernando Gonzalez-Ortiz [3], Milica Gregoric Kramberger [4], Andreja Speh [4], Per Selnes [6], Anders Sköldunger [1], Santiago Timón-Reina [6], Pieter Jelle Visser [2], Ellen Vromen [7], Bengt Winblad [1], Tormod Fladby [6]
[1]Karolinska Institutet - Solna (Sweden), [2]Maastricht Univertsity - Maastricht (Netherlands), [3]University of Gothenburg - Gothenburg (Sweden), [4]University Medical Centre Ljubljana - Ljubljana (Slovenia), [5]The Arctic University of Norway - Tromsø (Norway), [6]University of Oslo - Oslo (Norway), [7]Vrije Universiteit Amsterdam - Amsterdam (Netherlands)

LP098 **Assessing the Adequacy and Distribution of US Clinical Trial Sites for Alzheimer's Disease: Addressing Regulatory, Diversity, Equity, and Inclusion Challenges**
Sean Stanton [1], John Ahn [2], Sandra Torres [1], Stephanie Cassidy [1], Kerry Lovelace [1], Seth Goodman [1], Daniel Gautiera [1]
[1]K2 Medical Research - Orlando (United States), [2]K2 Medical Research - San Fransico (United States)

THEME 9: Epidemiology and clinical trials

P210 **Impact of Physical Activity on Risk of Dementia in Pre-Menopausal and Post-Menopausal Women**
Lim Eunye [1], Cho Ahyun [1]
[1]Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea - Seoul (Korea, Republic of)

P211 **Evaluating ICD-10 Medicare Claims Data as a Method of Identifying Persons Living with Dementia**
Joya Bhattacharyya [1], Yi Chen [2], Kan Gianattasio [3], Francine Grodstein [3], Bryan James [2], Ali Moghtaderi [1], Christina Prather [1], David Rein [3], Raj Shah [2], Emma Stapp [1], Melinda Power [4]
[1]George Washington University - Washington, Dc (United States), [2]Rush University - Chicago, Il (United States), [3]NORC - Chicago, Il (United States), [4]George Washington University - Washington (United States)

P212 **Use of Medications in Patients with Alzheimer's Disease Before and After Diagnosis**
Olga Sánchez-Soliño [1], Yael Barer [2], Sivan Gazit [2], Lisa Vinikoor-Imler [1], Gabriel Chodick [2]
[1]AbbVie - North Chicago (United States), [2]Maccabi Institute for Research and Innovation, Maccabi Healthcare Services - Tel Aviv (Israel)

P214 **The Dementia Datahub: Development of a National Surveillance System of Diagnosed Dementia in the United States**
David Rein [1], Kan Giannattasio [2], John Wittenborn [3], Samuel Knisely [4], Carrie Bao [4], Qian Gu [4], Melinda Power [5]
[1]NORC at the University of Chicago - Atlanta (United States), [2]NORC at the University of Chicago - Bethesda (United States), [3]NORC at the University of Chicago - Raleigh (United States), [4]KPMG - Mclean (United States), [5]KPMG - Washington District Of Columbia (United States)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon : 

P215 **Impact of Helicobacter pylori eradication on age-specific risk of incident dementia in patients with peptic ulcer disease: A nationwide population-based cohort study**
Kang Dong Woo [1]
[1]Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)

P216 **Epidemiological Survey of Dementia in the Korean Elderly Population**
Im Seok Koh [1,2], Jeewon Suh [1,2], Mookyung Oh [2], Jungrea Lee [2], Hyunsung Cho [2], Se Jin Kim [3]
[1]Department of Neurology, National Medical Center - Seoul (Korea, Republic of), [2]National Institute of Dementia, National Medical Center - Seoul (Korea, Republic of), [3]Korea Institute for Health and Social Affairs - Sejong (Korea, Republic of)

P217 **All-cause mortality increased with intracerebral hemorrhage in the United States Medicare Beneficiaries 65 years or older with mild cognitive impairment or Alzheimer's dementia**
Haixin Zhang [1], Babak Haji [1], Gao Ran [1], Michael Irrizary [1], Quanwu Zhang [1], Amir Abbas Tahami Monfared [1]
[1]Eisai - Nutley (United States)

 P219 **Epidemiological study of hospital morbidity due to Alzheimer's disease in Brazil from 2008 to 2023: a contribution to clinical trials.**
Julia Fahd [1], Gabriel Betez [1], Gustavo Santos [1], Julia Grilo [1], Isabelle Borges [1]
[1]Faculdade Sao Leopoldo Mandic de Araras, Medical School - Araras (Brazil)

 P220 **The importance of cognitive reserve in maintaining brain health in Alzheimer's disease**
Gabrielle Almeida [1], Gustavo Santos [2], Amanda Scarso [2], Beatriz Hara [2], Larissa Rubim [2], Giovana Villar [2], Fabiola Moraes [2]
[1]Faculdade Sao Leopoldo Mandic de Araras, Medical School - Araras (Brazil), [2]Faculdade Sao Leopoldo Mandic de Araras, Medical School - Louveira (Brazil)

LP099 **Diversity amongst the Phase 3 HOPE study participants is reflective of the real-world Alzheimer's Disease (AD) population**
Lily Lee [1], John Dwyer [1], Celine Houser [1], Alex Konisky [1], Evan Hempel [1], Tamiko Magee-Rodgers [1], Michael Hull [1], Christian Howell [1], Ralph Kern [1]
[1]Cognito Therapeutics - Cambridge, Ma (United States)

LP100 **Estimating by race and APOE ε4 carrier status counts of US adults with subjective cognitive decline with preclinical Alzheimer's disease**
Cai Gillis [1], Shardae Showell [1], Nancy Maserejian [1]
[1]Biogen - Cambridge (United States)

LP101 **Regional disparities in adherence of anti-dementia medications**
Young-Gun Lee [1], Eunyoung Lee [2], Sungwoo Kang [3]
[1]Inje University College of Medicine - Goyang (Korea, Republic of), [2]Boramae Medical Center - Seoul (Korea, Republic of), [3]Yonsei University College of Medicine - Seoul (Korea, Republic of)

 LP103 **Global estimates of number of persons across key subgroups of the Alzheimer continuum**
Nicholas Norton [1], Anders Gustavsson [1,2], Aiman Afaque [1]
[1]Quantify Research - Stockholm (Sweden), [2]Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden)

POSTER PRESENTATIONS

THEME 10: Animal model

P221 **Nanoscale imaging of pT217-tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early-stage neurodegeneration**

Dibyadeep Datta [1], Isabella Perone [1], Denethi Wijegunawardana [1], Feng Liang [2], Yury Morozov [1], Jon Arellano [1], Alvaro Duque [1], Zhongcong Xie [2], Christopher Van Dyck [1], Mary Kate Joyce [1], Amy Arnsten [1]

[1]Yale University - New Haven (United States), [2]Massachusetts General Hospital and Harvard Medical School - Boston (United States)

P222 **2D3A8 a p53 Conformation-Specific Antibody Reacts with Alzheimer's Disease-positive Tissue in human brain samples.**

Shmuel Agus [1], David Lynch [2], Madison Samples [2], Rakez Kayed [2], Simona Piccirella [3], Paul Kinnon [3]

[1]Diadem SpA - Roslindale (United States), [2]Mitchell Center for Neurodegenerative diseases, University of Texas Medical Branch (UTMB) - Galveston (United States), [3]Diadem SrL - Milano (Italy)

P225 **Cryo-EM Structures of Amyloid-β Fibrils from Alzheimer's Disease Mouse Models**

Fernanda Salome Peralta Reyes [1], Mara Zielinski [2], Lothar Gremer [2,3], Gunnar F. Schröder [2,4]

[1]Institut für Physikalische Biologie, Heinrich Heine Universität Düsseldorf - Düsseldorf (Germany), [2]Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich - Düsseldorf (Germany), [3]Institut für Physikalische Biologie, Heinrich Heine Universität Düsseldorf - Düsseldorf (Germany) - Düsseldorf (Germany), [4]Physics Department, Heinrich Heine University Düsseldorf - Düsseldorf (Germany)

THEME 13: Digital health/E-trials

P226 **Retinal AI-based Alzheimer's Disease Detection Model Identifies Poor Brain Health in Cognitively Unimpaired Subjects**

Vincent Chung Tong Mok [1], Ho Ko [1], Bonnie Yin Ka Lam [1], Huijing Zheng [1], Yuen Ting Ng [1], Lisa Wing Chi Au [1], Alex Yuk Lun Lau [1], Alan Hiu Fung Lam [2], Anran Ran [3], Xiaoyan Hu [3], Ha Ying Chiu [4], Carol Yim Lui Cheung [3]

[1]Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR - Hong Kong (Hong Kong), [2]Department of Mechanical and Automation Engineering, The Chinese University of Hong Kong, Hong Kong SAR - Hong Kong (Hong Kong), [3]Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR - Hong Kong (Hong Kong), [4]The Charles Kao Foundation for Alzheimer's Disease - Hong Kong (Hong Kong)

P227 **Cognitive therapy software for improving cognitive function for patients with MCI**

Hojin Choi [1], Jong Hyun Jeon [1], Yangki Minn [2], Chi Kyung Kim [3]

[1]Department of Neurology,Hanyang University Guri Hospital - Guri (Korea, Republic of), [2]Department of Neurology,Kangnam Sacred Heart Hospital - Seoul (Korea, Republic of), [3]Department of Neurology,Korea University Guro Hospital - Seoul (Korea, Republic of)

P229 **Earlier is better: Clinical Trial Simulator SimulAD quantifies the relationship between amyloid/tau load severity and the amplitude of cognitive benefits of anti-amyloid treatments.**

Anna Custo [1,2], Marco Lorenzi [3], Giovanni Frisoni [4], Valentina Garibotto [1,2,5]

[1]Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University - Geneva (Switzerland), [2]Neurocenter and Faculty of Medicine, University of Geneva - Geneva (Switzerland), [3]Inria Sophia Antipolis, Université Côte d'Azur - Sophia Antipolis (France), [4]Geneva Memory Center, Geneva University Hospitals and Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva - Geneva (Switzerland), [5]Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals and CIBM Center for Biomedical Imaging, Geneva University Hospitals - Geneva (Switzerland)

P230 **The CAN-THUMBS UP Brain Health Support Program: Outcome completion rates in a fully remote online intervention study**

Howard Feldman [1,2], Nicole Anderson [3], Sylvie Belleville [4,5], Paul Brewster [6], Andrew Lim [7], Manuel Montero-Odasso [8,9], Haakon Nygaard [10], January Durant [1,2], Jody-Lynn Lupo [1,2], Penelope Slack [10], Howard Chertkow [3]

[1]Department of Neurosciences, University of California San Diego - La Jolla (United States), [2]Alzheimer's Disease Cooperative Study, University of California San Diego - La Jolla (United States), [3]Rotman Research Institute, Baycrest Academy for Research and Education; University of Toronto - Toronto (Canada), [4]Centre de recherche de l'Institut Universitaire de gériatrie du CIUSSS du Centre-Sud-de-l'Île-de-Montréal - Montreal (Canada), [5]Université de Montréal - Montreal (Canada), [6]Cognition & Technology Research Group, Institute on Aging and Lifelong Health, University of Victoria - Victoria (Canada), [7]Sunnybrook Research Institute - Toronto (Canada), [8]Gait and Brain Laboratory, Lawson Health Research Institute, Parkwood Institute - London (Canada), [9]Schulich School of Medicine and Dentistry, Department of Medicine (Geriatrics), University of Western Ontario - London (Canada), [10]Division of Neurology, University of British Columbia - Vancouver (Canada)

P231 **Digital Assessment of Cognition for Optimizing Neuropsychology Workflow**

Ali Jannati [1], Karl Thompson [1], Claudio Toro-Serey [1], Russell Banks [1], Connor Higgins [1], Jeff Pobst [1], John Showalter [1], David Bates [1], Sean Tobyne [1], David Libon [1], Rod Swenson [1], Alvaro Pascual-Leone [1]

[1]Linus Health - Boston (United States)

P232 **Comparing Eye-Tracking Metrics for Figure-Copying in Amyloid-Negative and Amyloid-Positive Mild Cognitive Impairment**

Ko Woon Kim [1], Qi Wang [2], Su Jeong Wang [3], Byoung-Soo Shin [1]

[1]Jeonbuk National University Medical School and Hospital - Jeonju (Korea, Republic of), [2]Jeonbuk National University Medical School - Jeonju (Korea, Republic of), [3]Jeonbuk National University Hospital - Jeonju (Korea, Republic of)

P233 **Validation of a Lifestyle Risk Assessment 'Smart Tracker' tool**

Larissa Mcketton [1], Angela Troyer [2,3], Nicole Anderson [1,3,4]

[1]Rotman Research Institute, Baycrest Academy for Research and Education - Toronto (Canada), [2]Neuropsychology and Cognitive Health, Baycrest - Toronto (Canada), [3]Department of Psychology, University of Toronto - Toronto (Canada), [4]Department of Psychiatry, University of Toronto - Toronto (Canada)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon :

P234 **Agreement between Altoida's Digital Biomarker Platform and standard neuropsychological tests in individuals with subjective memory complaints**
M. Florencia Iulita [1], Alberto Ferrari [1], Gonzalo Sanchez Benavides [2], Victoria Brugada Ramentol [1], Silvia Fallone [1], Nicholas Griffin [1], Emmanuel Streel [1], Oriol Grau-Rivera [2], Carolina Minguillon [2], Claudia Porta-Mas [2], Mylea Charvat [1], Ioannis Tarnanas [1]
[1]Altoida Inc. - Washington Dc (United States), [2]BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain)

P235 **Reliability and validity of a tablet-based neuropsychological test (the Hellocog) for screening dementia**
Hee Won Yang [1], Daniel Hahnsam Seok [2], Ki Woong Kim [2]
[1]Chungnam national university hospital - Daejeon (Korea, Republic of), [2]Seoul National University - Seoul (Korea, Republic of)

P236 **Virtual reality-based cognitive training improves cognitive function in alzheimer's disease patients**
Ho-Won Lee [1], Dohun Kim [2]
[1]Dep. of Neurology, School of Medicine, Kyungpook National University - Daegu (Korea, Republic of), [2]G-L Co, Ltd - Daegu (Korea, Republic of)

P237 **The effectiveness of a virtual reality-based cognitive training program for mild cognitive impairment: A pilot study**
Eek-Sung Lee [1], Seung-Keun Lee [1], Tae-Kyeong Lee [1], Seuonghee Na [2], Yang Ho Kim [3]
[1]Soonchunhyang University Bucheon Hospital - Bucheon (Korea, Republic of), [2]Department of Neurology, Incheon St. Mary's Hospital, the Catholic University of Korea - Incheon (Korea, Republic of), [3]Tenetus Co. - Seoul (Korea, Republic of)

P238 **Memory features obtained through automated phone calls associate to the intensity of subjective cognitive decline in cognitively unimpaired individuals**
Clàudia Porta-Mas [1,2], Gonzalo Sánchez-Benavides [1,2,3], Elisa Mallick [4], Johannes Tröger [4], Nicklas Linz [4], Alexandra König [4], Andreea Radoi [1], Carlota Medina [1], Alba Cañas-Martínez [1], Anna Brugulat-Serrat [1], Lidia Canals-Gispert [1], Isabel Pérez-Gutiérrez [1], Marc Suárez-Calvet [1,2,3,5], Juan Domingo Gispert [1,2,3], Oriol Grau-Rivera [1,2,3,5]
[1]BarcelonaBeta Brain Research Center - Barcelona (Spain), [2]Hospital del Mar Research Institute (IMIM) - Barcelona (Spain), [3]Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III - Madrid (Spain), [4]ki:elements - Saarbrücken (Germany), [5]Servei de Neurologia, Hospital del Mar - Barcelona (Spain)

P239 **Quantifying Prediction Confidence in AI Models for EEG Analysis**
Mats Tveter [1,2], Thomas Tveitstøl [1,2], Ana Perez [1,2], Christoffer Hatlestad-Hall [1], Hanna Renvall [3,4], Fernando Maestú [5,6,7], Camillo Marra [8,9], Paolo Maria Rossini [10], Ira R. J. Hebold Haraldsen [1]
[1]Oslo University Hospital - Oslo (Norway), [2]Faculty of Medicine, University of Oslo - Oslo (Norway), [3]Aalto University - Helsinki (Finland), [4]BioMag Laboratory, Helsinki University and Aalto University School of Science - Helsinki (Finland), [5]Universidad Complutense de Madrid - Madrid (Spain), [6]Department of Experimental Psychology, Universidad Complutense de Madrid Madrid (Spain), [7]IdISSC, San Carlos University Hospital - Madrid (Spain), [8]Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), [9]Catholic University of the Sacred Heart - Rome (Italy), [10]IRCCS San Raffaele - Rome (Italy)

P240 **Self-supervised learning for feature extraction in EEG**
Thomas Tveitstøl [1,2], Mats Tveter [1,2], Christoffer Hatlestad-Hall [1], Camillo Marra [3,4], Hanna Renvall [5,6], Fernando Maestú [7,8,9], Paolo Maria Rossini [10], Ira R. J. Hebold Haraldsen [1]
[1]Oslo University Hospital - Oslo (Norway), [2]Faculty of Medicine, University of Oslo - Oslo (Norway), [3]Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), [4]Catholic University of the Sacred Heart - Rome (Italy), [5]Aalto University - Helsinki (Finland), [6]BioMag Laboratory, Helsinki University and Aalto University - Helsinki (Finland), [7]Universidad Complutense de Madrid - Madrid (Spain), [8]Cognitive Psychology and Speech and Language Therapy, Universidad Complutense de Madrid - Madrid (Spain), [9]IdISSC, San Carlos University Hospital - Madrid (Spain), [10]IRCCS San Raffaele - Rome (Italy)

P241 **All-cause mortality in patients with mild cognitive impairment or Alzheimer's dementia who experienced intracerebral hemorrhage**
Ying Wang [1,2], Peter Morin [3,2], Vanesa Arasa [3,4], Brant Mittler [5], Joel Reisman [2,6], Raymond Zhang [7], Amir Abbas Tahami Monfared [7,8], Quanwu Zhang [7], Weiming Xia [2,6,3]
[1]Wentworth Institute of Technology - Boston (United States), [2]VA Bedford Healthcare System - Bedford (United States), [3]Boston University - Boston (United States), [4]VA Boston Healthcare System - Boston (United States), [5]VA South Texas Healthcare System - San Antonio (United States), [6]University of Massachusetts - Lowell (United States), [7]Eisai, Inc - Nutley (United States), [8]McGill University - Montreal (Canada)

P241bis **All-cause mortality in patients with mild cognitive impairment or Alzheimer's dementia who experienced seizure**
Myriam Abdennadher[1], Ying Wang[2,3], Peter Morin[1,3], Vanesa Arasa[1,4], Brant Mittler[5], Joel Reisman[3,6], Raymond Zhang[7], Amir Abbas Tahami Monfared[7,8], Michale Irizarry[7], Quanwu Zhang[7], Weiming Xia[3,6,1]
[1]Boston University - Boston (United States), [2]Wentworth Institute of Technology - Boston (United States), [3]VA Bedford Healthcare System - Bedford (United States), [4]VA Boston Healthcare System - Boston (United States), [5]VA South Texas Healthcare System - San Antonio (United States), [6]University of Massachusetts - Lowell (United States), [7]Eisai, Inc - Nutley (United States), [8]McGill University - Montreal (Canada)

P242 **Screening for Dementia Using Acoustic Feature and Machine Learning of Free Conversation**
Toshiro Horigome [1], Kuo-Ching Liang [1], Taishiro Kishimoto [1]
[1]Keio University School of Medicine - Tokyo (Japan)

POSTER PRESENTATIONS

P243 **The HOGAR study: Home-based brain monitoring with a self-managed EEG to study cognitive decline in the ageing population**

Eduardo López-Larraz [1], Almudena Robledo-Menéndez [1], Esperanza Jubera-García [1,2], Olga Gelonch [3], Jorge de Francisco Moure [4,5], José María Marín [4,6], Nora Molina-Torres [4,7], Jose M. Pérez-Trullén [4,8], Elena Muñoz Farjas [9], Rosario Osta [4,10], Elena Lobo [4,11], Antonio Lobo [4,12], Pedro Modrego [4,13], Rosa Magallón-Botaya [4,14], Javier Minguez [1]

[1] Bitbrain, Zaragoza, Spain. [2] University of Cambridge, UK, Department of Psychology [3] Clinical Research Group for Brain, Cognition and Behavior, Hospital de Terrassa, Consorci Sanitari de Terrassa, Spain. [4] Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain. [5] Servicio de neurofisiología Clínica, Hospital Universitario Miguel Servet, Zaragoza, Spain. [6] Servicio de neumología, Hospital Universitario Miguel Servet, Zaragoza, Spain. [7] Servicio de geriatría, Hospital Nuestra Señora de Gracia, Zaragoza, Spain. [8] Servicio de neurología, Hospital Nuestra Señora de Gracia, Zaragoza, Spain. [9] Servicio de neurología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [10] Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, Spain. [11] Department of Preventive Medicine and Public Health, Universidad de Zaragoza, Spain. [12] Department of Medicine and Psychiatry, Universidad de Zaragoza, Spain. [13] Servicio de neurología, Hospital Universitario Miguel Servet, Zaragoza, Spain. [14] Department of Medicine, Psychiatry and Dermatology, Faculty of Medicine, University of Zaragoza, Spain.

P244 **Seizure in patients with mild cognitive impairment or Alzheimer's dementia who experienced intracerebral hemorrhage**

Myriam Abdennadher [1,2], Ying Wang [3,4], Peter J. Morin [4], Vanesa Carlota Andreu Arasa [5,6], Brant Mittler [7], Joel Reisman [8,9], Zhang Raymond [10], Amir Abbas Tahami Monfared [10,11], Michael Irizarry [10], Quanwu Zhang [10], Weiming Xia [9,12,13]

[1]Boston Medical Center - Boston (United States), [2]Boston University Chobanian & Avedisian School of Medicine - Boston (United States), [3]Wentworth Institute of Technology - Boston (United States), [4]Research Service, VA Bedford Healthcare System - Bedford (United States), [5]Neuroradiology, VA Boston Healthcare system - Boston (United States), [6] Radiology, Boston Chobanian & Avedisian School of Medicine - Boston (United States), [7]Geriatric Research Education & Clinical Center, VA South Texas Healthcare System - San Antonio (United States), [8]Center for Healthcare Organization & Implementation, VA Bedford Healthcare System – Bedford (United States), [9]Department of Biological Sciences, University of Massachusetts Lowell - Lowell (United States), [10]Alzheimer's Disease & Brain Health, Eisai Inc. - Nutley (United States), [11]McGill University – Montreal (Canada), [12]Geriatric Research Education and Clinical Center - Bedford, (United States), [13] Pharmacology, Physiology and Biophysics, Boston University Chobanian & Avedisian School of Medicine - Boston (United States)

P245 **Big Data from Smart Ecosystems Targeting Cognitive Impairment**

Razvan Ioan Trascu [1,2], Mircea Dan Marzan [1,2], Luiza Spiru [1,2]

[1]"Carol Davila" University of Medicine and Pharmacy - Bucharest (Romania), [2]Ana Aslan International Foundation - Bucharest (Romania)

P246 **MRI imaging biomarker prediction using Alzheimer's disease characteristic acoustic speech features**

Seonki Chung [1], Hyunsun Ham [2], Minju Bae [2], Hyeonjin Kim [2], Keun You Kim [2], Jun-Young Lee [2,1]

[1]Seoul National University College of Medicine - Seoul (Korea, Republic of), [2]SMG-SNU Boramae Medical Center, Department of Psychiatry - Seoul (Korea, Republic of)

P248 **Analysis of Connectivity in AI-Mind Data using Graph Neural Networks**

Mohamed Radwan [1], Pedro G. Lind [1], Rabindra Khadka [1], Asma Belhadi [1], Ira Haraldsen [2], Paolo Rossini [3], Camillo Marra [4], Fernando Maestu [5], Hanna Renvall [6], Erik Christensen [7], Anis Yazidi [1]

[1]Oslo Metropolitan University - Oslo (Norway), [2]Oslo University Hospital - Oslo (Norway), [3]Università Cattolica del Sacro Cuore - Milan (Italy), [4]IRCCS San Raffaele Pisana - Rome (Italy), [5]Universidad Politécnica de Madrid - Madrid (Spain), [6]Helsinki University Hospital - Helsinki (Finland), [7]Pre Diagnostics AS - Oslo (Norway)

P249 **EEG-JEPA: Self-Supervised Learning from EEG Signals with a Joint-Embedding Predictive Architecture**

Rabindra Khadka [1], Pedro G. Lind [1,2], Christoffer Hatlestand-Hall [3], Mohamed Radwan [1], Asma Belhadi [1], Gustavo Mello [1], Michael A. Riegler [1,4], Erik Christensen [5], Hanna Renwall [6,7], Fernando Maestú [8,9], Camillo Marra [10,11], Paolo M. Rossini [12], Ira H. Haraldsen [3], Anis Yazidi [1]

[1]Oslo Metropolitean University - Oslo (Norway), [2]Simula - Oslo (Norway), [3]University of Oslo - Oslo (Norway), [4]Simulamet - Oslo (Norway), [5]Pre Diagnostics AS - Oslo (Norway), [6]Aalto University, Helsinki, Finland - Helsinki (Finland), [7]Helsinki University Hospital - Helsinki (Finland), [8]Universidad Complutense de Madrid - Madrid (Spain), [9]San Carlos University Hospital, - Madrid (Spain), [10]Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), [11]Catholic University of the Sacred Heart - Rome (Italy), [12]Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele - Rome (Italy)

LP104 **Identification, Enrichment, and Longitudinal Tracking of Alzheimer's Disease Patients via the SiteRx CNS Disease Registry**

Sahaj Mahesh [1], Daniel Gautieri [1]

[1]SiteRx - New York (United States)

LP105 **Can an AI voice agent (Grove AI) successfully recruit participants into Alzheimer's Clinical Trials?**

Stephanie Cassidy [1], Kerry Lovelace [1], Tran Le [2], Sohit Gatiganti [2], Anthony Riley [2], Sandra Torres [1], Phuc Truong [3], Michael Isaac [1], Gina Cedano [1], Michelle Montone [1], Brandon Lenox [1], Natalia Torres [1], Dennis Moya [1], Stanton Sean [1]

[1]K2 Medical Research - Orlando (United States), [2]Grove AI - San Fransico (United States), [3]Vision Cycles - Boston (United States)

LP106 **Differential Diagnosis of Alzheimer's disease and frontotemporal dementia using multimodal Deep Learning**

Gianmarco Guarnier [1,2], Janis Reinelt [1], Eóin N. Molloy [1], Paul Glad Mihai [1], Pegah Einaliyan [1], Sofie Valk [3,4,5], Augusta Modestino [1], Matteo Ugolini [1], Aroma Dabas [1,6], Rhys Agombar [1], Karsten Mueller [3,7], Wu Qiong [3], Anahit Babayan [2], Marco Castellaro [8], Arno Villringer [3,9], Konstantin Thierbach [1,3], Matthias L. Schroeter [3,9]

[1]AICURA medical GmbH - Berlin (Germany), [2]Max Planck Institute for Human Cognitive and Brain Sciences - Leipzig (Germany) - Leipzig (Germany), [3]Max Planck Institute for Human Cognitive and Brain Sciences - Leipzig (Germany), [4]Institute of Neuroscience and Medicine, Brain & Behaviour (INM-7), - Jülich (Germany), [5]Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf - Düsseldorf (Germany), [6]Max Planck Institute for Human Cognitive and Brain Sciences - Leipzig, [7]Department of Neurology, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague - Prague (Czech Republic), [8]Department of Information Engineering, University of Padua - Padua (Italy), [9]Clinic for Cognitive Neurology, University Hospital Leipzig - Leipzig (Germany)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon : 

LP107 **Xpress0: a digital cognitive self-evaluation for population screening**
Willlem Huijbers [1], Johanna Gruber [1], Hans-Aloys Wischmann [2], Murray Gillies [1], Ziad Nasreddine [1]
[1]MoCA Cognition - Montreal (Canada), [2]Charité – Universitätsmedizin Berlin - Berlin (Germany)

LP108 **Prescribing remote digital self-testing for suspected mild cognitive impairment: results of the re.cogni.ze study on feasibility and acceptance with the neotivCare app**
Emrah Düzel [1,2], Claudia Bartels [3], Dirk Czesnik [4], Thomas Duning [5], Andreas Lüschow [6], Gereon Nelles [7], Gerd Reifschneider [8], Michael Schöttler [9], Björn Hendrik Schott [3], Martin Griebe [10]
[1]Deutsche Zentrum für Neurodegenerative Erkrankungen (DZNE) - Magdeburg (Germany), [2]Institut für Kognitive Neurologie und Demenzforschung, Otto von Guericke Universität - Magdeburg (Germany), [3]Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen - Deutschland (Germany), [4]Gemeinschaftspraxis für Neurologie - Göttingen (Germany), [5]Klinik für Neurologie - Klinikum Bremen-Ost (Germany), [6]MVZ Campus Benjamin Franklin - Charité Berlin (Germany), [7]Neuromed-Campus - Köln (Germany), [8]NeuroCentrum Odenwald - Erbach (Germany), [9]Roche Pharma AG - Grenzach-Wyhlen (Germany), [10]Neurologische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg - Heidelberg (Germany)

LP109 **Pilot program of digital cognitive testing by Primary Care Clinicians in a large Health System**
Darren Gitelman [1,2,3], Jennifer Mishos [1], Michael Malone [4,5]
[1]Advocate Health - Downers Grove (United States), [2]Rosalind Franklin University of Medicine and Science - Chicago (United States), [3]Northwestern University - Chicago (United States), [4]Aurora Health Care - Milwaukee (United States), [5]University of Wisconsin School of Medicine & Public Health - Madison (United States)

LP110 **Defining clinical contexts of use and performance standards for digital cognitive assessments: Recommendations from the Global CEO Initiative on Alzheimer's Disease**
Louisa Thompson [1], A.M. Barrett [2], Sol Fittipaldi [3,4], Barak Gaster [5], Dustin Hammers [6], Christopher Butler [7]
[1]Brown University - Providence (United States), [2]University of Massachusetts Chan Medical School - Massachusetts (United States), [3]Universidad Adolfo Ibáñez - Santiago (Chile), [4]University of California San Francisco - San Francisco (United States), [5]University of Washington - Seattle (United States), [6]Indiana University School of Medicine - Indianapolis (United States), [7]Imperial College London - London (United Kingdom)

LP111 **Real-World Care of Alzheimer's Disease Patients (n=2,153) in Germany: Insights from Registry of the Neurologists Network NeuroTransData (NTD) using the Physician/Patient Platform (DESTINY)**
Arnfin Bergmann [1], Stefan Braune [1], Oliver Fasold [1], Heidi Dikow [1], Niloofar Tavakoli [1]
[1]NeuroTransData GmbH, NTD Study Group, Neuburg an der Donau - Neuburg An Der Donau (Germany)

THEME 15: Clinical Trials Early Career Investigator Showcase

P250 **The risk factors affecting CDR-SOB changes in amyloid-beta negative individuals with mild cognitive impairment and subjective memory impairment**
Hyunji Lee [1]
[1]Pusan National Univalsity Hospital - Busan (Korea, Republic of)

P251 **Association of Alzheimer's disease biomarkers and emotional states: analysis of individuals with and without preclinical Alzheimer's disease in the A4 trial**
Taimur Kouser [1], James Kelbert [2], Ingrid Luo [1], Zihuai He [3], Irina Skylar-Scott [1]
[1]Stanford University - Palo Alto (United States), [2]University of Arizona - Phoenix (United States), [3]University of Arizona - Palo Alto (United States)

P252 **Changes in cognitive and neural markers of Alzheimer's disease in response to aerobic and non-aerobic exercise among cognitively healthy older African Americans: The role of body composition, genetics, and sex**
Bernadette Fausto [1]
[1]Rutgers–The State University of New Jersey - Newark (United States)

P253 **Association between cognitive performance and emotional states: analysis from the A4 trial**
James Kelbert [1], Taimur Kouser [2], Ingrid Luo [2], Christina Young [2], Zihuai He [2], Irina Skylar-Scott [2]
[1]University of Arizona - Phoenix, [2]Stanford University - Palo Alto (United States)

LP112 **Discrepancies in Dementia Self-Awareness: Correlations with Well-Being Across Daily Challenges**
Haruaki Horie [1], Fumiya Nakai [1], Taishiro Kishimoto [1], Masaru Mimura [1], Toshiro Horigome [1]
[1]Keio University Hospital - Tokyo (Japan)

CTAD would like to thank its 2024 privileged partners for their continued support.

Ultimate Sponsor

Alzheimer's Drug Discovery Foundation

Platinum Sponsor

Eisai

Lilly

Biogen

Gold Sponsors

Alzheimer's Disease Data Initiative

ALZHEIMER'S ASSOCIATION

LANTHEUS

Lundbeck

novo nordisk

Otsuka

Practical Details

Conference Venue

Madrid Marriott Auditorium Hotel & Conference Center

Avda de Aragon 400 - 28022 Madrid (Spain)

Airport shuttle: a complimentary shuttle is available to/from the airport.
The timetable is available on the mobile app and at the registration desk

ROOM LOCATOR

> Meeting Room

> Conference Room

All sessions will be held in the Auditorium in the Conference Center at Lobby Level.

> Posters Sessions and Coffee Breaks

Poster sessions will be held in the Italian Rooms - Meet our poster presenters during the coffee breaks. A poster assistance desk will be available to locate the posters.

> Registration desk opening hours:

- October 28: 04:00 p.m. to 06:00 p.m.
- October 29: 10:00 a.m. to 07:00 p.m.
- October 30: 07:30 a.m. to 06:00 p.m.
- October 31: 07:30 a.m. to 06:00 p.m.
- November 1: 07:30 a.m. to 05:45 p.m.

> Cloakroom opening hours:

- October 29: 02:00 p.m. to 10:00 p.m.
- October 30: 07:30 a.m. to 10:30 p.m.
- October 31: 07:30 a.m. to 10:30 p.m.
- November 1: 07:30 a.m. to 06:00 p.m.

> Lunch bags

Lunch bags will be available in the Poster Hall, Atrium Bar and Buffet Madrid on Wednesday, Thursday and Friday (see floorplan).

In your badge holder you have 3 lunch tickets with different colors corresponding to a different day, please hand the correct one to the catering staff to get your lunch bag.



> CTAD Networking Event with the Support of the Alzheimer's Association

Tuesday, October 29 from 7:00 p.m. to 8:00 p.m.
in the conference center.

ALZHEIMER'S ASSOCIATION

Practical Details

POSTER WALKING TOUR

Enjoy a morning coffee while touring the posters from 7:30 a.m. to 8:30 a.m. on Wednesday, Thursday and Friday.

New at CTAD this year

CTAD is dedicated to promoting the professional development of early career investigators to ensure their success and career advancement. Join us for the "flash session presentations" in the poster area during morning and afternoon coffee breaks and discover their exciting research work (see the program for the scheduled sessions).

Free WiFi available at CTAD

Login to: MarriotBonvoy_Conference no password needed

> Mobile App

Download the VFairs mobile app on the Apple Store or Google Play. Login with the email address used to register, then click on CTAD2024 and enjoy the conference at your fingertips, you can watch the livestream from the Ballroom, access the virtual poster hall and connect with your colleagues!

> CTAD24 digital platform

To access our digital platform simply go to www.ctad24.com and enter with your email address.

Follow us on social media!

@CTADConference
#CTAD24

CTAD Conference

CTAD Alzheimer

CTAD Congress > Email: ctad@ant-congres.com

www.ctad-alzheimer.com

CTAD 2025

Clinical Trials on Alzheimer's Disease

December 1-4, 2025

San Diego, CA, USA

Montpellier '08 • Las Vegas '09 • Toulouse '10 • San Diego '11 • Monte Carlo '12 • San Diego '13
Philadelphia '14 • Barcelona '15 • San Diego '16 • Boston '17 • Barcelona '18 • San Diego '19
Virtual '20 • Boston '21 • San Francisco '22 • Boston '23 • Madrid '24

www.ctad-alzheimer.com
Email: ctad@ant-congres.com

JPAD
The Journal of Prevention of Alzheimer's Disease